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Abstract 
Aim: To investigate the clinical, physiological, radiological and pathological 
changes which occur in the lungs in Anderson Fabry Disease (AFD)  
Methods: In this study we have used lung function testing, high resolution 
CT scanning and induced sputum examination to investigate the lung. We have 
measured sputum enzyme activity using fluorometric assays, cell populations 
using flow cytometry and cytokines using enzyme linked immunosorbent assays. 
We have compared investigation findings from AFD subjects with those from 
patient’s with airways disease in the form of chronic obstructive pulmonary 
disease (COPD) and healthy controls  
Results: We have shown that respiratory symptoms are common, and 
airway involvement is widespread though mild in AFD.  Pulmonary involvement is 
more common in males, in subjects with worse overall disease as measured by 
Mainz Severity Score Index, and is independent of smoking. No significant 
radiological changes were evident on CT chest imaging in AFD. We have 
presented novel data on α-galactosidase A activity from lung derived samples, 
which demonstrate low sputum enzyme activity in AFD males compared to 
controls and AFD females, and consistently higher enzyme activity in sputum 
derived leucocytes compared to those derived from peripheral blood. We did not 
find any detectable differences in blood or sputum α-galactosidase A activity in 
subjects on enzyme replacement therapy. Cell populations from induced sputum 
in AFD subjects demonstrated a predominance of monocytes/macrophages, 
similar to the COPD subjects, and there was the suggestion of an increased T cell 
population in AFD subjects with airway obstruction compared to those without. 
Elevated concentrations of sputum IL-8 were seen in the sputum of AFD subjects 
compared to controls.  
Conclusion: There is demonstrable and clinically relevant involvement of 
the lungs in AFD, which appears to occur as a result of deficient α-galactosidase 
A in the lungs and subsequent inflammatory processes. 
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1.1 The Nature of Lysosomal Storage Disorders  
1.1.1 Lysosomes 
Lysosomes are essential cellular organelles found in the cells of all human 
tissues. They contain a number of hydrolytic enzymes such as lipases, proteases, 
amylase, nucleases and phosphoric acid monoesters (1). They are responsible for 
the catabolism of peptides and carbohydrates, and for digestion of effete 
organelles and mitochondria. In addition they are involved in degradation of 
phagocytosed pathogens (2).  
Lysosomal enzymes are formed from the rough endoplasmic reticulum (3) 
and modified in the Golgi apparatus where mannose-6-phosphate residues are 
added to allow targeting to lysosomes via the mannose-6-phosphate receptor. 
However the mannose-6-phophate receptor is recycled from the late endosomes 
and therefore not found in the lysosome itself (4). Lysosomes are usually 
spherical, EM dense, and   granular (5). Each lysosome has a plasma membrane 
which protects the cell from hydrolytic enzymes, and can assist in repairing cell 
membrane damage if required. The interior of the lysosome is acidic compared 
to the cell cytosol, and this acidic environment is necessary for the optimal 
functioning of the hydrolytic enzymes. The pH difference also provides some 
protection to the cell should there be any leak of hydrolases into the cytosol, 
though despite this lysosomes do have a role in cell autolysis (6).  Lysosomes 
perform their function by fusing with other cellular vacuoles forming endo-
lysosomes and phago-lysosomes and allowing the hydrolases to contact the 
vacuole contents and digest them (7) .  
1.1.2 Lysosomal storage disorders (LSD) 
There are over 50 lysosomal storage disorders arising from dysfunction of 
lysosomal proteins. They are a diverse group of disorders occurring largely as a 
result of inherited deficiencies of lysosomal enzymes, although may also result 
from defects in protein cofactors, membrane proteins or proteins involved in 
post translational modification or enzyme transport.  As a result of the enzyme 
Chapter 1 - Introduction 
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deficiency there is an accumulation of substrate within various tissues, resulting 
in multi-organ pathology, which is progressive over time.  
Broadly LSDs may be divided into the Mucopolysaccharidoses (MPS), 
Sphingolipidoses and Mucolipidoses, in addition to type II glycogen storage 
disease Pompe disease, where there is a defect in the lysosomal enzyme acid 
maltase. Figure 1.0 demonstrates the pathways involved in glycosphingolipid 
metabolism, highlighting the lipids and intermediates involved, and the enzymes 
which have been shown to cause disease as a result of their absence or deficient 
activity.  
LSDs may present in childhood with conditions such as the 
mucopolysaccharidoses, GM2 gangliosidosis (Tay-Sachs disease) and infantile 
Pompe disease presenting overtly with developmental delay, neurological 
abnormalities and cardio-respiratory disease or more subtly with failure to thrive 
or musculoskeletal abnormalities. However a number of diseases such as 
Anderson Fabry Disease (AFD), Gaucher disease, the milder forms of MPS and 
adult onset Pompe may not become apparent until adolescence or adulthood. 
Presentation in adulthood is heterogenous such that many subjects will have 
seen multiple physicians of differing specialities before having an LSD diagnosis 
confirmed including cardiologists, neurologists, renal physicians, haematologists 
and dermatologists. As a result, diagnosis is often delayed and on occasion 
missed altogether. Given the recent significant advances in treatment in the form 
of enzyme replacement therapy (ERT) and specialist centre multidisciplinary care 
this could significantly impact on clinical outcome.  
The collective incidence of LSDs has been estimated at 1 in 8000 live births 
(8-10). The most common of these are the lipidoses, mainly sphingolipidoses, of 
which Anderson Fabry Disease and Gaucher disease have the highest prevalence.  
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Figure 1.0 Pathways and intermediates involved in lysosomal storage 
disorders with sphingolipids (black), deficient enzyme (red) and 
resulting disorder (blue)   
SAP = sphingolipid activator protein (diagram modified from Sandhoff et al (11)) 
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1.2 Anderson Fabry Disease (AFD) 
1.2.1 Defect 
Anderson Fabry Disease (AFD) (OMIM #301500) is an X-linked condition 
caused by mutations in the gene which encodes the enzyme -galactosidase A 
(GLA), resulting in an absolute or relative deficiency of this enzyme (12). This 
deficiency results in an accumulation of the glycosphingolipid 
globotriaosylceramide (Gb3) in plasma and in the lysosomes of cells (13-15) 
resulting in a multi-system disorder most detrimentally affecting the 
cardiovascular, renal and neurological system, but also affecting the skin, blood 
vessels and auditory systems and lungs.  
The nature of AFD as an X-linked disease results in disease manifestations 
that are more severe and occur earlier in males, though with further 
investigation it has been demonstrated that females are also significantly 
affected by the condition (16;17). Manifestations of the disease have been 
documented in childhood, largely comprising skin, gastrointestinal, neurological, 
auditory and ophthalmologic involvement (18). The clinical symptoms and signs 
worsen with age, with significant renal and cardiac involvement being major 
causes of morbidity and mortality of these patients in adulthood.  
1.2.2 Epidemiology 
The prevalence of AFD in the general population has been estimated to be 
1 in 117,000 in one Australian study (19) and 1 in 476,000 in another from the 
Netherlands (20), though it is thought likely that these underestimate true 
prevalence. Other studies have produced contrasting results such as that based 
on newborn screening in Italy where the condition was present at a frequency of 
1 in 3,100 males with mutations associated with later onset phenotypes (21). A 
similar study in Taiwan suggested 1 in 1,500 males were affected, also with later 
onset phenotypes, and a high frequency of a recognised splicing mutation (22). 
In part this finding may reflect some geographical variation but AFD occurs in all 
racial groups and is geographically widespread.   There is however a discrepancy 
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between the findings from newborn screening studies and the prevalence of 
diagnosed AFD patients in the general population, implying that not all subjects 
who have the disease will necessarily manifest significant clinical symptoms.  
1.2.3 Genetics 
Over 300 mutations of the GLA gene which is located on chromosome Xq22 
have been demonstrated. These include point mutations as well as deletions, 
substitutions, premature stop codons, missense and nonsense mutations. The 
majority of these have been shown to be private mutations (23;24). This, along 
with the large phenotypic differences evident between subjects with the same 
mutation, has made assessments of correlation between genotype and 
phenotype demanding (25). In addition the influence of modifiers on the 
penetration of symptoms leads to differences in disease manifestations and 
severity between individuals. 
However, it is likely that one of the factors influencing clinical presentation 
is the amount of residual enzyme activity associated with a mutation. This has 
been shown to affect the prevalence of neuropathic pain, the onset to significant 
renal disease (26), and to correlate with hearing loss (27). Broadly speaking AFD 
patients have been divided into those with a classic phenotype who have <1% 
residual enzyme activity, such as base deletions which are associated with little 
or no residual enzyme activity and produce more severe phenotypes (28), and 
those with variant phenotypes who have >1% residual enzyme activity and later 
onset disease.  Mis-sense mutations, such as N215S have been associated with 
higher levels of residual enzyme activity, and a later onset AFD phenotype (29). 
Whilst disease may be of later onset it is possible that over time ultimately the 
manifestations would be as severe as that of classic AFD. It has been suggested 
that mutations which result in a non-conservative amino acid chain have the 
lowest residual enzyme activity, and that the exon in which the mutation is 
present may be pertinent to this and therefore determine disease severity.  
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The phenomenon of X-inactivation also has a role in the heterogenous 
presentation of AFD phenotypes and severity in females (30). Historically it was 
thought that females were carriers of the disease with no clinical manifestations. 
Further investigation has shown this not to be the case, with evidence that some 
may be as severely affected as males (31;32).  
1.2.4 Diagnosis and screening 
 Once suspected, the diagnosis of Anderson Fabry Disease in males is 
confirmed by activity of α-galactosidase A enzyme in plasma, peripheral blood-
derived leucocytes, or in cultured fibroblasts, using either a fluorometric assay or 
tandem mass spectrometry. The fluorometric assay uses substrates such as 4-
methylumbelliferyl-α-D-galactopyranoside and measures enzyme activity by 
differences in the fluorescent properties of this substrate and its products of 
hydrolysis.  
In AFD females lyonisation results in potentially normal enzyme activity in 
both plasma and peripheral blood leucocytes despite subjects having clinical 
manifestations of the disease. It is therefore essential for all females, to undergo 
mutational analysis.  This is also advised in males to allow genetic counselling 
and may be used for rapid family screening. Genotyping is performed by 
polymerase chain reaction (PCR) sequencing. Genetic counselling is offered to all 
AFD patients who are considering starting a family.  
Further supporting evidence for the diagnosis of AFD may come from 
clinical features such as corneal verticillata and angiokeratomata though these 
are not condition-specific having been detected in patients receiving lysosomal 
toxic drugs such as chloroquine and amiodarone. In addition Gb3 may be 
quantified in both plasma and urine, where it has been shown to be significantly 
elevated in the majority of AFD patients (33). However it has been demonstrated 
that not all subjects have elevated Gb3 in the urine, with some subjects with the 
N251S mutation having been shown to have normal Gb3 levels in the urine (34). 
When the kidneys of such subjects have been examined histologically there has 
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been evidence of Gb3 deposition in podocytes, but not in other renal cell types 
or in the vascular endothelium (35). Demonstration of storage material on 
histological examination of biopsies from the kidney, skin or myocardium may 
provide conclusive evidence for AFD, though is clearly a more invasive way of 
making the diagnosis (36).  
 More recently there has been focus on non-invasive, quicker and more 
practical methods of diagnosing LSDs including AFD for the purposes of 
screening. Several studies have examined the utility of newborn screening using 
dried blood spots on filter paper with either fluorometric assays or tandem mass 
spectrometry (37-39). As enzyme activity may be normal in affected AFD 
females, this test is less sensitive in female neonates (40). 
The aim of newborn screening for any disease is to achieve earlier 
detection of the disease with a view to preventing the development of 
irreversible pathology. As a concept this is somewhat less straight forward in 
AFD, particularly with the detection of mutations that have been associated with 
later onset disease, as it calls into question whether these subjects would 
definitely develop significant morbidity in the future. The fact that such studies 
have demonstrated a much higher incidence of α-galactosidase A deficiency than 
the current estimated prevalence of the disease does suggest that a significant 
proportion of subjects may not ever manifest significant symptoms, especially 
females (41;42). In addition it has not been established as yet that treatments 
available such as enzyme replacement therapy would be effective in entirely 
preventing the sequelae of the disease if commenced prior to the clinical 
manifestations of the disease being evident.  
Screening for AFD in populations considered to be high risk may however 
be of benefit, such as those with renal failure, cardiomyopathy and strokes prior 
to the age of 55. There is a detectable yield, with one review suggesting the 
prevalence of AFD in males on dialysis to be 0.33%, and in subjects with left 
ventricular hypertrophy 1% (43). A recent European survey amongst subjects 
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with unexplained hypertrophic cardiomyopathy reported a prevalence of 0.5% 
AFD in this group (44). An  international multicentre study assessing the 
incidence of AFD in young stroke patients found that 0.5% of 18-55 year old 
subjects with stroke had a diagnosis of AFD and a further 0.4% were likely to 
have AFD though did not meet all of the diagnostic criteria (45). Screening using 
dried blood spot testing in such high risk populations has been performed, and 
suggests a similar prevalence (46-48), giving the advantage of examining samples 
on a much larger scale, with the additional ease of storage and transport of 
samples.  
1.2.5 Clinical Manifestations 
The combination of AFD’s relative rarity and its insidious nature results in 
average delays from onset of symptoms to correct diagnosis of 13.7 and 16.3 
years in males and females respectively (49). The spectrum of clinical symptoms 
and signs is similar in males and females, though the latter generally present 
with milder disease at an older age of onset and with slower progression (50).  
Findings from a UK-based survey demonstrated that the main causes of 
mortality amongst AFD subjects were renal failure, heart disease and stroke, with 
life expectancy of 50 years in males, and around 70 years in heterozygous 
females at a time prior to the introduction of enzyme replacement therapy (15).  
Data from the Fabry Registry reported in 2008 also showed significantly reduced 
life expectancy compared to the general US population at 58.2 and 75.4 years in 
males and females respectively - with the most common cause of death being 
cardiac disease (51), followed by renal and neurological disease. 
The main clinical manifestations of AFD are summarised in Table 1.2.5 
along with the common investigation findings and the findings from studies 
examining the histological changes present in the organs involved.  
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Table 1.2.5 Summary of clinical manifestations, investigation findings and histological changes in AFD
Organ system Clinical manifestations Investigation findings Histological findings 
Cardiac SOB, chest pain, reduced exercise 
tolerance; conduction abnormalities; 
sudden cardiac death (52); “cardiac 
variant” or atypical AFD (53;54)  
ECG abnormalities 
On echocardiography: concentric, non-
obstructive ventricular hypertrophy, 
changes in septal thickness (55); heart 
failure (56) 
Gb3 within cardiac myocytes and vascular smooth 
muscle and endothelial cells have 
abnormal coronary vascular flow (57);  myocardial 
fibrosis (58) 
Renal renal impairment; progressive renal 
failure requiring renal replacement 
therapy and transplantation(59-61)   
microalbuminuria ; proteinuria; reduced 
glomerular filtration rate  
widespread Gb3 in endothelial, parenchymal and  
epithelial cells (62); fibrosis, sclerosis, tubular 
atrophy (63;64) 
Neurological neuropathic pain, acroparaesthesia 
(65;66); transient ischaemic attacks; 
stroke (67); headaches, 
vertigo,dizziness and dementia (68;69) 
abnormal nerve conduction studies (70); 
periventricular white matter lesions on MRI 
brain (71;72); pulvinar sign (73) 
inclusions in peripheral nerves (74); widespread 
cerebral vasculopathy (75); cortical and brain stem 
lipid accumulation (76) 
Skin angiokeratomas in “bathing trunk” area 
and mucosa  
hypo/hyper/anhidrosis (77) 
abnormal quantitative sudomotor axon 
reflex and thermoregulatory sweat testing 
parameters (78) 
superficial angiomas (79) 
inclusions in sweat gland cells and axon of nerve 
(80)  
Gastrointestinal abdominal pain and bloating, nausea, 
vomiting, diarrhea on eating 
abdominal symptom scores  lipid deposition on duodenal, jejunal and rectal 
biopsy (81); depositon in muscularis mucosa and 
vasculature (82) 
Eyes and ears tinnitus; hearing loss corneal verticillata on slit lamp conjunctival 
and retinal vessel tortuosity on retinal 
imaging (83); high frequency sensorineural 
hearing loss(35) 
lipid deposition in subepithelial layer of cornea (84); 
cochlea Gb3 in AFD mice (85) 
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1.2.6 Initial investigation, follow up and monitoring 
At diagnosis a full and comprehensive assessment of all aspects of AFD is 
made and documented as a baseline, prior to the commencement of any 
treatments. This includes a full medical history and clinical examination, along 
with a family pedigree. Patients are asked to complete questionnaires to assess 
pain scores and quality of life. Further investigations into underlying organ 
involvement are undertaken. As summarised in Table 1.2.6. Patients are followed 
up at six-monthly intervals, with clinical assessment and examination, and 
investigations assessing disease progression and effectiveness of therapy. Those 
who are on ERT require annual measurement of renal and cardiac investigations, 
with repeat blood tests at six monthly intervals. Magnetic resonance imaging 
(MRI) brain scans are performed every 2 years, unless clinical indications suggest 
otherwise.  
Table 1.2.6 Summary of initial investigations on diagnosis of AFD 
Blood and 
urine  
Eyes and ear  Renal  Cardiac  Neurology  
- full blood 
count 
- urea & 
electrolytes  
- Liver function  
- Fasting Lipid 
profile 
- Plasma and 
urine Gb3 
- urine albumin/ 
creatinine 
-Slit-lamp 
examination  
-retro-
illumination 
-retinal 
examination 
and 
photography 
- pure tone 
audiogram 
- Glomerular 
Filtration Rate 
by Cr51 EDTA  
- 24 hour 
urine 
Creatinine 
Clearance if 
this is not 
available 
- 24 hour 
urine protein  
- renal biopsy  
- ECG 
- 24 hour ECG 
  - echocardiogram 
- exercise testing  
- MRI brain  
- QSART 
assessment 
of sweating  
- EMG  
 
QSART – quantitative sudomotor axon reflex and thermoregulatory testing 
EMG – electromyelography
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1.2.7 Treatment 
1.2.7.1 Supportive  
The clinical manifestations of AFD are managed with attention to symptom 
control, lifestyle advice, risk factor control and regular assessments of organ 
involvement. Patients are seen regularly by an appropriate specialist according to 
their pattern of organ involvement. Since the introduction of newer therapies, 
patients must be treated in specialist centres by a multidisciplinary team, who 
co-ordinate their care with the involvement of the appropriate specialist 
services. 
1.2.7.2 Enzyme Replacement Therapy (ERT) 
Following the example of successful therapy for Gaucher disease, enzyme 
replacement therapy for AFD was developed and subsequently introduced in 
2001 following double blind placebo controlled clinical trials (86;87). In Europe, 
two such products are in regular use. These are agalsidase alfa (Replagal®, Shire 
Pharmaceuticals, UK) produced using a human fibroblast cell line, and 
administered at a dose of 0.2mg/kg intravenously fortnightly, and agalsidase 
beta (Fabrazyme®, Genzyme Corporation, UK) produced using a Chinese hamster 
ovary cell line, and administered at a dose of 1mg/kg intravenously fortnightly.  
 There has been much interest in the efficacy of both enzyme preparations 
which have now been in use for over 10 years. Both the products are licensed for 
clinical use in AFD in Europe and the UK, and Fabrazyme® in the US. As is shown 
in Table 1.2.7.3 there have been numerous studies demonstrating good clinical 
outcomes in the different organs affected by AFD. This includes data from the 
original double blind placebo controlled clinical trials (original trials marked with 
*). However there have also been meta-analyses and systematic reviews of the 
Cochrane database of randomised controlled clinical trials in this area – and 
these do not indicate there to be robust evidence for efficacy with either product 
(88;89). The difference between the Cochrane review and the separate trials is 
likely due to the limited numbers of subjects in the trials, the heterogeneity of 
the condition and the differences in the end points between individual studies. 
Chapter 1 - Introduction 
30 
 
Data from the Fabry Outcome Survey (FOS) and the Fabry Registry have been 
much more compelling with regards to the efficacy of ERT. They have the 
advantage of data that arises from larger numbers of subjects followed up over 
longer periods of time (90).  
The two preparations of the enzyme have been shown to have similar 
biochemical properties and their activity per milligram, with only minor 
differences in glycosylation (91;92). The difference in dose between the two 
preparations has been the subject of much discussion. Whilst both preparations 
improve clearance of Gb3 from the plasma as well as renal and cardiac cells, data 
from randomised controlled clinical trials and open label extension studies 
suggest that algalsidase-β (Fabrazyme®) is of greater efficacy due to its use at a 
higher dosing regimen of 1mg/kg fornightly (93). ERT literature reviews which 
include more studies with broader criteria and greater heterogeneity in outcome 
measures show more similar efficacy between the two preparations (94;95).   
The demonstration of α-galactosidse A antibodies with both preparations 
of the enzymes has generated interest in the immunogenicity of the 
preparations. In one study 56% of males on algalsidase-α were shown to have 
antibodies (96); and 88% of males on agalsidase-β in another (97). Adverse 
events such as fever and chills appear to be more common in such individuals. 
There appeared to be no difference in the proportion of subjects developing 
antibodes when agalsidase-α and agalsidase β were given at the same dose of 
0.2mg/kg fortnightly (98). However, subjects receiving the recommended dose of 
algasidase-β at 1mg/kg fortnightly were much more likely to develop antibodies.  
It has been proposed that the presence of antibodies may affect clinical 
efficacy of the enzyme replacement therapy. The higher dose of agalsidase-β 
appears to overcome the effect of neutralising antibodies by significantly 
reducing urinary Gb3 - implying that in antibody positive subjects higher doses of 
enzyme may be beneficial (99). There is also some evidence to suggest that the 
presence of agalsidase-β antibodies reduces clearance of tissue substrate in mice 
and cultured fibroblasts (100). Overall, however, clinical impact of antibodies 
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requires further work, as studies to date have used different methodologies, 
which complicates the interpretation of their findings (101). 
Criteria for the commencement of ERT have been set out based on clinical 
measures of disease severity as summarised in Table 1.2.7.2. On the basis of 
initial investigations, validated severity scores including the Mainz Severity Score 
Index (MSSI) (102) and an age adjusted severity score (103) are calculated, which 
can then be used to follow the effect of treatment.  
Table 1.2.7.2 Clinical indications for the commencement of enzyme 
replacement therapy in AFD 
General and 
GI symptoms 
Renal disease Cardiac disease 
Neurovascular 
disease 
Abdominal 
pain, vomiting, 
altered bowel 
habit causing 
significant 
impact on 
quality of life 
GFR <80 
Proteinuria 
>300mgs/24 hrs 
Microalbuimnuria 
with renal biopsy 
evidence of 
endothelial 
deposits 
ECG: 
Left ventricular 
hypertrophy 
or 
Isolated repolarisation 
abnormalities 
or 
Conduction 
abnormalities 
Stroke/TIA in the 
absence of other 
risk factors 
Abnormal MRI 
scans with 
progressive change 
Uncontrolled 
pain 
 
Echocardiography: 
Increased left ventricular 
mass    
 
  
Arrhythmia on 24 hr 
ECG 
 
  Ischaemia in the 
absence of coronary 
artery disease  
 
TIA – transient ischaemic attack 
GFR – glomerular filtration rate 
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Table 1.2.7.3 Summary of clinical manifestation of AFD shown to improve with enzyme replacement 
therapy
Clinical 
manifestation  
Demonstrated benefit of ERT  Enzyme 
preparation 
Duration Study  
Acroparaesthesia Improved Brief Pain Inventory Scores 
Improve C-, A-delta and A-beta nerve fibre function 
Replagal® 
Fabrazyme® 
3 years 
18 months 
Schiffman et al 2003* 
Hilz et al 2004 
Hypo/anhydrosis Improvement in quantitative sudomotor axon reflex and 
thermoregulatory sweat testing parameters 
Replagal® 
 
3 years Schiffman et al 2003 
 
Hearing loss Improvement in sensorineural hearing loss from baseline 
testing  
Replagal® 12 months Hajioff et al 2007 
Abdominal pain Improvement in visual analogue score assisted 
assessments in paediatric subjects 
Fabrazyme® 1 – 8 years Bogwardt et al 2012 
Renal 
involvement 
Increased creatinine clearance, reduced urinary Gb3, 
improved clearance of Gb3 on renal biopsy, reduced rate of 
decline in GFR  
Clearance of Gb3 on renal biopsy 
Stabilisation of serum creatinine, eGFR and clearance of 
Gb3 from renal cells on biopsy 
Replagal® 
 
 
Fabrazyme® 
Fabrazyme® 
12 weeks 
 
 
20 weeks 
54 months 
Schiffman et al 2001* 
 
 
Eng et al 2001* 
Germain et al 2007 
Cardiac 
involvement 
Reduced QRS complex duration 
Reduction in LV mass on MRI and Gb3 deposition on 
endomyocardial biopsy 
Reduction on LV mass on echocardiography 
Sustained reductions in LV mass and midwall shortening  
Replagal® 
Replagal® 
 
Fabrazyme® 
Replagal® 
12 weeks 
6 months 
 
12 months 
5 years 
Schiffman et al 2001* 
Hughes et al 2008 
 
Spinelli et al 2004 
Mehta et al 2009 
Neurological 
Involvement  
Possible improvement in cerebral blood flow Replagal® 6 months Moore et al 2002 
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1.2.8 Pathophysiology  
The underlying pathological processes that result in the changes seen in 
different organs in AFD remain unclear. It is likely that factors beyond the effect 
of substrate accumulation contribute to end-organ damage. A disease model was 
described by Wanner  et al (104) involving three overlapping stages in a cascade, 
starting with Gb3 storage in the cells as the initial event. Over time this results in 
tissue damage due to ischaemia, inflammation, hypertrophy and fibrosis, 
ultimately leading to the third stage of gross organ damage and dysfunction.  
Supporting evidence for this comes from autopsy findings of AFD patients 
with significant cardiac involvement, who had received ERT, though late in their 
disease (105). Pathological examination of three cases with cardiac changes 
revealed that whilst cytoplasmic inclusion bodies were present, the extent of 
cardiac muscle thickening could not be accounted for by Gb3 deposition alone. 
Cardiac myocytes throughout the heart were hypertrophied and extensively 
vacuolated. There was evidence of focal myocyte apoptosis and necrosis with an 
associated accumulation of macrophages and a T cell infiltrate. In addition, there 
was significant myocyte disarray and extensive areas of fibrosis. The trigger for 
apoptosis under these conditions is not clear, but this may be key in 
understanding the changes seen in AFD.  
Whilst numerous studies have shown that ERT reduces plasma, urinary and 
tissue Gb3 (106), it has been shown that Gb3 does not appear to correlate well 
with disease severity, and therefore cannot be used as a biomarker for the 
disease (107;108). Factors such as deacylated Gb3, globotriosylsphingosine (lyso-
Gb3) have been proposed as having a causative role in the pathogenesis of AFD. 
This is because significantly elevated levels of lyso-Gb3 are present in AFD 
plasma,  and its presence results in smooth muscle proliferation and the 
production of factors that lead to kidney injury (109;110).  Levels of lyso-Gb3 
have also been shown to fall with ERT, though not to normalise entirely (111).  
AFD-associated vasculopathy appears to be key to the pathogenesis of the 
organ dysfunction seen in AFD, with widespread vascular changes seen in the 
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vessels of the brain, kidneys and heart (112), these being the major sites involved 
in morbidity and mortality (113-115). Although changes in the vessels involve 
both the vascular endothelium and the smooth muscle layers, it has been 
suggested that Gb3 deposition in the smooth muscle layer is of more clinical 
significance (116). It has also been shown that the use of ERT leads to clearance 
of substrate more readily from the vascular endothelial cells than the smooth 
muscle cells (117).  
Changes in the vascular smooth muscle affect arterial structure and 
function, with measurable increases of intima-medial thickness (118). This does 
not appear to result in much atherosclerosis, though may cause arterial stenosis 
(119). Evidence from studies assessing the effect of AFD subjects’ plasma on rat 
vascular smooth muscle cells suggests that hypertrophy of the smooth muscle 
cells occurs as a result of circulating growth factors (120). This may include 
factors such as sphinogosine-1-phosphate  as well as lyso-Gb3 (121;122) . It has 
been proposed that this smooth muscle hypertrophy and increase in intima-
media thickness is then responsible for triggering an inflammatory cascade 
through upregulation of angiotensin II, resulting in a pro-inflammatory state with 
increased local cytokines and chemokines such as vascular endothelial growth 
factor (VEGF) (123;124). 
Oxidative stress may be relevant as the presence of Gb3 in the vascular 
endothelium increases the production of reactive oxygen species and adhesion 
molecules (125). Lower concentrations of antioxidants and higher levels of the 
pro-inflammatory cytokines interleukin-6 (IL-6) and tumour necrosis factor-α 
(TNF-α) have been demonstrated in AFD subjects compared to controls (126). 
This adds further support to the concept of an inflammatory component being 
present. Safyan et al demonstrated a predilection for certain TNF-α and IL-10 
gene polymorphisms in patients with AFD when compared to controls, though 
could not show an association between cytokine and enzyme levels (127). 
Equally, markers of inflammation such as C-reactive protein are not elevated in 
individuals with AFD, either (128).  
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Apoptosis could  be an additional contributing factor to the changes in AFD, 
with sphingolipids having been shown to have a role in apoptosis in the heart 
(129).  There have also been studies demonstrating higher levels of apoptotic 
markers in peripheral blood mononuclear cells, correlating with Gb3 
concentrations in AFD patients, and of cell death when normal cells were treated 
with similar concentrations of Gb3 to that seen in patients (130).  
It has been postulated that differences in cell populations in the peripheral 
blood of AFD patients may contribute to the reported pro-inflammatory state. In 
the context of lipid antigen there has been some research focussed on iNKT cells 
and the pathophysiology of AFD. Gadola et al examined mouse models of 
lysosomal storage disorders and found reduced numbers of iNKT cells and iNKT 
cell-mediated lysis of antigen presenting cells carrying lipid antigen (131). They 
observed reduced numbers of iNKT cells in all stages of thymic development, and 
that the effects on thymic selection of iNKT cells resulted in the reduced 
presentation and processing of lipid antigen in mouse models of LSDs. This idea 
was also supported by work from Schuman et al (132) who demonstrated that 
lipid accumulation resulted in impaired lipid antigen presentation and processing 
in β-galactosidase and Niemann Pick C protein deficient mice. It was also 
suggested that the iNKT cells present may not be fully functional, given that it 
was not possible to detect the predicted cytokine response (133). 
Further studies in this area have demonstrated changes in T cell 
populations as well as NKT cells, where reduced numbers of CD4+ T cells and 
increased numbers of CD8+ T cells result in a two-fold reduction in the 
CD4+/CD8+ ratio  in the liver of Fabry mice compared to controls (134).  A similar 
imbalance of T cells was evident in the spleen of the mice, though less marked. In 
the same study, no such difference was present in the peripheral blood of AFD 
patients.  
However, elsewhere AFD patients’ peripheral blood contained a higher 
percentage of lymphocytes than controls (135). And whilst no difference was 
seen in CD4+ T cell and NKT cell numbers, the proportion of CD8+ T cells was 
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lower in AFD subjects naïve to ERT compared to those on ERT and controls; plus 
the percentage of B cells, monocytes and dendritic cells were higher in AFD 
subjects compared to controls.   
A more recent study in both AFD mice and AFD subjects showed a 
reduction in percentages of CD4+ iNKT cells and a corresponding reduction in 
anti-inflammatory cytokine IL-4, and percentage  increases in dendritic iNKT cells 
(136), further suggesting a pro-inflammatory state in AFD. This study also 
observed a reduction in CD8+ iNKT cells in the first month after the 
commencement of ERT, implying that iNKT cells may have a role in the 
pathophysiology of AFD.  
1.3 Rationale for a pulmonary study in AFD  
1.3.1 Existing evidence  
Lung involvement by AFD was initially regarded as non-existent. Bartimmo 
et al in 1972 (137) reported that AFD had little or no impact on the lung, and that 
any changes seen were likely to be secondary to other factors such as smoking or 
the cardiac components of AFD. However, Kariman et al in 1978 (138) 
documented a 32 year old male presenting with AFD and significant airway 
obstruction and bullous disease out of keeping with his smoking history, and with 
no evidence of another cause for his respiratory morbidity.  
Further evidence for lung involvement was subsequently presented by 
Rosenberg et al (139) who in 1980 reported significant chronic airflow 
obstruction in 7 AFD subjects and demonstrated the presence of inclusion bodies 
in bronchial brushings and biopsy samples of airway epithelium. In addition the 
possibility was raised that smoking might worsen the severity of the airflow 
limitation in AFD. 
Sometime after this in 1997, Brown et al undertook a larger study on lung 
involvement in AFD (140). They examined 25 male subjects, 72% of whom had 
never smoked, and found 36% had obstructive spirometry, all of them aged 26 or 
over. They also noted only a weak association between smoking and worsening 
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of airflow, with a similar frequency of reported symptoms (24%) including 
shortness of breath, cough and wheeze in smoking and non-smoking subjects. A 
number of the obstructed subjects demonstrated a degree of apparent 
reversibility to bronchodilators though on methacholine challenge testing, no 
positive responses were found. Radio-nuclide scanning was also performed on 18 
of the subjects, and no abnormalities demonstrated. Overall the findings of this 
study were highly suggestive of an effect of AFD on the lungs, restricted to the 
airways and not directly related to smoking. 
The largest study to date on the lung in AFD provides further evidence of 
airway obstruction. Here, Magage et al (141) examined 50 AFD subjects, 39 of 
whom were naïve to enzyme replacement  therapy (ERT). This study found 
mostly mild to moderate airway obstruction was present in men (assessed by all 
spirometric parameters compared to controls), which progressed with age. In 
women with AFD, significant reductions in FEV₁ and FEF25-75 were evident 
compared to controls. Small airway obstruction, as measured by FEF25-75, was 
widespread in both sexes and all age groups. This parameter was also shown to 
progress in women over a median duration of 24 months.  
Further supporting evidence for lung involvement in AFD has come from 
two separate case reports of individual female AFD subjects presenting with 
primarily pulmonary symptoms and signs and significant dyspnoea and hypoxia 
(142;143). In both cases the subjects demonstrated lung function abnormalities 
with obstructive and restrictive components and a significantly reduced diffusion 
capacity. Computerised tomography (CT) scanning demonstrated pulmonary 
infiltrates and air trapping, suggestive of both parenchymal lung involvement 
and small airways disease. In one case there was also evidence of significant 
pulmonary hypertension on CT and echocardiography, though no evidence of 
thromboembolic disease. In the other subject, an open lung biopsy revealed 
peribronchial and peribronchiolar fibrosis, with the demonstration of lamellar 
inclusion bodies, indicative of Gb3 deposition, within lung smooth muscle cells 
and vascular endothelium. In both of these cases there was a marked 
improvement in pulmonary symptoms and signs, as well as pulmonary function 
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tests and radiological appearance, on commencing enzyme replacement therapy. 
This was sustained for up to 2 years in one case.  
Whilst it is difficult to draw any firm conclusions from such cases, they 
suggest that enzyme replacement therapy may positively influence pulmonary 
dysfunction in AFD.  However the effect of ERT on lung changes in AFD requires 
further exploration, given that previous studies have largely involved enzyme 
naïve subjects (144). It is noteworthy that in both case reports the subjects were 
female. However due to the small numbers, possible gender differences in AFD 
lung involvement remains an area that requires further investigation.  
Given the high frequency and severity of cardiac involvement in AFD, 
symptoms such as shortness of breath and reduced exercise tolerance are likely 
to be attributed to cardiovascular dysfunction. However, it is possible that these 
symptoms may reflect respiratory involvement. One cardiac study in AFD 
patients that included cardiopulmonary exercise testing also reported a high 
incidence of respiratory symptoms, obstructive spirometry and two patients with 
abnormalities on CT (145), though overall it was judged that the reporting of 
pulmonary symptoms correlated best with the degree of left ventricular 
dysfunction. Elsewhere, cardiopulmonary exercise testing parameters in AFD 
subjects were reported to improve with enzyme replacement therapy (146). 
Here too it was proposed that the cardiovascular, as opposed to pulmonary, 
changes in AFD were the main contributor to reduced exercise tolerance in AFD. 
1.3.2 Other relevant factors   
1.3.2.1 α-galactosidase A activity 
The exact nature of the underlying changes in the lung in AFD is unclear. 
Whilst α-galactosidase A activity is most often measured in plasma and from 
peripheral blood leucocytes, it can also be detected in cultured fibroblasts, tissue 
homogenate and tears (147;148). However, little is known about α-galactosidase 
A activity in the lungs, as thus far this has not been quantified. Hence the 
relationship between enzyme activity in blood and lung is unknown. Given the 
phenotypic variations in AFD presentation that occur with differing levels of 
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residual enzyme activity, this may be relevant when exploring the possible 
mechanisms by which lung involvement occurs and the extent to which the lungs 
are affected.  
1.3.2.2 Airways disease 
 The finding of airway obstruction in reported pulmonary studies in AFD 
suggests that patients with similar airway dysfunction may be a useful reference 
population with which to compare AFD patients. The two commonest 
obstructive airway conditions are asthma and chronic obstructive pulmonary 
disease (COPD). Asthma is characterised by symptoms of wheeze, cough and 
chest tightness. These are features of airway hyper-reactivity, reversibility to 
bronchodilators and largely eosinophilic inflammation, which may be associated 
with atopy (149). It has been predominantly thought to be a large airways 
disease though there is evidence to suggest the small airways may also be 
involved (150). Chronic inflammation results in structural changes including the 
hyperplasia of mucous secreting cells and increases in airway smooth muscle 
cells and airway remodelling (151).   
The definition of COPD in the recently updated and published GOLD Report 
2013 includes the description of “…persistent airflow limitation, which is usually 
progressive and associated with an enhanced chronic inflammatory response in 
the airways and the lungs to noxious particles or gases…” (152). It has been 
shown to occur as a result of chronic inflammation, with a resultant fixed 
narrowing of the small airways and increased levels of inflammatory mediators 
including cytokines, growth factors and chemokines, and increased numbers of 
cytotoxic T cells, neutrophils and macrophages (153). COPD affecting the more 
peripheral airways in an irreversible manner is more in keeping with what is 
already known with regards to the nature of the lung changes in AFD. 
The relatively fixed airway obstruction reported in AFD suggests that COPD 
may be a helpful model with which to compare the AFD lung. Also, as the impact 
of smoking in previous AFD studies is conflicting, examination of COPD subjects 
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might also help to clarify whether changes seen in AFD are similar or distinct 
from those found in COPD, which largely arises as a consequence of smoking.  
1.3.2.3 The lungs in other LSDs 
The lungs have been shown to be involved in other lysosomal storage 
diseases to different extents and through different mechanisms, though data in 
this area are very limited. Lung involvement is uncommon in Gaucher disease, 
and tends to be present in severely affected patients, in whom the outcome is 
particularly poor. It manifests as interstitial pulmonary infiltrates which can 
improve on ERT (154). In a recent bronchoalveolar lavage study, lipid laden 
macrophages were seen, and lung biopsy revealed foamy histiocytes in the 
alveolar spaces and interstitium, though no fibrosis  (155). In some cases of 
Gaucher disease pulmonary hypertension and hepato-pulmonary syndrome can 
occur as complications of type I Gaucher disease (156). 
In the Mucopolysaccharidoses lung involvement when present tends to 
occur as a result of glycosaminoglycan deposition in the soft tissues upper and 
lower airway resulting in airway obstruction, recurrent respiratory tract 
infections, and in some cases restrictive lung disease secondary to skeletal 
abnormalities (157). In glycogen storage disease type II, Pompe disease, 
progressive respiratory muscle weakness results in ventilatory failure that leads 
to significant morbidity and mortality (158).  
Overall there is little known about the effect of LSDs on the lungs. Limited 
data suggest that other LSDs do not have similar pulmonary findings to those 
reported to occur in AFD.  
1.3.2.4 Induced sputum 
Induced sputum sampling is increasingly used as both a clinical and 
research tool in many different forms of pulmonary disease. This includes COPD 
(159-161), asthma (162) and pulmonary tuberculosis (163). In 2002 a European 
Respiratory Society Working Group reviewed studies on induced sputum 
sampling and reported on safety and methodology with a view to 
standardisation of induced sputum sampling (164;165). It has the advantage of 
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being non-invasive, well tolerated, quick and relatively simple to perform when 
compared to other methods of obtaining lung derived samples, such as 
bronchoscopy. It is however recognised that cell profiles obtained by induced 
sputum sampling are not the same as those from broncho-alveolar lavage (166). 
It is likely that the origin of induced sputum samples is from larger airways, and 
more in keeping with that seen in bronchial washings.  
Case reports in AFD have shown evidence of change at a cellular level 
through demonstration of storage material in induced sputum from an AFD 
subject (167). It is therefore possible that induced sputum may be a useful and 
non-invasive means of evaluating changes in the lung related to AFD, such as α-
galactosidase A activity, cytokine concentrations and for determining cell 
populations that may be of relevance in our understanding of lung involvement 
of AFD.  
1.3.2.5 Flow cytometry 
Examination of the cellularity of lung-derived samples and determining  
differential cell counts has largely been performed by the preparation of 
cytospins and cell counting with light microscopy (168;169). However, more 
recently flow cytometry has been used to delineate cell populations in samples 
such as resected lung parenchyma and bronchial biopsies in COPD where in 
particular CD8+ T cell populations have been identified (170;171). Subsequent 
studies have compared samples from COPD subjects obtained by BAL, bronchial 
washes and induced sputum using flow cytometry (172).  Here differences 
between the sample methods are predominantly due to changes in neutrophils, 
with the greatest proportion being present in induced sputum.  
In interstitial lung diseases, flow cytometry of bronchoalveolar lavage 
samples reveals increased CD4+/CD8+ T cell ratios. This can be used as an aid to 
diagnose pulmonary sarcoidosis (173). It has subsequently been shown to also 
apply to induced sputum sampling (174). The diagnostic value of induced sputum 
flow cytometry has been demonstrated for active pulmonary tuberculosis using 
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recognition of CD4+ T cells specific to Purified Protein Derivative of 
Mycobacterium tuberculosis (175). 
1.2.3.6 Other considerations  
It is not particularly surprising that there are only a limited number of 
studies investigating the lungs, as the main causes of significant disease in AFD 
result from renal, cardiac and neurological damage. However with the advent of 
enzyme replacement therapy offering the possibility of improved outcomes and 
an altered disease natural history (including greater longevity for AFD patients 
who are now at risk of non AFD age-related diseases), it is an opportune time to 
investigate the lung.  
Support for this argument comes from HIV medicine, where the significant 
advances in treatment and improvements in outcome have enabled there to be 
more focus on longer term conditions, such as bone disease, nephropathy 
(176;177) and smoking-related conditions, of importance in a surviving, ageing 
population. Whilst treatment of AFD is not as effective as that for HIV infection, 
better AFD therapies will result in longer survival and hence a greater risk of lung 
related disease.  
In the context of AFD one could also propose that further pulmonary 
investigation is warranted on the basis that for a multisystem disease which 
causes life threatening morbidity in other organ systems, the lungs appear 
“protected”. Hence there may be additional value in understanding the impact of 
AFD on the lungs as this may provide insights on the mechanisms of protection, 
and how pulmonary changes relate to overall disease severity.  
1.4 Study Hypothesis, Aims and Objectives  
Our aim was to examine the respiratory system of a cohort of AFD subjects 
with carefully documented disease under the care of the Royal Free Hospital. 
Such a cohort could be comprehensively investigated and consistently sampled 
in ways not previously performed. This could be undertaken both longitudinally 
and also by cross sectional analysis. We aimed to examine the pulmonary 
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changes in AFD through clinical, physiological, radiological and pathological 
assessments.  
Our overriding hypotheses were that AFD does involve the lung 
significantly though perhaps not severely, and that changes would be 
demonstrable on lung function testing, imaging and from sampling the lungs by 
induced sputum. We hypothesised that this would show similar changes to those 
seen in the other organs involved in AFD with α-galactosidase A activity lower 
than in controls, and that we would find differences in the sputum cell 
populations in AFD subjects, particulary lymphocytes, and that these may be 
similar to the changes seen in COPD.  
The hypotheses tested in each section of the study are summarised as 
follows:  
1.4.1 Lung function and imaging 
Hypotheses 
 The degree of pulmonary involvement in AFD  
 is related to  
o Gender 
o Age  
o Overall disease severity 
 Is progressive over time and not influenced by ERT 
 Is demonstrable on CT scanning 
 Is worsened by smoking 
Additional aims and objectives   
1. To establish the extent and severity of airway obstruction and changes in 
diffusion capacity in the AFD population  
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2. To examine the differences in spirometry and diffusion capacity between 
genders in AFD compared to sex matched controls  
3. To determine changes in spirometry and diffusion capacity over time in AFD  
4. To determine the impact on the airways of smoking in AFD subjects  
5. To examine the severity of lung involvement in AFD as measured by 
spirometry and diffusion capacity in relation to the duration of enzyme 
replacement therapy (ERT) 
6. To examine the relationship between lung involvement in AFD and overall 
disease severity and genotype 
7. To document pulmonary imaging findings in AFD using frontal chest 
radiographs and high resolution CT scanning 
1.4.2 Pulmonary α-galactosidase A activity 
Hypotheses 
α-galactosidase A activity: 
 is measurable in induced sputum  
 is lower in AFD subjects than in controls in sputum 
 is lower in AFD males than AFD females  
 is consistently related between blood and induced sputum 
 is lower in the induced sputum of AFD subjects with pulmonary  
involvement 
 is higher in AFD subjects on enzyme replacement therapy (ERT)  
Additional aims and objectives 
1. To establish a normal reference range for α-galactosidase A activity in 
induced sputum  
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2. To compare α-galactosidase A activity in the induced sputum of AFD 
subjects and controls 
3. To compare α-galactosidase A activity in the induced sputum of AFD males 
and females 
4. To delineate a relationship between peripheral blood and lung derived α-
galactosidase A enzyme 
5. To examine the effect of enzyme replacement therapy on α-galactosidase A 
activity in induced sputum  
6. To examine the relationship between induced sputum α-galactosidase A 
enzyme activity and lung involvement in AFD 
 
1.4.3 Induced sputum cell populations  
Hypotheses 
Induced sputum cell populations in AFD subjects with pulmonary 
involvement compared to those without would have:  
 a greater proportion of CD8+ T cells than in AFD subjects  
 a higher proportion of neutrophils than that of AFD subjects without 
airway obstruction 
 a higher concentration of pro-inflammatory cytokines IL-8 and IL-6  
Additional aims and objectives 
1. To delineate the cell populations present in the induced sputum of AFD 
subjects  
2. To compare cell populations in the induced sputum of AFD subjects to 
COPD and healthy control subjects 
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2. To compare the cell populations present in the induced sputum of AFD 
subjects with airway obstruction and those without  
3. To examine the inflammatory processes in the lung in AFD by examining 
cytokine profiles 
4. To examine the impact of smoking on inflammatory cytokines in induced 
sputum in AFD  
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2.1 Ethics   
The study was performed at the Royal Free Hospital, London, and all 
patient assessments and investigations performed on site. The study was 
approved and sponsored by the Royal Free Hospital Research and Development 
Department, and was ethically approved by the Local Research and Ethics 
Committee. 
All patient data were stored securely within a password protected system, 
under individual study numbers assigned at the time of recruitment. All potential 
study subjects were sent written information regarding the study in the form of 
the Patient Information Sheet (Appendix 1, Sections 1.0-3.0) relevant to the 
appropriate arm of the study for them, and contacted by telephone to answer 
any questions raised by the written study information. 
2.2 Recruitment and Clinical Assessments  
2.2.1 Anderson Fabry Disease (AFD) subjects  
Subjects were recruited from the clinical cohort of Anderson Fabry Disease 
patients under the care of the Lysosomal Storage Disorders Unit at the Royal 
Free Hospital, London. If willing to participate, arrangements were made for the 
study investigations to be performed on the day of their next clinic attendance, 
and at subsequent follow up appointments over the following 12 months.  
All AFD subjects were under the care of the Lysosomal Storage Disorders 
Unit at the Royal Free Hospital, a National Specialist Commissioning Advisory 
Group (NSCAG) designated centre for the diagnosis and management of 
lysosomal storage disorders.  Their attendance for study participation was timed 
to coincide with their scheduled medical appointment, in order to minimise any 
inconvenience or additional expense given that many subjects live some distance 
away from the hospital. Study data collection and investigations were performed 
alongside their routine clinical care.  
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2.2.1.1 Diagnosis 
All patients recruited to the AFD arm of the study had a confirmed 
diagnosis of Anderson Fabry disease by plasma enzyme activity and DNA 
mutational analysis, with the majority of these performed by the Molecular 
Diagnostic Laboratory at the Royal Free Hospital. If carried out elsewhere the 
mutation was confirmed by obtaining source data. In addition over half the 
subjects also had blood leucocyte enzyme activity from the time of diagnosis. 
2.2.1.2 Medical Assessment  
In general, AFD patients attend the Lysosomal Storage Disorders Unit for a 
clinical review on a six-monthly basis. This involves an assessment by a physician, 
with the completion of a clinical assessment proforma (Appendix 1, Section 8.0). 
A full set of observations is recorded at each visit, including blood pressure, pulse 
rate, oxygen saturations, temperature and weight. In addition a full clinical 
examination of the cardiovascular, respiratory, abdominal, neurological and 
musculoskeletal systems undertaken and documented. AFD patients also 
regularly undergo investigations for evidence of disease progression in the 
different organ systems affected. These include the following:  
 Blood tests (every six monthly) 
o Full blood count, clotting screen, iron studies  
o Bone profile, liver function tests 
o Glucose, lipid profile  
o Immunoglobulin levels 
 Renal assessments (every six months)  
o Blood test for urea, electrolytes, creatinine 
o Cr-51 EDTA GFR performed by the Nuclear Medicine Department  
o 24 hour urinary protein collection performed by Biochemistry 
Department  
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o Spot urine for albumin/creatinine ratio performed by Biochemistry 
Department  
 Cardiac assessments (six-monthly to annually) 
o Clinical review at the Heart Hospital, Westmoreland Street, 
London, by Dr. Perry Elliot (Consultant Cardiologist) and team  
o echocardiogram performed by Echocardiography Department at 
the Heart Hospital, with attention to left ventricular mass and 
septal wall thickness and other changes related to AFD 
o Cardiopulmonary Exercise Testing as indicated  
o ECG and 24 hour tape as indicated  
 Ophthalmology  (six monthly)  
o clinical review by Dr. Pauline Wilson (Consultant Ophthalmologist, 
Royal Free Hospital, London) 
o slit lamp examination  
o retinal photography 
 Dermatology (six monthly) 
o clinical review by Dr. Cate Orteu (Consultant Dermatologist, Royal 
Free Hospital, London) 
 Audiology (six monthly) 
o Pure tone audiograms performed by the Royal Free Hospital 
Audiology Department 
 Neurology (annually)  
o T2 weighted MRI scanning of brain performed by Radiology, MRI 
Department at Royal Free Hospital, with specialist neuroradiology 
reporting (two yearly) 
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o Clinical review by Professor Lionel Ginsberg (Consultant 
Neurologist, Royal Free Hospital, London) and team as indicated  
 
2.2.1.3 Additional Study Information 
For the purpose of the study, additional information was collected 
specifically related to the respiratory system and enzyme replacement therapy 
for each individual study subject. This included the following: 
 Smoking History 
o tobacco/pack years 
o recreational drugs 
 Drug History 
o bronchodilator use  
o frequency         
o use of beta blockers    
 Enzyme Replacement Therapy (ERT)  
o duration     
o dose 
o date of last infusion 
 Family History of respiratory disease 
 Social History 
 Employment History 
o asbestos exposure   
o dust/chemical exposure   
Chapter 2 – Methods  
52 
 
 Plasma enzyme activity at diagnosis  
 Leukocyte enzyme activity at diagnosis 
 
2.2.1.4 Severity Scores 
Mainz Severity Score Index (MSSI) 
Using the clinical information and investigation results gained from these 
reviews at the time of the first study visit, the Mainz Severity Score Index, a 
validated tool for assessment of the severity and monitoring of treatment 
response in AFD, was calculated for each AFD subject recruited at the start of the 
study (178). An overview of the clinical features considered in the calculation of 
the MSSI is given in Table 1.0.  
Age Adjusted Severity Score  
In addition, the age adjusted severity score based on the adapted Fabry 
Outcome Survey (FOS) MSSI was also calculated using the clinical information 
gathered at the first study visit (179) 
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Table 2.0 Clinical features taken into consideration for calculation of 
Mainz Severity Score Index in AFD 
 
2.2.2 Chronic Obstructive Pulmonary Disease (COPD) subjects 
Patients were recruited from the London COPD cohort based at the Royal 
Free Hospital, with the kind permission of Professor Wedzicha and the assistance 
of the Academic Respiratory Department and team. None of the patients 
recruited were participating in a clinical trial at the time, and care was taken to 
ensure that all study investigations were performed with the patients at 
baseline, at least six weeks clear of any pulmonary exacerbations.  
General appearance  Neurological Cardiovascular Renal 
Facial appearance  
Angiokeratoma 
Oedema  
 
Musculoskeletal 
abnormality 
 
Corneal verticillata 
 
Diaphoresis 
 
Abdominal pain 
Diarrhoea/constipation 
Haemorrhoids 
 
Pulmonary  
 
New York Heart 
Association (NYHA) 
Classification 
Tinnitus 
Vertigo 
 
Acroparaesthesia 
Fever pain crisis 
 
Cerebrovascular 
abnormalities 
 
Depression 
Fatigue 
Reduced activity 
level 
Changes in cardiac 
muscle thickness 
 
Valve insufficiency 
 
ECG abnormalities 
 
Pacemaker 
 
Hypertension 
Proteinuria 
 
Abnormalities of 
glomerular 
filtration  
Maximum score  
= 18 
Maximum score  
= 20 
Maximum score  
= 20 
Maximum score  
= 18 
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Patients were identified based on their close matching using gender, 
spirometry and age to an AFD subject with airway obstruction. All spirometric 
data used for matching were from within 6 months of recruitment to the study. 
Subjects were approached initially by the Academic Respiratory Department to 
ascertain whether they would be amenable to a discussion regarding the study at 
their next routine visit, and to receiving written information regarding the study 
through the post in advance of this visit.  If happy to participate they were 
reviewed, consented provided blood and respiratory samples under the direction 
of Dr. Nadia Shafi at their subsequent clinic visit, using the same standardised 
methods as the AFD group. Samples were processed on the same day of 
collection (within 2 hours for sputum samples). 
 
2.2.3 Healthy Control Subjects 
Control subjects were recruited from amongst healthy volunteers within 
the Royal Free Hospital, and matched as closely as possible to an AFD subject by 
gender, spiromtery and age. It was ensured that they did not have a diagnosis of 
a pre-existing respiratory condition, and had no clinical symptoms to suggest an 
undiagnosed lysosomal storage disorder. A smoking history was documented for 
each of the control subjects.  
2.3 Study Investigations  
2.3.1 Lung Function Testing 
All lung function tests were performed in the Lung Function Department at 
the Royal Free Hospital by qualified lung function technicians under the 
supervision of Ms Tina Adamou (Head, Lung Function Technician).  
2.3.1.1 Equipment  
The system used was a complete on-line computerised system 
MasterScreen PFT (Carefusion Vyasys Products) for recording flow-volumes 
loops, pulmonary diffusion capacity and lung volumes. This system uses a 
pneumotachograph to record volume as a function of integrated flow and 
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incorporates fast gas analysers for recording Helium, Oxygen and Carbon 
monoxide. It has a gas reservoir of up to 8 litres volume displacement.  
2.3.1.2 Method 
The method used for measuring absolute lung volumes was by the closed 
circuit helium dilution re-breathing method and gas transfer factor by single 
breath carbon monoxide. The system meets the technical minimum specification 
laid out by the European Respiratory Society (ERS) and American Thoracic Society 
(ATS) guideline standards. A graphical display of real-time gas analysis and tidal 
volume is available on the screen during the measurements. The flow, volume 
and gas analysers are calibrated daily for quality assurance according to the 
manufacturer’s instructions. The unit is assembled on a smoothly running trolley 
and has an adjustable support arm. 
2.3.1.3 Measurements  
All measurements were performed according to the American Thoracic 
Society/European Respiratory Society guidelines (180;181). The test gas used for 
DLCO was in the region of 0.28% carbon monoxide, 9% helium (He) balance 
nitrogen. The mean of two technically accepted recordings were obtained with a 
4 minute rest between measurements (rationale in guidelines). One 
measurement of functional residual capacity (FRC) was made using 9% He in air 
with a balance of nitrogen, with subjects asked to take relaxed deep breaths 
during the He dilution method to ensure mixing, and total lung capacity (TLC) 
and residual volume (RV) calculated. The system detects end-tidal breath 
automatically and will correct for any shift in the FRC resting level. The 
gases were provided from pre-prepared cylinders (BOC special medical gases), 
with additional Oxygen supplied by a separate cylinder containing 100% medical 
Oxygen. The CO2 in the circuit was removed by soda lime and the oxygen supply 
is controlled by an oxygen sensor.  
2.3.1.4 Results interpretation  
 All lung function tests were interpreted based on the criteria set out by 
the Global initiative for Chronic Obstructive Lung Disease (182), (Table 2.0). 
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2.3.1.5 Reversibility testing  
 All bronchodilator reversibility testing was performed using nebulised 
salbutamol 2.5mg in 2.5mls via a mouth piece. Post bronchodilator spirometry 
was performed 15 minutes after bronchodilator administration.  
Table 2.1 GOLD staging for spirometry in Chronic Obstructive 
Pulmonary Disease 
 
2.3.2 Blood Sample Preparation 
All blood samples obtained for the study were processed by Dr Nadia Shafi 
on the same day as acquired.   
2.3.2.1 Plasma 
Whole blood samples from study subjects were collected in 6 ml Lithium 
heparin tubes. Samples were kept on ice for 25 minutes prior to being 
centrifuged at 2500g for 5 minutes at 4°C. The plasma was carefully aspirated 
from these samples and stored in microcentrifuge tubes [Fisher Scientific, UK] at 
- 80 C until further use.  
GOLD Spirometric Criteria for COPD Severity 
I. Mild COPD 
 FEV₁/FVC < 0.7 
 FEV₁ > or = 80% predicted 
II. Moderate COPD 
 FEV₁/FVC < 0.7 
 FEV₁ 50% to 79% predicted 
III. Severe COPD 
 FEV₁ /FVC< 0.7 
 FEV₁ 30% to 49% predicted 
IV. Very Severe COPD 
 FEV₁ /FVC< 0.7 
FEV₁ < 30% predicted or 
 FEV₁ < 50% predicted with chronic 
respiratory failure 
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2.3.2.2 Peripheral blood mononuclear cells (PBMC) 
Whole blood samples form study subjects were collected in 10ml EDTA 
tubes. This was layered onto 5mls of Lymphoprep™ [Axis-Shield, Norway] in a 
15ml Falcon™ tube and centrifuged at 650g for 25 minutes at 4°C. Following 
gradient centrifugation, the white cell layer was removed using a sterile pipette, 
and the recovered cells placed in 3 or 4 1.7ml Eppendorf micro-centrifuge tubes 
depending on the volume obtained. The cells were then spun down in a micro-
centrifuge at 4000g for 2 minutes. The resulting cell pellets were re-suspended in 
1ml of red blood cell lysis solution (8.29g NH4Cl [Sigma Aldrich, UK]; 1g KHCO3 
[Sigma Aldrich, UK]; 0.02g EDTA, di-sodium [Sigma Aldrich, UK]; 1 litre distilled 
water) and left at room temperature for 5 minutes. This step was repeated if red 
cell lysis were incomplete, given that contaminating red blood cells may lead to 
artificially high results in enzyme assays. The peripheral blood mononuclear cells 
were subsequently washed in PBS (5 minutes; 300g) prior to cell lysis using 400µl 
of ProteoJET Mammalian Cell Lysis solution [Fermentas, Fisher Scientific]. The 
cell pellet was dispersed by pipetting up and down and vortexing for 30 seconds, 
and subsequently rocked at room temperature for 10 minutes at 80rpm. 
Following a further brief vortex, the sample was placed in the micro centrifuge 
for 15minutes at 10,000g. On removal of the sample the cell lysate was aspirated 
and stored at -80°C for future processing.  
2.3.3 Fluorometric assays for plasma and leucocyte α-galactosidase 
A 
For all measurements of enzyme activity the standardised protocol for the 
Royal Free Hospital Molecular Diagnostics Laboratory were followed for the 
sample type obtained. These enzyme assays are based on the use of a substrate, 
in this case 4-methylumbelliferyl-α--D-galactopyranoside, being hydrolysed at 
acid pH to 4-methylumbelliferone and galactose by α-galactosidase A. Stopping 
the enzyme reaction after a controlled time period, by adding an alkaline buffer, 
enables the differences in the fluorescent properties of the unhydrolysed 
substrate compared to the products of hydrolysis to be used to give a measure of 
α-galactosidase A activity.  
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Enzyme assays were performed using a BMG Fluorstar Galaxy fluorimeter, 
set at excitation 360nm and emission 460nm. For this study the measurement of 
sputum supernatant α-galactosidase A activity was performed as per plasma 
samples, and for sputum leucocytes as that for peripheral blood leucoytes, 
following sputum processing (subsequently described in this chapter).  
2.3.3.1 Plasma and sputum supernatant α-galactosidase A assay 
A minimum of 0.6ml plasma or sputum supernatant was used for each 
assay. For this assay, in order to accurately measure the activity of  
α- galactosidase A it was necessary to inhibit the activity of α-galactosidase B, as 
this has significant activity in plasma. This was achieved using an inhibitor of the 
enzyme, N-acetyl-D-galactosamine [MWt 221.2) Sigma Aldrich, UK]. The 
substrate used was 4-methylumbelliferyl-α-D-galactopyranoside in solution 
[250mg in 74ml of 0.5M acetate buffer (MWt 338), Sigma Aldrich, UK]. A 
substrate/inhibitor solution was made by dissolving 500mg of the inhibitor in 
11.3mls of substrate solution.  
The reaction mixture of 100µl plasma or sputum supernatant with 100µl of 
substrate/inhibitor was set up in duplicate in the last 2 wells of the 24 well plate. 
After 2 hours incubation at 37 oC, the reaction was stopped using the stopping 
reagent of 1M glycine buffer with a  pH 10.4 [55.7ml of 75g glycine/58g sodium 
chloride in 1 litre of distilled water with 44.3ml of 1M sodium hydroxide 
solution]. A standard for comparison was set up in Well 2 using an equal volume 
(200µl) of a standard solution of 4-methylumbelliferone [(MWt 176), 1nmol per 
200µl, Sigma Aldrich, UK], with a standard blank in the neighbouring well using 
an equal volume of water, adjacent to a substrate blank with 100µl of 
substrate/inhibitor and 100µl of plasma. These standards allow compensation 
for changes in fluorescence due to other factors such as haemolysis and drugs. 
With each step of addition, mixing was performed.  
The plate was then inserted into the BMG FLUOstar Galaxy™ plate reader 
(excitation 365nm, emission 450nm) to be read. For each sample using this 
method, the reading from the Standard minus the reading from the Standard 
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blank was equivalent to fluorescence of 1nmol 4-MU. The activity of the test 
sample was calculated using the formula:  
(T-B) x 60 x 1000  = nmol/hr/ml plasma 
   S           120   100                 
where T = average of the test readings for the sample, B = reading for blank 
sample, S = reading from standard sample 
The steps followed for each plasma or sputum supernatant sample in a 24 
well plate are summarised in order going down the table in Table 2.3.3.1. Results 
of the plasma enzyme activity were interpreted based on the reference range 
used by the Royal Free Molecular Diagnostics laboratory, as outlined below: 
 
Reference Range for plasma α- galactosidase A 
Normal   4.0 – 21.9 nmol/hr/ml 
Hemizygote Fabry  0 – 0.9 nmol/hr/ml 
Heterozygote Fabry  0.22 – 7.4 nmol/hr/ml 
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Table 2.3.3.1 Summary of procedure for the measurement of  
α- galactosidase A activity in plasma and sputum supernatant 
samples  
 
 
  
Well 2 Well 3 Well 4 Well 5 Well 6 
Standard Standard 
Blank 
Substrate 
Blank 
Reaction 
Mixture 
Reaction 
Mixture 
  100µl 
substrate/ 
inhibitor 
100µl  plasma 
+ 100ul 
substrate/ 
inhibitor 
100µl plasma 
+100ul 
substrate/ 
inhibitor 
   Mix Mix 
  Incubate at 37
o
C for 2 hours in cell culture 
incubator 
  1.0ml stopping 
reagent 
1.0ml stopping 
reagent 
1.0ml stopping 
reagent 
  100ul plasma   
200µl 
standard 
solution 
200µl  H2O    
0.9ml 
stopping 
reagent 
0.9ml stopping 
reagent 
   
100µl  plasma 100µl  
plasma 
   
Mix Mix    
Insert plate into plate reader to read fluorescence and calculate activity in 
nmol/ml/hr 
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2.3.3.2 Peripheral blood and sputum leucocyte α-galactosidase A 
assay 
In leucocytes usually over 95% of the total α-galactosidase activity is  
α-galactosidase A, with a much smaller contribution from α-galactosidase B.  
Peripheral blood leucoytes were obtained as described in Methods Section 
2.3.2.2, and sputum leucocytes as described in Methods Section 2.3.6.2. 
Leucocyte cell lysate from sputum samples was prepared as described in 
Methods Section 2.3.2.2.  
The protein content of the prepared cell lysate from both blood and 
sputum samples was measured using the Bicinchoninic Acid Protein Assay Kit 
[Sigma, product code BCA-1and B 9643] in a 96 well microtitre plate. Protein 
content was quantified by colorimetric measurement using a BMG FLUOstar 
Galaxy™ plate reader (absorbance wavelength 562nm; reference wavelength 
650nm), using a standard curve generated from dilutions of bovine serum 
albumin (BSA) between 0-1000 mg/ml to determine the protein content of each 
lysate sample. This was then used in the calculation of leucocyte α-galactosidase 
A activity for each sample.  
For leucocyte enzyme measurements the reagants used including the 
substrate/inhibitor, standard solution and stopping reagent were prepared as 
described in Methods Section 2.3.3.1. For each reaction mixture, which was set 
up in duplicate, 15µl of leucocyte protein sample was mixed with 150µl of 
substrate/inhibitor solution in a 24 well plate. This was incubated for 30 minutes 
at 37 oC before the reaction was stopped using the stopping reagent.  The 
substrate blank was set up using 150µl of substrate/inhibitor which was 
incubated with the reaction mixture before 1ml of stopping solution and 15µl of 
the leucocyte protein sample were mixed in. The standard blank and the 
standard were set up with 200µl of water 200µl of the standard solution 
respectively, along with 950µl stopping reagent and 15µl of sample.  With this 
set up, for each sample the difference in fluorescence between the Standard and 
the Standard blank was equivalent to a fluorescence of 1nmol 4-MU.  
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The formula used to calculate α-galactosidaseA activity in each sample was:  
Fluorescence of sample x 30min x  1000µl     x      1mg  
Fluorescence of standard 60min       15µl         Protein conc. (mg/ml) 
= leucocyte α-galactosidase A activity (nmol/hr/mg of protein)     
The steps followed in the procedure using a 24 well plate are summarised 
in Table 2.3.3.2. Sample results for peripheral blood leucocyte α-
galactosidaseactivity were interpreted based on the reference ranges used by 
the Molecular Diagnostics laboratory at the Royal Free Hospital as shown below:  
 
Reference Range for peripheral blood leucocyte α-galactosidaseA 
Normal   33 - 134 nmol/hr/mg of protein 
Hemizygote Fabry  0.4 - 5 nmol/hr/mg of protein 
Heterozygote Fabry  4.3 - 73 nmol/hr/mg of protein 
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Table 2.3.3.2 Summary of the procedure for measurement of  
α-galactosidase A activity in leucocytes   
Well 1 Well 2 Well 3 Well 4 Well 5 
Standard Standard 
Blank 
Substrate Blank Reaction 
Mixture 
Reaction Mixture 
   15µl leucocyte 
protein sample 
15µl leucocyte 
protein sample 
  150µl 
substrate/ 
inhibitor 
150µl 
substrate/ 
inhibitor 
150µl 
substrate/ 
inhibitor 
  Mix Mix Mix 
  Incubate at 37
o
C for 30 minutes in cell culture 
incubator 
  1.0ml stopping 
reagent 
1.0ml stopping 
reagent 
1.0ml stopping 
reagent 
  15ul leucocyte 
protein sample 
  
200µl 
standard 
solution 
200µl H2O    
950µl 
stopping 
reagent 
950µl 
stopping 
reagent 
   
15µl 
leucocyte 
protein 
sample 
15µl 
leucocyte 
protein 
sample 
   
Mix Mix    
Insert plate into plate reader to read fluorescence and calculate activity in nmol/ml/hr 
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2.3.4 Radiology 
All chest radiographs (CXR) and high resolution computed tomography 
(HRCT) scans were performed by the Radiology Department at the Royal Free 
Hospital using standardised protocols. Films were reported by different members 
of the Radiology Department and then reviewed by a specialist Consultant 
Thoracic Radiologist (Dr. J. Haddock, Royal Free Hospital, London).  
2.3.4.1 CXRs 
All chest radiographs were performed using digital radiography at the first 
study visit. The film taken was in the standard postero-anterior, non-rotated 
position with scapula rotated away from the lung fields and with full inspiration 
on exposure. The equipment used 125kVp and automatic exposure chambers 
(AEC), with a scatter reduction grid delivering an average of 1.8mAs for the 
average sized adult. The focal film distance (FFD) was 180cm. The approximate 
average dose per CXR was 0.9dGycm2.  
2.3.4.2 HRCT scans 
 Scans were performed on a Brilliance 64 [Philips Medical Systems] or GE 
Lightspeed [GE Healthcare] CT scanners using the same lung algorithm. 
Inspiratory and expiratory images were captured using 1.25mm slices at 10mm 
increments with 120kVp and 200mA, with a 0.5s rotation time and field of view 
(FoV) of 350mm. Both scanners possessed 2 x 0.625mm detectors with lung 
enhanced filters.  
2.3.5 Sputum Induction Procedure  
2.3.5.1 Equipment and setting 
All sputum induction procedures were performed in the isolation system 
housed in the Out Patient Department of the Royal Free Hospital, London. This 
isolation system consists of a framework 2.2m high x 1.5m wide, glass clear 
envelope with a Nyplax reinforced floor fitted with inner polypropylene sheet. It 
has a single inlet and double outlet filter pack with high efficiency particulate air 
fan unit with single extraction and fixed negative pressure. Fifteen air exchanges 
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occur per hour within the chamber.  Waste air is double HEPA filtered and then 
extracted from the chamber via a hose.   
An ultrasonic nebuliser [DeVilbiss Ultraneb 3000] was set up inside the 
chamber for the delivery of the hypertonic saline, with the use of disposable 
cups and lids, elephant tubing and mouthpieces to ensure no possibility of cross 
infection between subjects. This nebuliser operates at a nebuliser rate of 
3ml/min delivering a maximum flow rate of 20l/min, with a particle size of <4µm. 
This ensures a good delivery of the hypertonic saline to the lower airways in 
order to generate a sputum sample representative of this part of the lung.  
Experiments were performed on volunteers to determine the optimal 
concentration of hypertonic saline that would yield sufficient cell numbers per 
sample obtained, and therefore 4% hypertonic saline was used in all induced 
sputum sampling.  
2.3.5.2 Procedure  
All subjects were given written and verbal information with regards to the 
procedure, and given the opportunity to ask questions prior to the procedure. 
Subjects were all sampled in their baseline state, and were excluded from 
induced sputum sampling if they had any symptoms of chest infection within the 
preceding 6 weeks.  
Sputum induction was performed after the subjects had undergone lung 
function testing to ensure that poor lung function did not preclude them from 
having the procedure (FEV₁<1litre). They were encouraged to keep well hydrated 
leading up to the procedure by drinking water, but not to eat in the 2 hours 
immediately prior to the procedure if at all possible. Baseline oxygen saturations 
were also taken. 
In order to minimise the possibility of bronchospasm, subjects were pre-
medicated with Salbutamol either in nebulised form during their lung function 
tests, or with a 200mcg dose via a metered dose inhaler. At least 10 minutes 
after this a baseline measurement of FEV₁ was recorded using a MicroPlus hand 
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held spirometer [MicroMedical, UK] with a bacterial/viral filter. This reading was 
used for comparison with subsequent readings through the course of the 
procedure to ensure there was no significant bronchospasm as a result of saline 
inhalation.  
For study subjects up to a total of 40mls of 4% hypertonic saline was used 
in each sputum induction procedure - each of which was performed under the 
supervision of the same operator, Dr. Nadia Shafi. Subjects were asked to sit 
inside the chamber and inhale the nebulised saline via a mouthpiece, breathing 
in and out normally, with a deep breath every tenth breath. They were 
encouraged to keep their mouth free of saliva by spitting into a waste pot rather 
than swallow, and to blow their nose if required to minimise salivary 
contamination of the sample.  
After 5 minutes of inhalation, subjects were asked to rinse their mouth out 
with water, to take 2 deep breaths and then encouraged to cough and 
expectorate any sputum produced into a collection pot. They were also taught 
the technique of huffing to assist expectoration. Following this, a repeat measure 
of FEV₁ was taken, and as long as there had not been a drop of >15%, the steps 
were repeated a further 3 times to a total of 20 minutes of saline inhalation. At 
the end of the whole procedure subjects were kept in the chamber for a further 
10 minutes until they had stopped coughing altogether. 
The expectorated sample was then taken to be processed within 2 hours of 
obtaining it to ensure maximal cell viability.  
2.3.5.3 Safety  
Resuscitation equipment in the form of cannulae, Guedel airways, bag and 
mask, oxygen cylinder and emergency drugs were also available in the room at 
all times, including Adrenaline 1:10000, Hydrocortisone 200mg, Piriton 10mg for 
anaphylaxis, and Salbutamol 2.5mg nebules for bronchospasm. In addition 
Salbutamol metered dose inhalers were available for pre-medication. 
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At 5 minute intervals throughout the course of the procedure repeat 
measures of FEV₁ were taken using a hand held MicroPlus spirometer, as a safety 
measure, to ensure that no significant bronchospasm was occurring as a result of 
hypertonic saline inhalation. Should there have been a significant drop in FEV₁ 
(>15% from baseline), the procedure would have been stopped, and subject 
given further inhaled Salbutamol if required, and observed until their FEV₁ had 
returned to close to baseline.  
Bacterial/viral filters were used on all equipment to ensure no possibility of 
cross infection of any respiratory pathogens between subjects. Following each 
sputum induction procedure, the sputum induction chamber and equipment 
within were all cleaned using Tristel Sterilising Wipes [Tristel Solutions Ltd, 
Cambridgeshire, UK] to ensure no possibility of cross infection of any kind 
between subjects.  
Overall, the procedure was very well tolerated by all patients. The 
procedure did not have to be stopped for any safety reasons during the study. 
2.3.6 Preparation of sputum samples, fluid and cellular components  
Induced sputum sample processing was commenced with 2 hours of 
obtaining the samples at all times to ensure accurate measurement of cell counts 
and viability. The samples were kept at room temperature until processed.  
The processing method used was based on the recommendations of the 
European Respiratory Society Working Group on methods for sputum processing 
for cell counts (183) with some modification to account for the accurate 
measurement of α-galactosidase A in both the fluid and cellular phase of the 
sputum. Experiments were performed to determine the effect of 0.1% 
Dithiothreitol (DTT) on α-galactosidase A enzyme activity in both fluid and 
cellular components of the sputum, and the recommended processing method 
was adjusted for this.  
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2.3.6.1 Experiments 
These were performed on blood from healthy volunteers, given that the 
method for measurement of enzyme activity in blood components is established 
using this medium. 
2.3.6.1a Effect of 0.1% DTT on α-galactosidase A activity in plasma 
This experiment was performed to ascertain the impact of 0.1% DTT on 
enzyme activity or its measurement in the fluid - which is equivalent to the fluid 
phase of sputum.  Α-galactosidase A activity was measured in ratios of between 
1:1 and 1:4 of the following:   
Plasma alone  
Plasma with Phosphate Buffered Saline (PBS)  
Plasma with 0.1% Dithiothreitol (DTT)  
α-galactosidase A activity was then measured using the standard 
fluorometric assay for plasma as previously described in Methods Section 
2.3.3.1, and corrected for the dilution factor for each sample.  
This experiment revealed that 0.1% DTT significantly reduces the  
α-galactosidase A activity in plasma (Figure 2.3.6.1a).  
Figure 2.3.6.1a Effect of 0.1% DTT on α-galactosidase A activity in 
plasma  
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2.3.6.1b Effect of 0.1% DTT on α-galactosidase activity within intact 
blood leucocytes  
This experiment was performed to ascertain the impact of 0.1% DTT on the 
measurement of α-galactosidase A activity in peripheral blood derived 
leucocytes from for the purpose of extrapolating the results to apply to sputum 
derived leucocytes. Five healthy controls donated leucocytes; and these were 
separated from the peripheral blood as described previously in Methods Section 
2.3.2.2. Any contaminating red blood cells were lysed from the cell pellet. The 
intact leucocytes were then re-suspended in 4 mls PBS and divided into 4 equal 
portions.  
Either PBS or 0.1% DTT was added to the cells in ratios of 1:1 or 1:4 and the 
samples subsequently processed in the same way as planned for study sputum 
samples, in that they were placed in a water bath at 37°C and shaken at 100rpm 
for 20 minutes. The samples were subsequently filtered through a 50µm filter, 
and centrifuged at 400g for 10 minutes.  
The cells from each sample were washed twice using PBS [Sigma Aldrich, 
UK], then lysed using 200µl of ProteoJET Mammalian Cell Lysis solution 
[Fermentas, Fisher Scientific, UK] and the lysate collected as previously 
described. The α-galactosidase A activity was subsequently measured using the 
fluorometric assay as described in Methods Section 2.3.3.2 in each sample and 
compared. 
This experiment demonstrated no significant difference in the  
α-galactosidase A activity between intact peripheral blood leucocytes that had 
been treated with 0.1% DTT and those that had not, demonstrating that 0.1% 
DTT did not affect α-galactosidase A activity within intact leucocytes (Figure 
2.3.6.1b) (One way ANOVA and Friedman’s test).  
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Figure 2.3.6.1b Effect of 0.1% DTT on α-galactosidase A activity from 
peripheral blood derived leucocytes 
 
 
 
 
 
 
 
2.3.6.1c Effect of 0.1% DTT on α-galactosidase activity in blood 
leucocyte lysate  
Peripheral blood samples from volunteers were collected and the 
leucocyte lysate prepared as previously described in Methods Section 2.3.3.2. 
Varying ratios of the lysate were then made up with PBS and 0.1% DTT, and 
warmed to 37ºC in the water bath at the same time as being shaken for 20 
minutes. α-galactosidase A activity was then measured using the standard 
fluorometric assay outlined previously and results compared. 
α-galactosidase A activity was found to be lower in blood leucocyte lysate 
when mixed with 0.1% DTT than when mixed with equal volumes of PBS, having 
corrected for the dilution factor. This suggested that 0.1% DTT may affect the 
activity of the enzyme from lysed leucocytes (Figure 2.3.6.1c).  
Figure 2.3.6.1c Effect of 0.1% DTT on blood leucocyte lysate α-
galactosidase A activity compared to PBS 
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2.3.6.2 Sputum processing method  
To maximise yield and viability of the cellular sample, induced sputum 
processing was commenced within 2 hours of obtaining the sample as 
recommended in the Report of the ERS Working Group 2002 (184). The whole 
sample was weighed, and this documented, before being transferred into a petri 
dish, where the plugs of sputum were picked out from the saliva to minimise the 
salivary contamination of the sample  (185).  
The separated sputum sample was then transferred into a 50ml Falcon 
tube and re-weighed. This weight was used to determine the actual volume of 
the sample, where 1gm of sputum was equivalent to 1ml. This volume was 
subsequently used to determine the volumes of the reagents required in the 
processing method.  
The sputum sample was then diluted with an equal volume of PBS [Sigma 
Aldrich, UK], and the mixture vortexed to homogenise it.  On the basis of the 
results from the experiment performed (Methods Section 2.3.6.1a) prior to the 
addition of any further reagents, a portion was taken in 1.7ml Eppendorf tubes 
and centrifuged at 4000g for 2 minutes. The supernatant, being representative of 
the fluid phase of the sputum, from these samples was then aspirated and stored 
at -80°C for future enzyme and cytokine assays, and the remainder of each 
returned to the sputum/PBS mixture.  
Following this 0.1% DTT was added to the sputum/PBS mixture, also in an 
equal volume to that of the sputum, and vortexed for a further 30 seconds, prior 
to being placed in a water bath warmed to 37°C and shaken at 100rpm for a total 
of 20 minutes.  
On completion of this step the sample was removed from the water bath, 
and filtered through a 50 micron mesh filter [CellTrics 50µm filters, Partec, UK] to 
remove any debris without significant loss of cells from the sample.  
This filtrate was then centrifuged at 400g for 10 minutes and a cell pellet 
formed. The cell pellet was dispersed, the cells washed with PBS and re-spun in a 
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micro centrifuge for 2 minutes at 4000g before re-suspending in R10 growth 
medium containing RPMI 1640 [Sigma Aldrich, UK], 10% heat-inactivated foetal 
calf serum [Invitrogen™, Paisley, UK], 10mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer [Invitrogen, Paisley, UK], 2mM L-
glutamine [Sigma Aldrich, UK] and penicillin/streptomycin [>10,000U/ml 
penicillin, >10mg/ml streptomycin; Sigma Aldrich, UK].  
Cell counts were performed by light microscopy using a Neubauer 
haemocytometer with an etched grid system. 10µl of cell suspension was added 
to 10µl of 0.2% trypan blue (diluted in filtered phosphate buffered saline, PBS; 
[Sigma Aldrich, UK]) for 1 minute in a micro-centrifuge tube. Assessment of cell 
viability was based on cell appearance under light microspcopy, with live cells 
being colourless and dead cells staining blue due to their inability to exclude dye. 
A minimum of 200 cells were analysed. Only samples with 80% cell viability, not 
including squamous cells, were used for further studies. All samples used had a 
squamous cell count of <20% of the total cell number.  
The cells obtained were then divided up for the study investigations 
required, depending on total cell number. 
2.3.7 Sputum α-galactosidase A assays 
2.3.7.1 Sputum supernatant 
For the measurement of α-galactosidase A in the fluid phase of the 
sputum, stored samples of sputum supernatant which had been frozen at -80°C 
were allowed to thaw at room temperature. Once fully thawed, they were 
vortexed for 30 seconds to ensure full mixing. Measurement of α-galactosidase A 
activity was then performed as described in Methods Section 2.3.3.1.    
2.3.7.2 Sputum leucocytes  
A minimum of 1 x10^6 sputum leucocytes from sputum samples processed 
as per Methods section 2.3.6.2 were used for the measurement of sputum 
leucocyte α-galactosidase A  activity. Cell pellets were lysed using 200µl of the 
ProteoJET Mammalian Cell Lysis Solution [Fermentas, Fisher Scientific, UK] and α-
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galactosidase A activity in the cell lysate measured flourometrically using the 
procedure described in Methods Section 2.3.3.2.  
2.3.8 Preparation and staining of sputum cell cytospins  
Of the cells obtained from sputum samples a proportion were used to 
make cytospin slides for the purpose of examining cell morphology and for 
correlation with flow cytometry findings if required. For this purpose the 
concentration of the cell suspension was adjusted to 0.5 x10^6 cells/ml with R10, 
and 100µl of this cell solution was used for each slide.  
Slides were labelled with the study number and date of sample prior to 
being loaded into the metal holders along with adsorbent filter paper [Thermo 
Electron Co-operation, East Grinstead, UK]. Cuvettes were secured into place, 
and 100µl of the cell suspension pippetted into each. The cuvettes with slides 
were then loaded into place in the centrifuge [Shandon Cytospin  2] and spun at 
450rpm for 2 minutes.  
On removing the cuvettes from the centrifuge, slides were allowed to air 
dry for 2 hours prior to any fixing procedures. For each sample obtained, one 
cytospin slide was stained with Giemsa. Air dried slides were fixed fully 
submerging in methanol for 7 minutes before being removed and allowed to air 
dry once more. Once dry, slides was fully submerged in Giemsa [Sigma Aldrich, 
UK] having been diluted 1 in 20 with distilled water and filtered, for 25 minutes 
before being rinsed and air dried. Glass coverslips were mounted on each 
cytospin slide using DPX mountant [Sigma Aldrich, UK] with care to avoid 
introduction of air bubbles into the fixative, and allowed to dry for at least 1 hour 
prior to the slides being viewed under a light microscope.  
If cell numbers allowed, additional cytospin slides from the samples were 
fixed after the initial air drying step by submerging in a 1:1 mixture of methanol 
and acetone for 20 minutes, and allowed to dry. Following this they were 
wrapped in aluminium foil and stored in a container with silica gel to remove any 
moisture, in a fridge at - 20°C for future staining.  
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2.3.9 Flow Cytometry 
To examine the cell populations present, cells obtained from the induced 
sputum of subjects were stained with fluorescent antibodies. For the majority of 
samples, a 3 colour Becton Dickinson (BD) FACScan flow cytometer was used to 
acquire cell data, along with BD antibodies. The antibodies used were direct 
conjugates with fluorescein isothiocyanate (FITC), R-Phycoerythrin (PE) and 
peridinin-chlorophyll-protein complex (PerCP) and following fluorochrome 
excitation, emitted light was detected in the FL1, FL2 and FL3 channels 
respectively. In addition, on a small number of samples a fourth fluorochrome 
APC was used and emitted light detected in the FL4 channel of a 4 colour BD 
FACScan.  
Templates for flow cytometry plots and gating were established using 
blood cells stained with the same antibodies as used for the sputum cells. 
Sputum samples were processed as described in Methods Section 2.3.6.2.  
For each flow cytometry sample a cell suspension of 1x10^6 cells/ml in PBS 
[Sigma Aldrich, UK] was used, with 100µl of cell suspension incubated in the dark 
for 15-30 minutes with 5-10µl of antibody in separate tubes. Excess antibody was 
removed by washing twice in PBS before the cells were re-suspended in 400µl of 
PBS [Sigma Aldrich, UK] prior to acquisition. Up to 4 tubes were prepared for 
each sputum sample using the antibodies shown in Table 2.3.9 in the following 
combinations:  
Tube 1 : unstained 
Tube 2 : CD3, CD4 and CD8 
Tube 3 : CD3, CD16, CD56 
Tube 4 : CD45, CD14, CD15  +/- CD19  
Flow cytometry data were analysed with CellQuestProTM (BD) or Flowjo 
7.6.1 software ( Tree Star, Inc, Oregon, USA). For each flow cytometry sample, 
the maximum number of events possible was recorded until the sample was 
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entirely used up, to ensure as many cells as possible were identified with a 
minimum of 1,000 gated events collected for analysis. 
Table 2.3.9 Antibodies used for cell staining of sputum derived cells 
for flow cytometry analysis 
 
Targets Species Ig 
Class 
Product 
code 
Company Clone Conjugate Dilution/ 
incubation 
time 
Human 
CD3 
Mouse IgG1k 345766 BD SK7 PerCP 
1:20 
15 minutes 
Human 
CD4 
Mouse IgG1k 345768 BD SK3 FITC 
1:10 
15 minutes 
Human 
CD8 
Mouse IgG1k 345773 BD SK1 PE 
1:10 
15 minutes 
Human 
CD16 
Mouse 
IgG1k 335035 BD NKP15 FITC 
1:10 
15 minutes 
Human 
CD56 
Mouse 
IgG1k 345810 BD MY31 PE 
1:5 
15 minutes 
Human 
CD45 
Mouse 
IgG1k 345809 BD 2D1 PerCP 
1:10 
15 minutes 
Human 
CD14 
Mouse 
IgG2k 345785 BD MøP9 PE 
1:10 
15 minutes 
Human 
CD15 
Mouse 
IgMk 332778 BD MMA FITC 
1:10 
15 minutes 
Human 
CD19 
Mouse 
IgG1k 345777 BD 4G7 PE 
1:10 
15 minutes 
 
2.3.10 Cytokine Assays 
 Concentrations of the cytokines interleukin 6 (IL-6) and interleukin 8 (IL-8) 
were measured using ELISA kits for the purpose. For IL-6 this was the BD 
OptEIA™ ELISA Set for human IL-6 [BD Sciences, San Diego, California; Cat. No. 
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555220], and for IL-8 the Quantikine® Human CXCL8/IL-8 ELISA [R&D systems; 
Cat. No. D8000C] 
2.3.10.1 IL-6 assay  
 Sputum leucocyte lysate samples were prepared as described in Methods 
Section 2.3.6.2 and 2.3.7.2, with a minimum of 1x10^6 cells used for cytokine 
measurements. Frozen samples were thawed at room temperature prior to use.  
 Assays were performed in the 96 well plates provided, with the 
microwells pre-coated with 100µl of a solution of capture antibody (80µl anti-
human IL-6 monoclonal antibody) diluted in coating buffer buffer (20mls of 0.1M 
sodium carbonate, pH 9.5 [2.1g NaHCO₃ and 0.89g Na₂CO₃ in 250mls deionised 
water]) sealed and incubated overnight at 4°C. Wells were aspirated and washed 
thoroughly 3 times with >300µl of freshly made up well wash buffer (50µl of 
0.05% Tween-20 in 100mls PBS [Sigma Aldrich, UK]). Plates were then blocked 
with at least 200µl of freshly prepared assay diluent per well (250mls PBS [Sigma 
Aldrich, UK] with 2.5mls 10% FBS [Hyclone; Cat. No. SH30088; heat inactivated]), 
incubated at room temperature for 1 hour, after which the wells were aspirated 
and washed thoroughly.  
 A stock standard solution was prepared by reconstituting the lyophilised 
standard [120ng recombinant human IL-6] warmed to room temperature with 
1.0ml of deionised water, vortexing gently to mix and allowed to equilibrate for 
15 minutes. A 300pg/ml standard prepared from the stock standard was then 
used to make standard solutions of 150pg/ml, 75pg/ml, 37.5pg/ml, 18.8pg/ml 
and 4.7pg/ml by serial dilution, with the assay diluent alone serving as the zero 
standard. 100µl of each standard, sample and control were pipetted into a 96 
well plate in duplicate, and the plate sealed and incubated at room temperature 
for 2 hours, after which the wells were aspirated and washed thoroughly with 
wash buffer.  
 Following this, 100µl of working detector (Detection antibody 
[Biotinylated anti-human IL-6] and enzyme reagent [Avidin-horseradish 
peroxidise conjugate]) were added to each well, and the plate sealed and 
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incubated at room temperature for a further 1 hour prior to aspirating and 
washing thoroughly again, with soaking of the wells in wash buffer for 30-60 
seconds for each wash at least 7 times. Subsequently, 100µl of substrate solution 
[Tetramethyl benzedine (TMB) and hydrogen peroxide; BD Pharminogen™ TMB 
Substrate Reagent set; Cat. No. 555214] was added to each well, and the plate 
incubated without sealing at room temperature in the dark for 30 minutes. At 
this point, 50µl of stopping reagent [1M H₂SO₄] was added to each well. The 
plate was then read within 30 minutes by colorimetric measurement using a 
BMG FLUOstar Galaxy™ plate reader (absorbance wavelength 450nm; reference 
wavelength 570nm). The IL-6 concentration of the samples was ascertained by 
their absorbance on the standard curve.  
2.3.10.2 IL-8 assay  
 Sputum leucocyte lysate samples were prepared as previously described 
in Methods Section 2.3.6.2 and 2.3.7.2. Concentrations of IL-8 were measured in 
samples from AFD subjects and controls using the Quantikine® Human  
CXCL8/IL-8 ELISA kit, using the equipment and reagants provided. The IL-8 
standard was prepared by reconstituting with 5.0mls of single strength Calibrator 
Diluent RD5P. Serial dilutions were performed using this 2000pg/ml stock 
solution to obtain solutions of 1000pg/ml, 500pg/ml, 250pg/ml, 125pg/ml, 
62.5pg/ml and 32.5pg/ml with the calibrator diluent alone serving as the zero 
standard.    
100µl of the assay diluent RDI-85 were added to wells in a microstrip plate, 
followed by 50µl of IL-8 standard, control or sample. Plates were then left to 
incubate at room temperature for 2 hours.  
 Wells were then aspirated and washed thoroughly using wash buffer. 
Following this 100µl of the IL-8 conjugate (polyclonal antibody against IL-8 
conjugated to horseradish peroxidise with red dye and preservatives) was added 
to each well, and the plate sealed and incubated for a further hour at room 
temperature, after which the wells were again aspirated and washed. 
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 A substrate solution was freshly prepared using equal volumes of 
stabilised hydrogen peroxide and stabilised tetramethylbenzidine as the 
chromogen, and 200µl of substrate solution added per well. Plates were then 
incubated in the dark at room temperature for 30 minutes before adding 50µl of 
stop solution (2N sulphuric acid) to each well, and thorough mixing was ensured 
by observation of the colour change within the wells from blue to yellow. The 
optical density of each well was then measured using a BMG FLUOstar Galaxy™ 
plate reader (absorbance wavelength 450nm; reference wavelength 570nm), 
with sample IL-8 concentrations calculated by comparison with the standard.  
2.3.11 Transmission Electron Microscopy 
A proportion of the cells obtained from the induced sputum were also used 
for electron microscopy imaging to ascertain the presence of any storage 
material within the lysosomes. Cell pellets were obtained as previously described 
in Methods Section 2.3.6.2, and 1ml of EM preservative media refrigerated 
fixative solution (20mls of 20% parformaldehyde [Sigma Aldrich, UK], 16mls of 
25% glutaldehyde [Sigma Aldrich, UK] and 59mls of PBS) was added to the pellet 
in a 1.7ml Eppendorf micro centrifuge tube and kept refrigerated at 4°C prior 
overnight until further preparation for EM was performed by Mr. Innes 
Clatworthy, Department of Electron Microscopy, Royal Free Hospital, London.  
Cells were washed twice in PBS and incubated for 10 minutes in staining 
solution (1% osmium tetroxide [TAAB Laboratories Equipment, Aldermaston, 
UK], 1.5% potassium ferricyanide [TAAB Laboratories Equipment], PBS). Cells 
were washed 5 times in distilled water and dehydrated with increasing 
concentrations of ethanol (30%, 50%, 70%, 90% and 100%). Samples were left in 
a mixture of 50% alcohol/50% Lemix epoxy resin [TAAB Laboratories Equipment] 
on a mixer overnight. The following day, resin infiltrated samples were placed in 
100% Lemix resin for at least 4 hours before being embedded in 100% Lemix 
Resin overnight. Semi-thin (1µm) sections were cut, using glass knives, on a 
Reichert-Jung Ultracut microtome before being stained with 1% Toluidine Blue 
overnight [TAAB Laboratories Equipment].  Ultra-thin sections were cut using a 
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diamond knife [Diatome; TAAB Laboratories Equipment] and collected on 300HS 
3.05mm copper grids [Gilder Grids, Grantham, UK].  
Sections were stained with saturated alcoholic uranyl acetate [TAAB 
Laboratories Equipment] for 5 minutes and transferred into Reynold’s lead 
citrate [TAAB Laboratories Equipment] for a further 5 minutes. Specimens were 
viewed and photographed using a Phillips CM120 transmission electron 
microscope [Philips, Eindhoven, Netherlands]. 
2.4 Statistical Methods  
All experimental data were analysed using GraphPad Prism 5.0™ (GraphPad 
Software Inc, California, USA) or Microsoft Excel 2003 (Microsoft Co-operation, 
California, USA). All data were tested using the D'Agostino & Pearson omnibus 
normality test to identify whether the data had a Gaussian distribution. Standard 
deviation (SD) and mean were used to express results for parametric data, whilst 
median and range were used to summarise non-parametric data. 
An unpaired t-test was used to compare parametric data, whereas non-
parametric data were analysed using a Mann-Whitney U test. One-way ANOVA 
(analysis of variance) was used to compare the means of 3 or more discrete 
populations where required. A paired t-test and Wilcoxon signed rank test were 
used for paired parametric and non-parametric data respectively. A p value <0.05 
was considered to be statistically significant.  
Data correlations were performed using a Spearman rank test. All 
statistical tests were two-tailed.  Multivariate linear regression analyses were 
performed on normally distributed data using SPSS version 20 (IBM SPSS 
Statistics, USA).  All statistical analysis was reviewed by a statistician, Dr. Colette 
Smith (Lecturer in Biostatistics, Royal Free Hospital, London).  
 
 
Chapter 3 – Demographics, clinical features, pulmonary function and imaging  
80 
 
 
 
 
 
 
 
 
 
 
Chapter 3 – Demographics, clinical features, 
pulmonary function and imaging  
  
  
Chapter 3 – Demographics, clinical features, pulmonary function and imaging  
81 
 
3.1 Introduction 
Overall, studies into the involvement of the lungs in AFD have been limited. 
Those that exist have established that respiratory symptoms such as wheeze, 
cough and dyspnoea are frequently reported by AFD patients (186), and that 
airway obstruction occurs commonly, particularly in men, and worsens with age 
(187). Whilst this pattern between the genders is in keeping with the pattern of 
AFD involvement in other organ systems, no links between lung involvement and 
overall disease severity have been investigated in either sex.  
From previous data, there has been the suggestion that the airflow 
limitation seen may be partially reversible to bronchodilators, though in one of 
these studies no response was seen on methacholine challenge testing. 
However, establishing the presence of airway reversibility may be pertinent to 
symptoms, to the consideration of cardiac comorbidity and the choice of drugs 
used for this (188).  
The suggestion has also been raised that smoking may be particularly 
detrimental in the context of AFD and the lung, and smoking cessation advice is 
given to patients though the limited evidence from studies on the lung has been 
conflicting (189;190). Clearly this advice is also beneficial from a cardiac 
perspective, and so also relevant in this context. 
Case reports have raised the possibility of spirometric and radiological 
improvement on commencing ERT in cases of AFD where presentation of the 
disease has been primarily with respiratory symptoms (191).  However, there has 
not as yet been any assessment of the potential impact of ERT and AFD in the 
lung in the wider scheme, as in these previous studies the majority of subjects 
had not been commenced on ERT. In addition radiological findings in AFD 
subjects have varied, with some reports of bullous changes, and some reports of 
interstitial changes in cases where subjects have been further investigated on 
the basis of respiratory symptoms (192). 
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3.2 Hypotheses 
This chapter aimed to test the following hypotheses: 
Hypothesis 1:  
The presence and severity of airway involvement in AFD is related to gender, 
age and overall disease severity 
Rationale:  
Aspects of the disease in different organ systems have been shown to be 
more severe in males, and with increasing age higher disease severity scores 
Hypothesis 2: 
The severity of airway obstruction in AFD is progressive over time, 
independent of ERT 
Rationale:  
On the basis of the accumulation of storage material over time, and the 
inability of ERT to completely halt this process in other organ systems  
Hypothesis 3:  
Pulmonary involvement in AFD is demonstrable on HRCT imaging 
Rationale:  
Air trapping on CT scanning representing small airways disease is recognised 
in many conditions and this has been reported in AFD  
Hypothesis 4: 
 A significant smoking history is associated with increased severity of airway 
obstruction in AFD 
Rationale: 
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The impact of smoking in AFD has previously been suggested to be more 
harmful in terms of airway changes than in non-AFD subjects, though not 
proven 
3.3 Objectives 
The main objectives of this chapter were: 
1. To establish the extent and severity of airway obstruction and changes in 
diffusion capacity in the AFD population  
2. To examine the differences in spirometry and diffusion capacity between 
genders in AFD and compared to sex matched controls  
3. To determine changes in spirometry and diffusion capacity over time in AFD  
4. To determine the impact on the airways of smoking in AFD subjects  
5. To examine the severity of lung involvement in AFD as measured by 
spirometry and diffusion capacity in relation to the duration of enzyme 
replacement therapy (ERT) 
6. To examine the relationship between lung involvement in AFD and overall 
disease severity and genotype 
7. To document pulmonary imaging findings in AFD using frontal chest 
radiographs and high resolution CT scanning  
3.4 Methods  
All recruitment, including contacting and consenting of study subjects, as 
well as clinical data collection and historical data collection from patient case 
notes were performed personally by Dr. Nadia Shafi, in addition to all clinical 
assessments at each study visit. All study investigations were also organised and 
co-ordinated by Dr. Shafi.  
Lung function testing was performed by the Lung Function Department at 
the Royal Free Hospital using the same equipment as described in Method 
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Section 2.3.1.  This was undertaken and reported according to the European 
Respiratory Society and American Thoracic Society guidelines for lung function 
testing (193;194). Analysis and interpretation of the lung function data for 
individual study subjects were performed by Dr. Nadia Shafi. Individual lung 
function parameters were compared between AFD subjects and healthy controls 
to investigate possible differences in both spirometry and diffusion capacity, 
which were felt to be of most interest. 
All recruited subjects were asked to undergo induced sputum sampling on 
each study visit for the purposes of analysis of enzyme activity, cell populations 
and cytokine concentrations. Samples were collected from all those who 
consented and where time allowed around their scheduled clinical 
investigations, which had been arranged prior to their appointments.   
For all study subjects, plain chest radiographs (CXR) were performed at the 
first study visit. All subjects were also offered high resolution computed 
tomography scans (HRCT scans) of the chest, and if in agreement these were 
arranged for their next attendance. All CXRs and HRCT scans were performed by 
the Radiology Department at the Royal Free Hospital using standard lung 
algorithms as outlined in Methods Section 2.3.4.1 and 2.3.4.2, with assessment 
of air-trapping made on inspiratory and expiratory CT images. Images were 
reviewed by a Consultant Thoracic Radiologist, Dr. Jamanda Haddock, and the 
data collated by Dr. Nadia Shafi.  
3.5 Patient Population   
3.5.1 Recruitment and follow up 
Forty five study subjects were prospectively recruited to the AFD group 
over the period of a year from 02/06/2009 to 08/06/2010, including 20 males 
and 25 females. Of these, follow up lung function data were collected from 30 
subjects at 6 months and from 14 subjects at 12 months.  
 A control cohort of 9 healthy volunteers was also recruited, matched for 
age and gender only to 9 of the AFD subjects (Appendix 2, Table 1.0). The main 
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purpose of this matched cohort was for comparison of sputum findings in 
subsequent chapters.  Therefore for the analysis of lung function data these 
subjects were analysed with the AFD group as a whole.  
A COPD cohort of 14 subjects was also recruited from the London COPD 
cohort based at the Royal Free Hospital. As outlined in Methods Section 2.2.2, 
these COPD subjects were matched as closely as possible to 14 of the AFD 
subjects with airway obstruction. Priority for matching was given to gender and 
spirometric GOLD stage over age. As a consequence, the participants in the 
COPD group were significantly older than those in the AFD group and the healthy 
control group (Appendix 2, Table2.0), (p<0.0005). Despite matching for GOLD 
stage, individual lung function parameters aside from FVC% predicted were 
significantly lower in the COPD group compared to the matched AFD group 
(Appendix 2, Table2.0), (p<0.05 for each). The purpose of this COPD cohort was 
mainly for the comparison of induced sputum samples. The COPD subjects were, 
therefore, not included in all of the lung function analysis.  
3.5.2 Respiratory symptoms in AFD subjects  
Clinical information was collected at baseline study visits for all study 
subjects with AFD. In total 28 of the 45 AFD subjects (62%) reported at least one 
of the following symptoms: shortness of breath on exertion, cough or wheeze. 
Eighteen of the 45 subjects (40%) noted shortness of breath on exertion, with 
40% reporting cough and 31% (14 of 45) reporting wheeze.  
3.5.3 Gender and ethnicity 
The AFD group consisted of 20 (44%) males, the COPD group 9 (64%) 
males, and the healthy control group 5 (56%) males. Forty-four out of 45 (98%) 
of the AFD subjects were Caucasian, with the remaining subject being of African 
origin. All 14 of the COPD control subjects were Caucasian, as were 8 of the 9 
(89%) healthy control subjects with the remaining one being of Asian extraction. 
Given the nature of AFD as an X-linked disease and not associated with ethnicity, 
it is likely that gender would be more relevant to the interpretation of results 
than race.   
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Table 3.5.1 Demographics of AFD, COPD and healthy control 
subjects recruited to study 
Parameter (%) AFD Healthy control COPD 
n 45 (100) 9 (100) 14 (100) 
Age  [years] 
Mean (+/- SD) 
46.5 
(+/- 14.7) 
41.7 
(+/- 10.5) 
65.8* 
(+/- 10.0) 
Males, 
females 
20 (44), 
25 (55) 
5 (56), 
4 (44) 
9 (64), 
5 (36) 
Smoking history 
>10 pack years 
14 (31) 2 (22) 13 (93) 
ERT 37 (82) - - 
Caucasian 44 (98) 8 (89) 14 (100) 
Beta blocker use 6 (13) 0 0 
Beta agonist use 7 (16) 0 14 (100) 
*p<0.001 compared to AFD and healthy control group using 1 way ANOVA 
3.5.4 Smoking history 
Of the AFD group 31% (14 of the 45) had a smoking history of >10 pack 
years, whereas this was the case for 92% of the COPD subjects, and 22% of the 
healthy control group (Table 3.5.1). Of the AFD subjects, 5 were current smokers 
at the time of the study. None of the COPD subjects or healthy control subjects 
were ongoing smokers.  
There was no history of occupational exposure to asbestos or other 
significant respirable agents in the AFD subjects or healthy controls. 
3.5.5 Relevant Medication History  
Six of the 45 AFD subjects (13%) were on beta blocker medication for 
cardiac co-morbidity, with 3 subjects on bisoprolol at a maximum dose of 2.5mg 
once daily, and 3 subjects on atenonol at a maximum of 50mg once daily. In 
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addition 7 of the AFD subjects (16%) had been prescribed an inhaled 
bronchodilator in the form of salbutamol to use on an as required basis (though 
on questioning none of them were using this regularly). All study subjects were 
asked to refrain from using any inhaled bronchodilators prior to their lung 
function assessments. Of the 45 participants in the AFD group, 82% were already 
receiving enzyme replacement therapy, with 8 of the 45 being enzyme naïve 
(Table 3.5.1). 
3.5.6 Genotypes 
Of the AFD subjects recruited, the genetic mutation in the α-galactosidase 
gene had been documented in all of the 45 subjects. This comprised 22 different 
mutations, with the most frequent mutation being the missense mutation N215S 
present in 11 of the 45 subjects, followed by R227X (6 subjects) and 1317T (4 
subjects) (Table 3.5.6). 
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Table 3.5.6 Genotypes of Anderson Fabry Disease subjects recruited 
to the study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotype 
 
Frequency 
n (%) 
Total 45 (100) 
N215S 11 (24) 
R227X 6 (13) 
1317T 4 (9) 
exon 1 deletion 3 (7) 
R310X 2 (4) 
P205T 2 (4) 
P293H 2 (4) 
A309P 1 (2) 
B/3316E 1 (2) 
R342Q 1 (2) 
I90.T 1 (2) 
G261V 1 (2) 
G208H 1 (2) 
520-T 1 (2) 
c.277G>T D93Y 1 (2) 
c925G>C 1 (2) 
c92C>T 1 (2) 
c.334C>T 1 (2) 
c.972-G in exon 6 1 (2) 
c.748_801+8del62 1 (2) 
c.802-3_802-2 del 1 (2) 
c520delT 1 (2) 
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3.6 Results - Lung function data 
3.6.1 Spirometry and diffusion capacity 
Baseline lung function tests at recruitment were compared between the 
AFD and healthy control groups. Although 9 of the 45 AFD subjects were 
matched for age and gender to the 9 healthy controls, these subjects were kept 
in the group for the purposes of lung function data analysis as they were not 
matched on this parameter.   
Significant differences were seen in spirometry between the AFD and 
healthy control group, including FEV₁ %predicted, FVC %predicted and FEV₁/FVC 
which were all found to be lower in the AFD group (Table 3.6.1). This was also 
the case for measurements of peak expiratory flow rate (PEFR).  
In the AFD group 80% of subjects (36 out of 45) had evidence of smaller 
airway obstruction (based on the presence of an MEF50 <70%predicted), though 
no difference was seen in RV/TLC between the groups.  
Diffusion capacity, measured by TLCO, was found to be lower in the AFD 
group compared to the healthy control group (p=0.04), though this was not 
evident when corrected for alveolar volume, KCO (Table 3.6.1) 
On analysis of the age and gender matched sub-group of 9 AFD subjects 
and healthy controls, the same pattern of significant differences in airway calibre 
was found (Appendix 2, Table 1.0). However the difference in gas transfer as 
measured by TLCO was not evident in the age and gender matched groups.   
As would be expected, all of the spirometric parameters and measures of 
diffusion capacity were significantly lower in the COPD group compared to the 
healthy control group (data shown here for descriptive purposes, comparison 
not shown). For the 14 AFD and matched COPD subjects, data are shown in 
Appendix 2, Table 2.0.  
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Table 3.6.1 Spirometry and diffusion capacity in AFD, healthy control 
and COPD subjects, with comparison between AFD and healthy 
control groups 
% predicted 
Mean 
(+/- SD) 
AFD Healthy 
Control 
COPD p value 
(unpaired 
t test) 
n 45 9 14 - 
FEV₁ 89.8 
(+/- 11.9) 
109.6 
(+/- 16.3) 
70.2 
(+/- 13.1) 
<0.0001 
FVC 104.1 
(+/- 12.2) 
117.4 
(+/- 18.6) 
103.7 
(+/- 18.0) 
0.009 
FEV₁ /FVC 0.7 
(+/- 0.08) 
0.8 
(+/- 0.08) 
0.6 
(+/- 0.02) 
0.02 
PEFR 105.7 
(+/- 15.6) 
119.1 
(+/- 19.7) 
81.9 
(+/- 18.2) 
0.03 
MEF50 57.8 
(+/- 18.2) 
93.9 
(+/- 38.7) 
25.5 
(+/- 14.3) 
<0.001 
RV/TLC 88.6 
(+/- 15.7) 
86.3 
(+/- 14.1) 
117.7 
(+/- 18.1) 
0.5 
TLCO 86.4 
(+/- 12.2) 
95.4 
(+/- 12.1) 
69.7 
(+/- 16.3) 
0.04 
KCO 96.0 
(+/- 13.3) 
98.8 
(+/- 12.6) 
78.7 
(+/- 19.4) 
0.56 
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3.6.3 Reversibility to bronchodilators 
Reversibility to bronchodilators was tested by repeating spirometry 15 
minutes after the administration of 2.5mg of nebulised salbutamol at the 
baseline visit on 43 of the 45 AFD subjects recruited, with significance 
interpreted ≥ 15% improvement from baseline on the repeat test.  
Only 5% of subjects tested (2 of the 43) had any significant improvement in 
FEV₁ %predicted and PEFR with a mean improvement of 18% and 19.5% 
respectively (Table 3.6.3).  
More significant reversibility to bronchodilators was evident in 37% of AFD 
subjects showing significant improvement in MEF50 %predicted on repeat 
spirometry, though it is acknowledged that in general this measure may be 
subject to some variability (Table 3.6.3).  
Table 3.6.3 Summary of positive bronchodilator reversibility tests in 
AFD subjects  
 
Parameter 
(% predicted) 
FEV₁ PEFR MEF50 
n (%) 2 (5) 2 (5) 16 (37) 
Mean % 
improvement 
(+/- SD) 
18.0 
(+/- 4.2) 
19.5 
(+/- 4.6) 
31.4 
(+/- 17.6) 
n=number of subjects out of total 43 with a significant bronchodilator response 
of ≥15%  
3.6.4 Lung function in relation to symptoms 
Of the 18 subjects who reported shortness of breath on exertion, 8 (44%) 
had evidence of airway obstruction with FEV₁/FVC <0.7, whilst 78% (14 of the 18) 
had MEF50 <70% predicted.  
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Of those reporting cough, 67% (12 of 18) had an FEV₁/FVC <0.7, as did 83% 
(10 of 12) of the AFD subjects reporting wheeze, with 85% and 88% of subjects 
who reported cough or wheeze having MEF50 <70 %predicted.  
3.6.5 Comparison of AFD subjects with and without airway 
obstruction   
Within the AFD group, 21 out of the total 45 subjects (47%) had evidence 
of airway obstruction based on the criteria of FEV₁/FVC <0.7. The mean age of 
the AFD subjects with airways obstruction was 49.8 years, which was older than 
those AFD subjects without airways obstruction at 43.8 years, though this was 
not statistically significant (Table 3.6.5). In addition the AFD group with airway 
obstruction contained more male subjects (62% vs 29%) and more subjects with 
a smoking history of greater than 10 pack years (43% vs 21%) than the 
unobstructed AFD group.  
Examining the overall disease severity of the groups using the Mainz 
Severity Score Index, it was apparent that the AFD subjects with airway 
obstruction had significantly more severe disease than those without airway 
obstruction (p=0.007) (Table 3.6.5). However, on using the Age Adjusted Severity 
Score, although the AFD group with airway obstruction scored higher than those 
without, this was not found to be statistically significant between the groups.  
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Table 3.6.5 Comparison of demographics of AFD subjects with and 
without evidence of airway obstruction as defined by FEV₁/FVC <0.7  
Parameter AFD with airway 
obstruction 
AFD without 
airway 
obstruction 
P value 
(unpaired t test) 
n (%) 21 (47) 24 (53) - 
Age, years 
(mean +/-SD) 
49.8 
(+/- 14.0) 
43.8 
(+/- 15.0) 
0.17 
Males, 
females 
(% of n) 
13 (62), 
8 (38) 
7 (29), 
17 (71) 
- 
- 
Smokers 
>10 pack years 
(% of n) 
9 (43%) 5 (21%) 0.009 
On ERT 
(% of n) 
18 (86%) 20 (83%) - 
MSSI 27.2 
(+/- 12.2) 
16.35 
(+/- 10.6) 
0.007 
Age adjusted 
severity score 
4.4 
(+/- 8.4) 
0.1 
(+/- 6.9) 
0.11 
 
3.6.6 Gender differences in spirometry and diffusion capacity in AFD, 
COPD and healthy control subjects  
Thirteen of the 20 AFD males (65%) had evidence of airway obstruction as 
defined by an FEV₁/FVC <0.7. There were significant differences in spirometric 
measures with FEV₁ %predicted, FVC %predicted, FEV₁/FVC and PEFR all being 
lower in AFD males compared to healthy control males (Table 3.6.6). In addition 
16 of the 20 AFD males (80%) had MEF50 <70 %predicted, with measures of 
MEF50 %predicted being significantly lower than in healthy control males. 
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However, no differences in RV/TLC were seen between the two male groups 
(Table 3.6.6).  
In AFD females, 7 of the 25 (28%) had evidence of airway obstruction with 
FEV₁/FVC <0.7, and FEV₁ %predicted was found to be significantly lower than in 
healthy control females (p=0.02). In 17 of the 25 AFD females (68%) MEF50 was 
found to be low at <70 %predicted (Table 3.6.6), and overall MEF50 %predicted 
was found to be significantly lower than that in healthy control females (p=0.02) 
(Table 3.6.6). 
Between the genders in AFD there were some significant differences in 
spirometric parameters with FEV₁ %predicted and FVC %predicted being lower in 
AFD males than AFD females (p=0.03 and 0.008 respectively), though measures 
of diffusion capacity were similar (Table 3.6.6).  
Measures of gas transfer were similar in AFD males compared to healthy 
control males, and in AFD females compared to healthy control females. No 
difference in diffusion capacity was seen between genders in AFD subjects.  
There were no differences found in any of the parameters between males 
and females in the healthy control group (Table 3.6.6) or in the COPD group 
(Appendix 2, Table 3.0).  
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Table 3.6.6 Spirometry and diffusion capacity in AFD and healthy 
control males and females  
 
% 
predicted 
Mean 
(+/SD) 
AFD males Healthy 
control 
males 
p AFD females Healthy 
control 
females 
p 
n 20 5 - 25 4 - 
FEV1 85.7 § 
(+/- 9.7) 
107.7 
(+/- 14.1) 
0.005 93.0 
(+/- 12.6) 
111.9 
(+/- 20.7) 
0.04 
FVC 98.8 § 
(+/- 9.1) 
112.3 
(+/- 12.3) 
0.02 108.3 
(+/- 13.0) 
123.7 
(+/- 25.0) 
0.2 
FEV₁ 
/FVC 
0.6 
(+/- 0.07) 
0.8 
(+/- 0.1) 
0.04 0.7 
(+/- 0.08) 
0.8 
(+/- 0.06) 
0.27 
PEFR 102.8 
(+/- 16.1) 
125.6 
(+/- 23.1) 
0.02 108.1 
(+/- 15.2) 
111.0 
(+/- 12.9) 
0.72 
MEF50 53.87 
(+/- 15.3) 
97.82 
(+/- 50.3) 
0.01 60.96 
(+/- 20.1) 
89.13 
(+/- 24.4) 
0.05 
RV/TLC 92.53 
(+/- 16.6) 
88.76 
(+/- 18.5) 
0.66 85.68 
(+/- 14.8) 
83.23 
(+/- 7.3) 
0.75 
TLCO 87.6 
(+/- 14.4) 
99.8 
(+/- 13.8) 
0.11 85.4 
(+/- 10.4) 
89.9 
(+/- 7.9) 
0.41 
KCO 99.7 
(+/- 14.1) 
103.8 
(+/- 14.6) 
0.57 93.1 
(+/- 12.2) 
92.5 
(+/- 6.9) 
0.93 
Comparison of AFD groups and sex matched controls performed using Mann 
Whitney U test given small numbers 
§ p<0.05 AFD males compared to AFD females using unpaired t test 
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3.6.7 Impact of smoking history on spirometry and diffusion capacity 
Fourteen AFD subjects with >10 pack years of smoking and 31 AFD subjects 
with <10 pack years of smoking were compared to 7 healthy controls with <10 
pack years smoking history.  
In the 31 AFD subjects who had little in the way of a smoking history (<10 
pack years) spirometric measures including FEV₁ %predicted, FVC %predicted, 
FEV₁/FVC and PEFR were all significantly lower than in the healthy control group 
(Table 3.6.7). MEF50 %predicted was also significantly lower in the AFD group 
compared to the healthy controls though no difference was seen in RV/TLC. No 
significant differences in gas transfer were evident between the groups with <10 
pack years of smoking. However, in AFD subjects who had a >10 pack years 
smoking history there was a significant reduction in diffusion capacity as 
measured by TLCO and KCO (p=0.02 for both) (Table 3.6.7).  
3.6.8 AFD lung function change over time   
AFD subjects were followed up at 6 months intervals, and lung function 
data collected as frequently as possible during the study. For 12 of the 45 AFD 
subjects recruited, lung function was performed on 3 separate occasions at 6 
month intervals (spirometry as shown in Figure 3.6.8). All of these subjects were 
receiving enzyme replacement therapy fortnightly. There was no significant 
variation in any of the measured parameter of large airways, small airways or gas 
transfer over a follow up period of 12 months (Table 3.0, Appendix 1). 
For 15 of the 45 subjects, baseline and 6 month lung function follow up 
data were collected and for 4 subjects, baseline and 12 month lung function data 
were collected (data not shown).  
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Table 3.6.7 Spirometry and diffusion capacity in AFD subjects in 
relation to smoking history  
% predicted 
Mean 
(+/- SD) 
AFD 
>10 pack 
years 
AFD 
<10 pack years 
Healthy controls 
<10 pack years 
p 
(unpaired 
t test) 
n 14 31 7 - 
FEV₁ 88.7 
(+/- 13.4) 
90.6 
(+/- 11.4) 
112.4 
(+/- 17.4) 
0.0002 
FVC 105.0 
(+/- 13.1) 
103.3 
(+/- 12.3) 
116.6 
(+/- 20.9) 
0.03 
FEV₁/FVC 0.7 
(+/- 0.07) 
0.7 
(+/- 0.07) 
0.8 
(+/- 0.07) 
0.01 
PEFR 104.9 
(+/- 15.3) 
106.1 
(+/- 16.0) 
121.1 
(+/- 21.5) 
0.04 
MEF50 52.2 
(+/- 18.9) 
60.3 
(+/- 17.7) 
103.8 
(+/- 38.5) 
<0.0001 
RV/TLC 88.3 
(+/- 18.6) 
88.8 
(+/- 14.5) 
87.4 
(+/- 16.1) 
0.83 
TLCO 79.9* 
(+/- 12.8) 
89.3 
(+/- 11.0) 
98.1 
(+/- 12.3) 
0.07 
KCO 89.2* 
(+/- 12.4) 
99.1 
(+/- 12.7) 
101.7 
(+/- 12.7) 
0.62 
p values shown for comparison between AFD <10 pack years of smoking and 
healthy control group using unpaired t test 
* p=0.02 compared to AFD <10 pack years using unpaired t test, p >0.05 for all 
other parameters  
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Figure 3.6.8 Spirometry in AFD subjects receiving fortnightly enzyme 
replacement therapy at baseline, 6 months and 12 months follow up  
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3.7 Results - Imaging 
Plain chest radiographs (CXRs) were performed at baseline according to the 
protocol outlined in the Methods section 2.3.4.1 on the first study visit for 38 of 
the 45 AFD subjects, and were reported by standard radiology criteria by the 
Royal Free Hospital Radiology Department. Of these, 34 CXRs were reported as 
normal with clear lung fields. The remaining CXRs showed various abnormalities 
as outlined in Table 3.7. These changes were not thought to be related to 
pulmonary involvement of AFD though clearly some were likely related to 
cardiac involvement of AFD.   
Seventeen of the 45 AFD subjects also had high resolution computed 
tomography (HRCT) scan of the chest (protocol described in Methods section 
2.3.4.2), with inspiratory and expiratory images to highlight the presence of air 
trapping as an indicator of small airways disease. None of the 17 scans were 
reported to show evidence of air trapping, though abnormalities were noted on 
the scans from 3 male subjects in the form of scattered bullae in one, a small 
amount of emphysema on another with this being the only subject with a 
significant smoking history of 40 pack years, and an area of linear atelectasis in a 
third study. One of the HRCT scans was performed in inspiration only, and 
therefore a full assessment of the presence of air trapping could not be made, 
though no other abnormality was seen.  
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Table 3.7 Summary of Imaging studies in AFD subjects  
 Normal 
n (%) 
Abnormal 
n (%) 
Abnormalities seen 
CXR 34 (89%) 4 (11%) 1. cardiomegaly + ICD 
2. prominent vasculature 
3. blunted left  costophrenic angle  
4. bilateral apical fibrosis  
HRCT 
chest 
14 (82%) 3 (18%) 1. scattered bullae 
2. emphysema  
3. linear atelectasis 
CXR – chest radiograph, HRCT – high resolution computed tomography scan,  
ICD – implantable cardiac device  
3.8 AFD disease severity, enzyme replacement therapy and 
genotype  
3.8.1 Enzyme replacement therapy (ERT) and disease severity 
Of the AFD subjects 37 were on ERT with a mean duration of 53 months 
(SD +/-31.2) and 8 of the AFD subjects were enzyme naïve. There appeared to be 
no significant difference in spirometric parameters or diffusion capacity between 
those AFD subjects on ERT and those who were not on ERT (Table 3.8.1).  
As might be expected, the disease severity of the AFD subjects on enzyme 
replacement therapy, as measured by both the Mainz Severity Score Index 
(MSSI) and the Age Adjusted Severity Score was significantly worse in the group 
on enzyme replacement therapy compared to the enzyme naïve group (p=0.001 
and 0.009 respectively) (Table 3.8.1).  
When analysing the data as continuous variables there appeared to be a 
weak but significant negative correlation between FEV₁/FVC ratio and MSSI (r = -
0.41, p=0.01), though again this was not evident with the Age Adjusted Severity 
Score (Figure 3.8.1i) and ii)).  
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Figure 3.8.1 Correlation between disease severity scores and  
FEV₁ /FVC in AFD 
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Table 3.8.1 Disease severity and enzyme replacement therapy in AFD 
subjects in relation to lung function 
% predicted 
Mean (+/- SD) 
ERT No ERT 
n 37 8 
MSSI 
Median (range) 
26.0 ** 
(14.0 - 32.0) 
3.0 
(1.75 - 13.5) 
Age adjusted severity 
score 
Median (range) 
3.89** 
(-2.74 - 9.93) 
-4.790 
(-6.148 - -2.52) 
FEV₁ 90.67 
(+/- 11.9) 
85.63 
(+/- 11.4) 
FVC 104.4 
(+/- 12.4) 
102.5 
(+/- 12.4) 
FEV₁/FVC 0.72 
(+/- 0.07) 
0.72 
(+/- 0.08) 
PEFR 107.5 
(+/- 15.7) 
97.38 
(+/- 12.8) 
MEF50 58.4 
(+/- 18.7) 
55.0 
(+/- 16.4) 
RV/TLC 88.19 
(+/- 15.0) 
91.17 
(+/- 21.3) 
TLCO 85.41 
(+/- 12.3) 
90.75 
(+/- 11.4) 
KCO 95.81 
(+/- 14.0) 
96.86 
(+/- 9.4) 
**p<0.01 compared to no ERT group using Mann Whitney U test 
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3.8.2 Lung function in relation to genotype  
The spirometric parameters of the most common genotypes from the 
group were compared, and FEV₁/FVC ratio was seen to be lowest in subjects with 
the mutation R227X and highest in the subjects with exon 1 deletions, though 
the numbers within each group were very small (Figure 3.8.2) Between the 
genotype sub-groups, mean age was greatest in the N215S group, and overall 
disease severity as measured by MSSI was worst in the exon 1 deletion group, 
though with the Age Adjusted Severity Score, overall disease severity was worst 
in the 1317T sub-group (Table 3.8.2) 
 
Table 3.8.2 Severity scores for AFD cohort by genotype  
Genotype N215S R227X 
 
Exon 1 
deletion 
1317T 
n (%) 11 (24) 6 (13) 3 (7) 4 (9) 
FEV₁/FVC 
Median (range) 
0.75 
(0.59 -0.81) 
0.63 
(0.59 – 0.72) 
0.83 
(0.74 – 0.89) 
0.72 
(0.68 – 0.85) 
Age [years] 
Mean (+/- SD) 
53.4 
(+/- 15.8) 
42.1 
(+/- 12.4) 
44.3 
(+/- 17.5) 
47.5 
(+/- 21.8) 
MSSI 
Median (range) 
21.5 
(1.0 – 44.0) 
20.5 
(2.0 – 32.0) 
26.0 
(19.0 – 30.0) 
21.0 
(18.24) 
Age adjusted 
severity score 
Median (range) 
-4.55 
(-6.9 – 8.0) 
2.7 
(-2.0 – 8.2) 
0.08 
(-3.5 – 11.8) 
7.1 
(1.4 – 12.8) 
Smoking history 
[pk years] 
Median (range) 
15.0 
(0 – 40) 
2.5 
(0 – 35) 
0 
(0) 
17.5 
(11.0 – 22.5) 
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3.8.3 Multivariate analysis 
To investigate the impact of factors associated with FEV₁/FVC and MEF50 
%predicted after controlling for other potential confounders, multivariate linear 
regression analyses were.  The potential factors considered were gender, 
smoking, age, residual enzyme activity and disease severity as measured by 
MSSI. Both FEV₁/FVC and MEF50 %predicted were confirmed to be normally 
distributed, ensuring that performing a linear regression was reasonable. The 
models were performed using SPSS version 20 (IBM SPSS Statistics, USA). The 
findings of the analyses did not reveal any significant factors influencing 
FEV₁/FVC and MEF50 %predicted when taking into account all the potential 
confounders, though there was a suggestion that MSSI may be a more influential 
factor in FEV₁/FVC and gender in MEF50 %predicted.  
Table 3.8.3.1 Multivariate analysis FEV₁/FVC in AFD  
Factor  Comparator Univariate Multivariate 
Regression 
coefficient 
95% 
CI 
P 
value 
Regression 
coefficient 
95%  
CI 
p 
value 
Gender Male vs. 
Female 
-0.04 -0.08, 
+0.01 
0.13 -0.031 -0.12, 
0.82 
0.47 
Smoking >10 pyrs vs. 
<=10 pyrs 
-0.05 -0.09, 
+0.002 
0.06 -0.032 -0.09, 
0.02 
0.23 
Age Per 5 years 
older 
-0.005 -0.013, 
0.003 
0.20 0.010 -0.004, 
0.025 
0.16 
Residual 
enzyme 
activity 
Per 1 higher 0.01 0.002, 
0.02 
0.02 -0.005 -0.028, 
0.019 
0.70 
MSSI 
score 
Per 1 higher -0.002 -0.004, 
0.000 
0.02 -0.003 -0.005, 
0.000 
0.09 
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Table 3.8.3.2 Multivariate analysis of MEF 50% predicted in AFD  
Factor  Comparator Univariate Multivariate 
Regression 
coefficient 
95%  
CI 
p 
value 
Regression 
coefficient 
95%  
CI 
p 
value 
Gender Male vs. 
Female 
-6.82 -17.78, 
4.14 
0.22 -20.77 -45.03, 
3.49 
0.09 
Smoking >10 
vs. <=10 
pk yrs 
-8.12 -19.84, 
+3.60 
0.17 -5.47 -20.19, 
9.25 
0.45 
Age Per 5 years 
older 
-0.98 -2.86, 
0.90 
0.30 2.84 -1.19, 
6.88 
0.16 
Residual 
enzyme 
activity 
Per 1 
higher 
1.67 -0.89, 
4.22 
0.20 -4.86 -11.48, 
1.77 
0.14 
MSSI 
score 
Per 1 
higher 
-0.42 -0.85, 
0.02 
0.06 -0.56 -1.37, 
0.26 
0.17 
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3.9 Discussion 
 Prior to this study pulmonary abnormalities have documented in Anderson 
Fabry disease within mainly case reports and the occasional clinical series. Here, 
we find that 62% of AFD subjects recruited had at least one respiratory 
symptom, and 40% of subjects two or more. Whilst it is possible that some of 
these symptoms are attributable to underlying cardiac involvement, given the 
findings from this study, it is difficult to discount pulmonary disease as being a 
significant factor. We confirm what has been suggested by the limited published 
data that pulmonary involvement in AFD in the form of airway obstruction is 
common. In this cohort 47% of the AFD subjects demonstrated an FEV₁/FVC of 
<0.7, the current widely used definition of obstructive airways disease in clinical 
respiratory medicine (195;196), with 80% of all AFD subjects showing some 
evidence of small airways obstruction on MEF50 measurement.  This is similar to 
previous work by Magage et al (197)who found that only 16% of their AFD cohort 
showed no abnormality on spirometry when tested.  Also, Brown et al (198) 
reported 36% of their cohort of 25 subjects demonstrated criteria in keeping 
with airway obstruction.   
All 21 of the AFD subjects who had evidence of airway obstruction had 
either mild or moderate disease on spirometry, with 13 subjects classed as GOLD 
Stage I, and 8 classed as GOLD Stage II, similar to the degree of airway 
obstruction reported in the aforementioned studies, though there have been 
case reports of more severe airway obstruction (199). Our study goes on to show 
that differences in airway calibre in AFD compared to healthy controls are also 
evident using peak expiratory flow rate (PEFR) measurement.  This is a simple 
bedside measure of mainly large airways, and can be easily performed and 
monitored by subjects at home. This may be useful for future studies as a 
method of evaluating respiratory symptoms and assessing pulmonary 
involvement in AFD.  
In addition there was seen to be a reduction in one measure of gas transfer 
in the form of TLCO in AFD subjects compared to controls, though when 
corrected for alveolar volume (KCO) this was not consistently so. When carefully-
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matched AFD and healthy control sub groups were compared, this difference 
was lost. Whether this reflects smaller sample size in the latter populations or 
the genuine effect of removing confounders is unclear.  Previously Wang et al 
(200) reported a case of AFD with significantly reduced transfer factor and 
evidence of pulmonary infiltrates on CT imaging, which stabilised on 
commencement of ERT, whilst Bartimmo and colleagues (201) also reported 
reductions in diffusion capacity in a family with AFD, though it was suggested 
that the effects of smoking may have had a significant part to play in that 
particular case. The work reported within this study would tend to support the 
latter suggestion, given that smoking with a pack year history of >10 in AFD 
subjects appeared to be associated with statistically significant reductions in 
both TLCO and KCO compared to AFD subjects with a smoking history of <10 
pack years.  
Despite widespread evidence of small airway obstruction, no significant 
differences were demonstrated in static lung volumes in the AFD subjects 
compared to controls in this study. In previous case series where elevated 
residual volumes (RV) have been reported, these have been only in smokers with 
other evidence of emphysema, and therefore difficult to assign to changes 
related to AFD (202;203). In our series however there was no physiological 
evidence of significant air trapping with RV/TLC measures similar in AFD subjects 
and healthy controls; though as would be expected, this was elevated within the 
COPD cohort.  
Very few of the AFD subjects demonstrated significant improvement in 
spirometry following nebulised bronchodilators, with only 2 subjects showing 
any increase in FEV₁ %predicted and PEFR out of the 43 tested (5%). More 
widespread improvement was seen in small airway parameters with 30-40% of 
AFD subjects showing a significant increase in MEF25, MEF50 and MEF75 
%predicted following administration of the drug.  The clinical significance of this 
is less clear, given that there can be significant variability in the measurement of 
these latter parameters. In contrast, Brown et al (204) reported that 5 of 8 male 
subjects showed an improvement in FEV₁ following bronchodilator 
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administration, though this was using a cut off of 12% improvement as being 
significant, as opposed to 15% as in this and most other studies. They also 
performed methacholine challenge testing on their subjects, but did not report 
any positive responses in the 10 subjects tested suggesting a lack of 
bronchoconstrictive tendency.  Magage et al (205) also reported only partial 
reversibility in some of their subjects who underwent bronchodilator testing. 
We hypothesised that the changes seen in AFD in the lungs would be 
evident in both males and females, though more common and more severe in 
men. Analysis of lung function data by gender confirmed this, with two thirds of 
male subjects demonstrating evidence of significant airway obstruction 
(FEV₁/FVC of <0.7), whereas for females this was just under one third.  
On further analysis it was apparent that the extent of the changes was 
greater in AFD males compared to sex matched controls, with changes in AFD 
females limited to FEV₁ %predicted and MEF50 %predicted, though the number of 
subjects in each of the control groups was small. As was anticipated, the extent 
of change in spirometry was more significant in AFD males compared to AFD 
females. No differences were seen in any of the lung function parameters when 
analysed by gender in either the COPD cohort or the healthy control cohort, 
suggesting that the difference seen between AFD males and females appears to 
result from AFD rather than other gender related factors. Older age did not 
appear to explain the degree of airway obstruction in AFD subjects.  
This pattern of lung involvement by gender is similar to that found in a 
previous AFD study (206). This is of particular importance as in particular as in 
the past the extent of lung changes in AFD was mainly documented in  male 
subjects (207). Data on AFD females prior to this have been largely confined  to 
case reports (208;209). Data from the Fabry Outcome Survey (FOS) has 
highlighted that females are affected by the systemic disease in a similar manner 
to males, though clinical sequalea tend to occur up to a decade later (210). This 
may, in part, explain the difference in prevalence of airway involvement in the 
gender-divided groups of a similar age.  
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 Stratifying AFD subjects by their smoking history enabled us to examine 
the potential impact of smoking on lung function. It was evident when comparing 
AFD subjects with little in the way of smoking history to healthy control subjects 
with a similar degree of smoking history that the changes seen in airway calibre 
in AFD cannot be explained by smoking alone. Significant reductions in both large 
and small airway parameters were found in AFD subjects with <10 pack year 
history of smoking when compared to healthy controls. No differences were seen 
in lung volumes or measures of diffusion capacity between these groups.  
Further reductions in these parameters were present with >10 pack years 
of smoking, with significant worsening of spirometric measures compared to 
healthy controls, as well as AFD subjects with  <10 pack years smoking. In 
addition, these AFD subjects with a heavier smoking history also showed 
significant reductions in diffusion capacity, both TLCO and KCO - making these 
changes (when present) more likely to be related to smoking than to AFD itself. 
From a clinical perspective this underlines the need to emphasise the importance 
of smoking cessation in this group of patients, given that it would appear to 
promote pulmonary change which may already be ongoing as a result of AFD.  
Given the nature of AFD as a condition shown to progress over time (211), 
we were keen to determine whether this pattern also applied within the lungs. 
The maximum follow up for this study however was only 12 months, and over 
this time no significant changes to lung function parameters were noted. It is 
likely that this follow up period was not long enough to detect longitudinal 
change in individual lung function parameters. In previous studies with longer 
follow up periods (of maximally 60 months), there was a trend towards falling 
spirometric measures, though these did not reach significance (212). Given that 
the majority of subjects in this study were on enzyme replacement therapy, and 
the cohort in the previously mentioned study were enzyme naïve, it is difficult to 
argue that any lack of progression over time was as a result of a therapeutic 
intervention such as ERT.  
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Plain chest radiographs in the AFD subjects did not reveal obvious lung 
abnormalities. The great majority of these were reported as normal, apart from 
one where changes were thought likely secondary to previous undiagnosed 
bacterial infection. The other abnormalities seen on the remaining CXRs were 
largely cardiac in nature, and likely secondary to cardiac morbidity associated 
with AFD.  This is similar to findings from Brown et al (213) who reported normal 
chest radiographs in 24 of their 25 male AFD subjects, with streaky shadowing 
bibasally in the one remaining individual.  
High resolution computed tomography (HRCT) scanning in 17 AFD subjects 
revealed normal lung parenchyma in 82% of subjects, with evidence of bullae 
and emphysema in 2, and a small area of atelectasis in a third subject. Of note, 
the emphysematous changes were seen in one of the AFD subjects with a >20 
pack year smoking history, though neither of the other 2 AFD subjects were 
current smokers. Inspiratory and expiratory HRCT images were performed 
specifically to assess for evidence of air trapping, a marker for small airways 
disease, demonstrated by mosaic changes of the lung parenchyma. In our series 
this was not evident in any of the AFD subjects. Evidence of air trapping with 
severe mosaic attenuation along with ground glass opacity have previously been 
documented in a case report of a female AFD subject with respiratory symptoms, 
whose air trapping persisted on CT despite symptomatic and physiological 
improvement following commencement of enzyme replacement therapy (214) as 
have bullous changes and pneumothoraces.  
Although the majority of the AFD subjects recruited to the study were 
already established on ERT, there were a number who were enzyme naïve, 
mainly due to a lack of clinical indication for commencement of ERT. As a result it 
is not surprising that the disease severity scores of the AFD subjects on ERT using 
both the Mainz Severity Score Index (MSSI) (215) and the Age Adjusted Severity 
Score (216) were significantly worse in the group on ERT compared to enzyme 
naïve subjects. However, given there was no significant difference between the 
groups in any of the lung function parameters measured, one might propose that 
ERT has little demonstrable impact on lung function in AFD. However, further 
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longitudinal follow up and ideally larger numbers would be required to ascertain 
whether ERT might slow the rate of decline in lung function over time with 
increasing age that has been suggested is the natural history of lung involvement 
in AFD by previous studies  (217;218).  
Examining MSSI scores in AFD subjects with and without airway 
obstruction, it would appear that those with airway obstruction are likely to have 
more severe overall AFD pathology. However it is difficult to draw any firm 
conclusion given that there are a number of other confounding factors, such as 
age, smoking history and gender which may also influence this within our study.  
By the same token, and given the limited numbers within the study, it is 
difficult to draw any firm conclusions regarding the influence of genotype on the 
presence and severity of pulmonary involvement in AFD. It would appear that 
within this small group, subjects with the mutation R227X had most significant 
pulmonary disease when assessed by FEV₁/FVC. Given that this group had the 
youngest subjects and was not found to be most severe by either the MSSI or the 
Age Adjusted Severity Scores, this finding is less likely to be attributable to age, 
overall disease severity or smoking as these patients had one of the lowest pack 
year histories. However, as some of the subjects within some of these groups 
were family members, one could argue that familial tendencies and common 
environmental factors need to be taken into consideration as they might 
influence the changes seen.   
  
Chapter 3 – Demographics, clinical features, pulmonary function and imaging  
112 
 
3.10 Conclusions  
 The data in this chapter demonstrates that respiratory symptoms and 
pulmonary involvement in AFD subjects is mild but common and can be 
summarized by the following: 
 
1. The involvement of the lungs in AFD mainly takes the form of airway 
obstruction, and this can be further characterised as: 
 affecting both large and small airways, and detectable on spirometry 
 largely fixed, though with some bronchodilator reversibility evident in 
small airways 
 more common and more severe in males compared to females  
 having no impact on diffusion capacity 
 more likely to be present with increasing disease severity as measured 
by the Mainz Severity Score Index  
2. Both large and small airway obstruction are more severe in smokers with 
>10 pack yrs 
3. No significant change in lung function parameters can be demonstrated 
over a twelve month follow up period 
4. Pulmonary changes in AFD are not evident on chest radiograph or CT 
imaging 
5. Genotype may influence the severity of airway involvement in AFD  
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4.1 Introduction  
In Anderson Fabry disease (AFD) α-galactosidase A activity in both plasma 
and peripheral blood leucocytes has been characterised (219). In males the 
diagnosis of AFD can be made solely on the finding of reduced α-galactosidase A 
activity, whereas in females plasma and peripheral blood leucocyte α-
galactosidase activity can fall within the normal range, presumably as a result of 
lyonisation in the peripheral blood (220), and therefore genotyping is essential 
when the diagnosis is suspected.  
The reference ranges for plasma and peripheral blood leucocyte α-
galactosidase activity used at the Royal Free Molecular Diagnostics Laboratory 
are as below:  
Plasma    
Normal    4 – 21.9 nmol/hr/ml 
Hemizygote AFD 0 – 0.9 nmol/hr/ml 
Heterozygote AFD 0.22 – 7.4 nmol/hr/ml 
Peripheral blood Leucocyte   
Normal    33 – 134 nmol/hr/mg protein 
Hemizygote AFD 0.4 – 5 nmol/hr/mg protein 
Heterozygote AFD 4.3 – 73 nmol/hr/mg protein  
 
Reduction in α-galactosidase A activity results in accumulation of 
globotriaosylceramide (Gb3) which can be demonstrated at a cellular level by 
electron microscopy, histological staining using toluidine blue, or 
immunohistochemistry. Total Gb3 in plasma, urine or tissue homogenate can be 
quantified using mass spectrometry or high performance liquid chromatography 
(HPLC).  α-galactosidase A activity can also be measured in cellular homogenates 
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from various organs or body fluid including tears, though this is not performed 
routinely (221). Although storage material in sputum-derived cells has been 
demonstrated by light and electron microscopy (222), α-galactosidase A activity 
in sputum has not been quantified.  
Evidence from clinical trials suggests that enzyme replacement therapy 
infused fortnightly by AFD subjects produces improvement in both the clinical 
manifestations of the disease and clearance of Gb3 on serial biopsy at end organ 
sites such as liver, kidney and skin (223;224).  This has not been assessed in the 
lung. As α -galactosidase  A activity within the lung has not been quantified, it is 
unknown to what degree enzyme replacement therapy penetrates lung sites, 
and if so what its impact might be, though there have been case reports of 
clinical benefit in the lung (225).  
Therefore, for the purposes of examining the involvement of the 
pulmonary system in more detail, a method to measure α-galactosidase A 
activity in both the fluid phase and cellular phase of induced sputum was 
established (described in Methods Sections 2.3.6 and 2.3.7). Measurement of 
induced sputum α-galactosidase A activity allowed variations in lung function in 
AFD patients and controls to be related to local enzyme activity.  
The presence of inclusion bodies representing Gb3 deposition within 
bronchial epithelial cells suggests the presence of intrinsic airway involvement 
and have been shown to be similar to those found in other organ systems 
involved in AFD (226). These “zebra” bodies have been documented in the 
kidney through renal biopsy (227) and examination of urine sediment (228). They 
have also been reported in the gastrointestinal tract (229), skin (230) as well as in 
cardiac myocytes (231) and nerves (232). Studies looking at the underlying 
pathology in the lung are limited to case reports of sputum and broncho-alveolar 
lavage findings of Gb3 inclusion bodies within respiratory derived cells (233;234). 
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4.2 Hypotheses 
This chapter aimed to test the following hypotheses: 
Hypothesis 1: 
α-galactosidase A activity is measurable in induced sputum and is lower in 
AFD subjects than in controls  
Rationale:  
It is likely that in the lung the pattern of α-galactosidase A activity will follow 
that of blood in AFD  
Hypothesis 2:  
α-galactosidase A activity in induced sputum is lower in AFD males than AFD 
females  
Rationale: 
AFD females may have blood and plasma α-galactosidase A activity within the 
normal range though this is always low in males 
Hypothesis 3: 
There is a consistent relationship between blood and induced sputum α-
galactosidase A activity 
Rationale:  
α-galactosidase A activity in sputum is likely to reflect that of peripheral blood 
given that sputum is consistent mainly of leucocytes originally from the blood 
Hypothesis 4:  
α-galactosidase A activity is lower in the induced sputum of AFD subjects with 
pulmonary  involvement compared to those without 
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Rationale: 
Pathology in AFD occurs as a result of deficient α-galactosidase A activity  
Hypothesis 5:  
α-galactosidase A activity will be similar in AFD subjects on enzyme 
replacement therapy (ERT) than those who are enzyme naïve 
Rationale: 
The half life of exogenous enzyme is short so that it is unlikely to be 
detectable for very long after infusion  
4.3 Objectives  
 
1. To establish a normal reference range for α-galactosidase A activity in 
induced sputum  
2. To compare α-galactosidase A activity in the induced sputum of AFD 
subjects and controls 
3. To compare α-galactosidase A activity in the induced sputum of AFD males 
and females 
4. To delineate a relationship between peripheral blood and lung derived α-
galactosidase A enzyme 
5. To examine the effect of enzyme replacement therapy on α-galactosidase A 
activity in induced sputum  
6. To examine the relationship between induced sputum α-galactosidase A 
enzyme activity and lung involvement in AFD 
Chapter 4 – Pulmonary α-galactosidase A 
118 
 
4.4 Methods  
All collection of data, induced sputum and blood samples were performed 
by the same operator, Dr. Nadia Shafi. Paired samples of blood and induced 
sputum were obtained from control and AFD subjects and prepared as described 
in Methods Section 2.3.2 and 2.3.6.2. Samples were processed on the same day 
with sputum samples processed no more than 2 hours after being obtained, and 
stored for subsequent enzyme assays. Enzyme assays were performed according 
to the protocols outlined in Methods Section 2.3.3 and 2.3.7.   
The further preparation and examination of induced sputum samples by 
electron microscopy were performed by Mr. Innes Clatworthy of the EM 
Department at the Royal Free Hospital London, as outlined in Methods Section 
2.3.11.  
Statistical analysis was performed using unpaired t test for normally 
distributed data, Mann Whitney U test for non-parametric data, with Wilcoxon 
Signed Rank test for paired non-parametric data.  
4.5 Results  
4.5.1 Overview 
α-galactosidase A enzyme activity was measured in paired blood and 
induced sputum samples from 23 AFD subjects and 23 non-AFD controls. The 
non-AFD control group was made up of the 9 healthy control subjects and 14 
COPD control subjects recruited to the study. Given that none of the control 
group had clinical features of AFD, and in addition all of the COPD controls and 
all females were genotyped to exclude the possibility of an underlying diagnosis 
of AFD, they were felt to be a valid control group for the purposes of comparison 
of enzyme activity.  This was borne out on measurement of enzyme activity in 
blood.   
Participants in the healthy control group were matched to AFD subjects by 
gender and age. Subjects in the COPD group were matched to AFD subjects by 
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gender and spirometry. As a result, because age was not a primary matching 
criteria in the COPD group, the mean age of the AFD subjects was significantly 
younger than of the non-AFD control subjects (p=0.02, Table 4.5.1.1). Both the 
AFD and control groups contained 13 males and 10 females. 
The mean FEV₁/FVC ratio of the AFD and control groups was not 
significantly different at 0.68 for each group (Table 4.5.1.1). When analysed 
separately, as expected the healthy control group was found to have a 
significantly higher FEV₁/FVC ratio than the COPD control group (p<0.0001, Table 
4.5.1.2). Of the AFD subjects 18 were receiving enzyme replacement therapy 
(ERT). Of the 5 subjects not receiving ERT, 2 were male.  
A diagnosis of AFD was excluded in all members of the non-AFD control 
group by measurement of plasma α-galactosidase A activity, peripheral blood 
leucocyte α-galactosidase A activity and genetic analysis if necessary. For the 
majority of the control subjects the plasma enzyme activity fell within the normal 
reference range with only 1 subject from the COPD control group with a plasma 
enzyme activity outside the upper limit of the reference range at  
31.0 nmol/hr/ml (Figure 4.5.1.1). 
Peripheral blood leucocyte enzyme activity fell within the normal reference 
range of the RFH Molecular Diagnostics Laboratory for 16 of the 23 control 
subjects. In the remaining 7, peripheral blood leucocyte enzyme activity was 
between 22.31 and 32.44 nmol/hr/mg protein. Genetic analysis did not reveal 
the presence of any disease-causing mutations in the α-galactosidase A gene in 
these subjects.  
When compared to the AFD subjects both plasma and peripheral blood 
leucocyte enzyme activity was significantly higher in the control groups, both 
when analysed as separate groups (1-way ANOVA, Kruskal-Wallis test p<0.05, 
Figure 4.5.1.1) and when combined (Mann Whitney U test p<0.0001, Table 
4.5.1.1). As such, subsequent analysis of enzyme data was performed with the 
healthy controls and COPD control combined as one group of non-AFD controls.  
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Figure 4.5.1.1 Plasma and peripheral blood leucocyte α-galactosidase 
A activity in AFD subjects compared to control groups 
 
 
 
 
 
 
* p<0.05 using 1 way ANOVA, Kruskal-Wallis test   
Table 4.5.1.1 Demographics of AFD and non-AFD control groups 
used to examine differences in α-galactosidase A enzyme activity. 
Parameter AFD Non-AFD 
Control 
p value 
Unpaired t test 
n (%) 23 (100) 23 (100) - 
Males, 
Females 
13 (57), 
10 (43) 
13 (57), 
10 (43) 
- 
Age [years] 
Mean (+/- SD) 
45.7 
(+/- 13.7) 
55.7 
(+/- 16.2) 
0.02 
FEV₁/FVC 
Mean (+/- SD) 
0.68 
(+/- 0.06) 
0.68 
(+/- 0.12) 
0.68 
Plasma 
nmol/hr/ml 
Median (range) 
0.49 
(0.1 – 5.2) 
7.5 
(4.1 – 31.4) 
<0.0001 
Blood leucocyte 
nmol/hr/mg protein 
Median (range) 
3.60 
(0.1 – 79.9) 
41.9 
(22.3 – 81.2) 
<0.0001 
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Table 4.5.1.2 Demographics for healthy control and COPD control 
subgroups 
 
4.5.2 Blood and sputum α-galactosidase A activity in AFD and non-
AFD control subjects  
4.5.2.1 Plasma 
As expected plasma α-galactosidase A activity was significantly lower in the 
AFD group compared to the control group (p<0.0001) (Table 4.5.2.1). Plasma 
enzyme activity was lower in AFD males than females (p<0.0001) and in each 
case lower than sex matched controls (p<0.0001 for males, p=0.002 for females, 
Table 4.5.2.2).  
4.5.2.2 Peripheral blood leucocytes 
Peripheral blood leucocyte α-galactosidase A activity in the AFD group was 
significantly lower than in the control group (p<0.0001, Table 4.5.2.1). Again 
enzyme activity in AFD males was significantly lower than in AFD females 
(p<0.01) and in each case lower than sex matched controls (p<0.0001 for males, 
p=0.002 for females, Table 4.5.2.2). 
Parameter Healthy Control COPD Control p value 
Unpaired t test 
n (%) 9 (39) 14 (61) - 
Age [years] 
Mean (+/- SD) 
41.0 
(+/- 10.0) 
66.9 
(+/- 9.4) 
<0.0001 
Males, 
females 
5 (22), 
4 (17) 
9 (39), 
5 (22) 
- 
FEV₁/FVC 
Mean (+/- SD) 
0.82 
(0.72 – 0.85) 
0.61 
(0.58 – 0.66) 
0.0003 
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4.5.2.3 Induced sputum supernatant   
α-galactosidase A activity in the fluid phase of the sputum was found to be 
similar in AFD subjects and controls in the group taken as a whole (Table  
4.5.2.1). When analysed by gender, the sputum supernatant enzyme activity in 
AFD males was significantly lower compared to control males (p<0.0001) and 
AFD females (p<0.01, Table 4.5.2.2). However no difference was found between 
AFD females and control females.  
 4.5.2.4 Induced sputum derived leucocytes  
The pattern of α-galactosidase A activity in sputum-derived leucocytes was 
similar to that seen in sputum supernatant: it was not significantly different 
between AFD and control subjects in the group taken as a whole (Table  4.5.2.1), 
though enzyme activity in AFD males was significantly lower than that in both 
control males (p=0.003) and AFD females (p<0.01, Table  4.5.2.2). 
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Table 4.5.2.1 α-galactosidase A activity in blood and sputum 
compartments in AFD and non-AFD control subjects  
Sample type AFD Non-AFD control p value 
(MWU test) 
n 23 23 - 
Plasma 
nmol/hr/ml 
Median (range) 
0.5 
(0.1 – 5.2) 
7.5 
(4.1 – 31.4) 
<0.0001 
Blood leucocyte 
nmol/hr/mg protein 
Median (range) 
3.60 
(0.1 – 79.9) 
41.9 
(22.3 – 81.2) 
<0.0001 
Sputum supernatant 
nmol/hr/ml 
Median (range) 
2.3 
(0.3 – 21.5) 
2.8 
(1.1 – 10.4) 
0.8 
Sputum leucocyte 
nmol/hr/mg protein 
Median (range) 
54.1 
(3.9 – 281.4) 
82.8 
(19.6 – 225.4) 
0.2 
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Table 4.5.2.2 Blood and induced sputum α-galactosidase A activity in 
male and female AFD and non- AFD control subjects 
# p<0.01 compared to AFD females 
 4.5.3 Relationship between sputum and blood α-galactosidase A 
activity in AFD and non-AFD control subjects  
The relationship between sputum and blood α-galactosidase A activity was 
examined using paired samples taken from the 23 AFD and non-AFD control 
subjects.  Samples were taken at the same study visit for each subject and 
processed on the same day.  The Wilcoxon signed rank test was used for the 
statistical analysis of paired samples of non-parametric data, with the Mann 
Whitney U test for unpaired data.  
Sample type 
Median 
(range) 
AFD males Non-AFD 
males 
p AFD 
females 
Non-AFD 
females 
p 
n 13 13  10 10  
Plasma 
nmol/hr/ml 
0.3# 
(0.1 – 0.8) 
7.6 
(4.2 – 31.4) 
<0.0001 3.0 
(1.2 – 5.2) 
7.4 
(4.1 – 10.9) 
0.0002 
Blood 
leucocyte 
nmol/hr/mg 
protein 
1.6# 
(0.1 – 10.6) 
43.0 
(25.4 – 81.2) 
<0.0001 13.9 
(3.4 – 79.9) 
34.4 
(22.3 –59.8) 
0.002 
Sputum 
supernatant 
nmol/hr/ml 
1.3# 
(0.3 – 3.9) 
4.0 
(1.5 – 10.4) 
 
0.005 3.2 
(0.7 – 21.5) 
2.6 
(1.1 – 3.2) 
0.10 
Sputum 
leucocyte 
nmol/hr/mg 
protein 
33.9# 
(3.9 – 118.0) 
78.5 
(26.9 –225.4) 
0.003 109.5 
(24.4-281.4) 
103.2 
(19.6-177.0) 
0.3 
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 4.5.3.1 Sputum supernatant and plasma  
In the non-AFD control group as a whole, the α-galactosidase A activity in 
induced sputum supernatant was significantly lower than that in plasma 
(p<0.0001). When examined by gender, both non-AFD control males and females 
had significantly higher enzyme activity in plasma compared to paired samples of 
sputum supernatant (p=0.001 and p=0.004, Table 4.5.3.1).  
However in the AFD group the reverse appeared true with the sputum 
supernatant enzyme activity found to be significantly higher than that in plasma 
for the group as a whole (p=0.007). When examined by gender, AFD males had 
higher enzyme activity in sputum supernatant than plasma (p=0.0002, Table 
4.5.3.1) whereas no significant difference was seen between enzyme activity in 
sputum supernatant and plasma in AFD females.  
The ratio of sputum supernatant to plasma was shown to be consistent in 
the control group as a whole and when examined by gender. The sputum 
supernatant/plasma enzyme activity ratio was significantly higher in the AFD 
groups compared to their relevant control groups (p<0.001, Table 4.5.3.1).  
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Table 4.5.3.1 α-galactosidase A activity in paired samples of sputum 
supernatant and plasma in AFD and non-AFD controls 
# p<0.001 for each compared to matched non-AFD control group 
 4.5.3.2 Induced sputum derived leucocytes and peripheral blood 
leucocyte  
In both the non-AFD control group and the AFD group the α-galactosidase 
A activity in sputum-derived leucocytes was significantly higher than that in 
peripheral blood derived leucocytes (p=0.002 and  p<0.0001, Table  4.5.3.2). This 
finding persisted when analysed by gender for both non-AFD controls (males 
p=0.001, females p=0.02) and AFD subjects (males p=0.0005, females p=0.002) 
(Table 4.5.3.2).  
α-galactosidase A activity nmol/hr/ml 
Median (range) 
Sample type/ 
Group 
n Sputum 
supernatant 
Plasma p Sputum 
supernatant/plasma 
enzyme ratio 
Non-AFD 
controls 
23 2.8 
(1.1 – 10.4) 
7.5 
(4.1 – 31.4) 
<0.0001 0.3 
(0.1 – 0.9) 
AFD 23 2.3 
(0.3 – 21.5) 
0.5 
(0.1 – 5.2) 
0.007 1.8# 
(0.4 – 15.4) 
Non-AFD males 13 4.0 
(1.5 – 10.4) 
7.6 
(4.2 – 31.4) 
0.001 0.3 
(0.2 – 0.9) 
AFD males 13 1.3 
(0.3 – 3.9) 
0.3 
(0.1 – 0.8) 
0.0002 2.1# 
(0.6 – 15.4) 
Non-AFD 
females 
10 2.6 
(1.1 – 3.2) 
7.4 
(4.1 – 10.9) 
0.004 0.3 
(0.1 – 0.4) 
AFD females 10 3.2 
(0.7 – 21.5) 
3.0 
(1.2 – 5.2) 
0.25 1.2# 
(0.4 – 7.0) 
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The ratio of sputum to blood leucocyte α-galactosidase A activity was very 
similar in the non-AFD control group as a whole and in male and female control 
groups, and was significantly greater in AFD subjects compared to matched 
controls. The difference between the sputum/blood enzyme ratio between AFD 
males and AFD females was not statistically significant.  
Table 4.5.3.2 α-galactosidase A activity in paired samples of induced 
sputum and peripheral blood leucocytes from AFD and non-AFD 
control subjects 
# p<0.001 for each compared to matched non-AFD control group 
Leucocyte α-galactosidase A activity nmol/hr/mg protein 
Median (range) 
Sample type/ 
Group 
n Sputum Peripheral 
Blood 
p Sputum/blood 
leucocyte ratio 
Non-AFD 
controls 
23 82.8 
(19.6 – 225.4) 
41.9 
(22.3 – 81.2) 
0.002 1.9 
(0.7 – 5.5) 
AFD 23 54.1 
(3.9 – 281.4) 
3.6 
(0.1 – 79.9) 
<0.0001 17.1# 
(0.7 – 196.7) 
Non-AFD 
control 
males 
13 
78.5 
(26.9 – 225.4) 
43.0 
(25.4 – 81.8) 
0.001 1.8 
(1.0 – 5.5) 
AFD males 13 33.9 
(3.9 – 118.0) 
1.6 
(0.1 - 10.6) 
0.0005 19.9# 
(0.7 – 361.0) 
Non-AFD 
control 
females 
10 
103.2 
(48.98 – 124.6) 
34.44 
(30.02 – 48.64) 
0.02 2.7 
(0.7 – 3.2) 
AFD females 10 109.5 
(24.4 – 281.4) 
13.9 
(3.4 – 79.9) 
0.002 7.2# 
(2.7 – 47.0) 
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4.6 Impact of enzyme replacement therapy (ERT) and disease 
severity on α-galactosidase A activity 
 4.6.1 Plasma  
In order to examine the impact of ERT, measurements of plasma α-
galactosidase A activity taken at the time of diagnosis (prior to initiation of ERT) 
were compared to repeat plasma enzyme measurements at baseline study visit 
in 33 subjects who had been receiving ERT for different durations following 
diagnosis. The median duration of ERT for this group was 54.4 months, with a 
range 5 to 121 months. All subjects were currently receiving fortnightly enzyme 
infusions.  
The median plasma α-galactosidase A activity of this group at diagnosis was 
2.10 nmol/hr/ml (range 0.01 – 7.5) and at baseline study visit 1.82 nmol/hr/ml 
(range 0.1 – 7.3). There was no statistical difference demonstrated (p=0.1, 
Wilcoxon signed rank test, Figure 4.6.1 a)) 
To further examine the effect of ERT, plasma α-galactosidase A activity was 
compared in 36 AFD subjects receiving ERT (median 2.1 nmol/hr/ml, range 0.1 – 
7.3) and 8 enzyme naïve subjects (median 3.5 nmol/hr/ml, range 0.1 – 4.3).  
Again, there was significant difference found (p=0.7, Figure 4.6.1 b)). 
In a sub-group of 14 AFD subjects a composite plasma enzyme profile was 
made using multiple measurements of plasma α- galactosidase A at different 
time points over the two week period between one enzyme infusion and the 
next. These were compared to the same subject’s plasma enzyme activity at 
diagnosis (Day 0) (Figure 4.6.1 c). Although measurements were taken at 
different infusion cycles within the same subject, it was ensured that there had 
been no changes in day of delivery of the infusion or dose between enzyme 
cycles. The largest variation of plasma α-galactosidase A activity within a study 
subject was 3.4 – 7.5 nmol/ml/hr, with the smallest being 0.11 – 0.16 
nmol/hr/ml. Overall there was little variation in plasma α-galactosidase A activity 
within AFD subjects regardless of the timing of sampling following enzyme 
infusion (Figure  4.6.1c)).  
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Figure 4.6.1  Effect of ERT on enzyme activity in AFD plasma 
a)      b)    
 
 
 
 
 
c) 
 
 
 
 
 
 
a) Plasma α-galactosidase A activity in AFD subjects receiving ERT, measured at 
the time of diagnosis and on the day of first study visit (median and range 
shown) 
b) Plasma α-galactosidase A activity in AFD subjects receiving ERT and enzyme 
naïve subjects (median and range shown) 
c) Profile of plasma α-galactosidase activity in 14 AFD subjects on ERT; 
measurements were performed at different time points during different infusion 
cycles in individual subjects with activity at diagnosis used for day 0 (t=duration 
of ERT in months) 
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4.6.2 Peripheral blood leucocytes  
Peripheral blood leucocyte α-galactosidase A activity at time of diagnosis 
and at baseline study visit were compared in a similar manner in 15 AFD subjects 
receiving ERT. The median duration of ERT for this group was 54.0 months with a 
range of 7 to 121 months. 
The median blood leucocyte α-galactosidase A activity at diagnosis was 
12.0 nmol/hr/mg protein (range 0.2 – 88.0) and at baseline study visit was 5.6 
nmol/hr/mg protein (range 0.2 – 79.9), again with no significant difference seen 
between the two (p=0.1, Wilcoxon signed rank test, Figure  4.6.2 a)).   
Blood leucocyte α-galactosidase A activity was compared in 23 AFD 
subjects on ERT (median 3.6 nmol/hr/mg protein, range 0.1 – 79.9), and 5 
enzyme naïve subjects (median 9.6 nmol/hr/mg protein, range 2.7 – 19.3) and 
was not found to be significantly different (p=0.3, Figure  4.6.2 b). 
In 12 AFD subjects, repeat measurements of blood leucocyte α-
galactosidase A activity were performed at different time points in different 
enzyme infusion cycles, and plotted as a composite profile alongside enzyme 
activity at diagnosis (Day 0) (Figure  4.6.2 c). The largest range of blood leucocyte 
α-galactosidase A activity within a study subject was 20.78 – 54.00 nmol/hr/mg 
protein (Subject 7); whilst the smallest range was 0.19 – 1.08 nmol/hr/mg 
protein (Subject 11).  
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Figure 4.6.2 Effect of ERT on enzyme activity in peripheral blood 
leucocytes in AFD  
a)             b)     
    
 
 
 
 
 
c) 
 
 
 
 
 
 
a) Blood leucocyte α-galactosidase A activity in AFD subjects on ERT measured at 
the time of diagnosis compared to blood leucocyte enzyme activity on the day of 
first study visit (median and range shown).  
b) Blood leucocyte α-galactosidase A activity in AFD subjects on ERT and enzyme 
naïve subjects (median and range shown) 
c) Profile of peripheral blood leucocyte α-galactosidase activity in 12 AFD 
subjects on ERT; measurements were performed at different time points during 
different infusion cycles in individual subjects with activity at diagnosis used for 
day 0 (t=duration of ERT in months) 
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4.6.3 Sputum  
Α-galactosidase A activity in sputum supernatant and from sputum-derived 
leucocytes was not significantly different in AFD subjects receiving ERT compared 
to those who had never received ERT, though numbers in the ERT naïve group 
were small (Table 4.6.3). Paired sputum and blood samples were used to 
calculate sputum supernatant/plasma and sputum leucocyte/blood leucocyte 
enzyme ratios. There appeared to be no significant difference in the ratios 
between subjects receiving ERT and those who were ERT naïve (p=0.9 and p=0.2 
respectively). 
 4.6.4 Severity of disease in subjects on ERT and ERT naïve subjects 
Disease severity scores in the form of the Mainz Severity Score Index 
(MSSI) and the Age-Adjusted Fabry Outcome Survey-MSSI were calculated for 
the AFD subjects on ERT and those who were enzyme naïve at the first study 
visit. 
As disease severity would have been the trigger for the instigation of 
enzyme replacement therapy, severity scores of AFD subjects on ERT were 
significantly higher than enzyme naïve AFD subjects (p=0.001 for MSSI and 
p=0.02 for Age adjusted Severity Score using Mann Whitney U test, Table  4.6.3). 
When examined further, no difference in sputum/blood enzyme ratio was 
seen in AFD subjects with milder disease (MSSI <20) compared to those with 
more severe disease (MSSI >20) (Table 4.6.4). 
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Table 4.6.3 Effect of overall disease severity and ERT on                        
α-galactosidase A enzyme activity  
Parameter On ERT 
Median (range) 
ERT naïve 
Median (range) 
P value 
 
n 23 6 - 
MSSI 27.0 
(8.0 - 44.0) 
3.0 
(1.0 – 15.0) 
0.001 
Age adjusted Severity 
Score 
6.5 
(-10.5 - 18.7) 
-5.0 
(-6.9 - -2.0) 
0.02 
Plasma 
α-galactosidase A 
activity 
nmol/hr/ml 
0.5 
(0.1 – 5.2) 
2.5 
(0.1 – 4.3) 
0.7 
Blood leucocyte            
α-galactosidase A 
activity 
nmol/hr/mg protein 
3.6 
(0.1 – 79.9) 
9.6 
(2.7 – 19.3) 
0.3 
Sputum supernatant 
α-galactosidase A 
activity 
nmol/hr/ml 
2.4 
(0.3 – 36.1 ) 
3.6 
(0.3 - 7.4) 
0.8 
Sputum leucocyte 
α-galactosidase A 
activity 
nmol/hr/mg protein 
47.40 
(3.9 – 371.0) 
75.80 
(21.0 – 120.6) 
0.6 
Sputum 
supernatant/plasma 
enzyme activity ratio 
1.8 
(0.4 – 15.4) 
2.1 
(1.0 – 2.9) 
0.9 
Sputum/blood 
leucocyte enzyme 
activity ratio 
19.3 
(0.7 – 361.0) 
6.2 
(4.5 – 19.9) 
0.2 
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Table 4.6.4 Comparison of sputum/blood ratios in AFD subjects on 
ERT with milder disease compared to more severe disease as 
measured by Mainz Severity Score Index 
 
 
 
 
 
 
 
 
 
 MSSI <20 MSSI >20 p value 
n 13 5 - 
Sputum 
supernatant/plasma 
ratio 
1.5 
(0.4 – 11.4) 
6.0 
(1.4 – 8.0) 
0.2 
Sputum/blood 
leucocyte ratio 
19.9 
(2.7 – 148.0) 
18.8 
(0.7 – 196.7) 
0.7 
Chapter 4 – Pulmonary α-galactosidase A 
135 
 
4.7 Α-galactosidase A activity in relation to airflow limitation  
Α-galactosidase A enzyme activity in plasma and peripheral blood derived 
leucocytes was found to be significantly lower in AFD subjects with airway 
obstruction (defined as FEV₁/FVC <0.7) than those without airway obstruction 
(p=0.03 for plasma, p=0.04 for peripheral blood leucocytes, Table 4.7.1).  
Examination of α-galactosidase A activity in sputum from AFD subjects with 
and without airway obstruction did not reveal statistically significant differences 
either from the sputum supernatant or sputum derived leucocytes. However, 
there was a trend towards sputum leucocyte enzyme activity being lower in 
airway obstructed AFD subjects (p=0.08). Sputum supernatant/plasma ratio was 
significantly higher in the obstructed AFD subjects compared to the 
unobstructed, though there was no difference in sputum/blood leucocyte 
enzyme ratio between the groups (p=0.02 and p=0.5, Table 4.7.1).  
No significant difference was seen in enzyme activity from plasma, 
peripheral blood derived leucocytes, sputum supernatant or sputum derived 
leucocytes when comparing obstructed and unobstructed AFD subjects by 
gender (see Appendix 1, Table 1.0). There was a trend towards lower blood 
leucocyte enzyme activity in AFD males with airway obstruction compared to 
AFD males without (p=0.07).  
When analysed as continuous variables, there were no strong correlation 
found between FEV₁/FVC and α-galactosidase A activity in plasma, peripheral 
blood leucocytes, sputum supernatant and sputum derived leucocytes, or 
sputum/blood leucocyte enzyme ratio. Weak correlations were evident between 
FEV₁/FVC and plasma enzyme activity (r=0.3, p=0.03) and FEV₁/FVC and sputum 
supernatant/plasma ratio (r=0.4, p=0.02, Figure 4.7.2). 
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Table 4.7.1 α-galactosidase A activity in AFD subjects with and 
without airway obstruction  
(airway obstruction defined as FEV₁/FVC <0.7) 
Sample type for  
α-galactosidase A 
activity 
n Obstructed 
Median (range) 
n Unobstructed 
Median 
(range) 
p value 
 
Plasma 
nmol/hr/ml 20 
0.4 
(0.1 – 6.1) 24 
3.0 
(0.91 - 4.66) 
 
0.03 
Blood leucocyte 
nmol/hr/mg protein 15 
2.6 
(0.1 – 20.8) 13 
10.6 
(1.6 - 79.9) 
 
0.04 
Sputum supernatant 
nmol/hr/ml 16 
1.5 
(0.3 – 21.5) 15 
2.8 
(0.3 – 36.1) 
 
0.2 
Sputum leucocyte 
nmol/hr/mg protein 18 
43.5 
(3.9 – 164.2) 11 
80.0 
(21.0 -371.2) 
 
0.08 
Sputum Supernatant/ 
plasma ratio 16 
3.0 
(0.4 – 15.4) 15 
1.4 
(0.6 – 7.6) 
 
0.02 
Sputum /blood 
leucocyte ratio 15 
18.8 
(0.7 – 361.0) 12 
12.3 
(2.0 – 115.6) 
 
0.5 
 
Figure 4.7.2 α-galactosidase A activity in relation to airflow limitation 
in a) plasma and b) sputum supernatant/plasma ratio 
a)      b) 
 
      
 
 
 0.50.60.70.80.9
0
2
4
6
8
r = 0.3
p<0.05
FEV1/FVC ratio
P
la
s
m
a
 e
n
z
y
m
e
 a
c
ti
v
it
y
 n
m
o
l/
h
r/
m
l
0.50.60.70.80.9
0
5
10
15
20 r = -0.4
p<0.05
FEV1/FVC ratioS
p
u
tu
m
 s
u
p
e
rn
a
ta
n
t/
p
la
s
m
a
 e
n
z
y
m
e
 a
c
ti
v
it
y
 r
a
ti
o
Chapter 4 – Pulmonary α-galactosidase A 
137 
 
4.8 Induced sputum electron microscopy  
Of the 3 induced sputum samples from AFD male subjects prepared and 
examined for evidence of storage by EM, inclusion bodies were evident in one of 
the samples. This sample was from a 32 year old male with the mutation P205T, 
who had been receiving ERT for a total duration of 30 months. This subject had 
an MSSI of 11 at recruitment, and had an FEV₁/FVC of 0.68, but no reported 
respiratory symptoms. As shown below in Figure 4.8.1 his sputum derived cell 
contained inclusion bodes which had the typical lamellar structure that has been 
previously documented in AFD (235).  
 
 
Figure 4.8.1 Transmission electron microscopy of induced sputum 
cell from male AFD subject demonstrating inclusion bodies typical of 
Gb3 storage  
a) magnification x31000  b) magnification x110000 
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 4.9 Discussion  
 α-galactosdase A activity has been quantified in a number of different 
sites in subjects with Anderson Fabry Disease, including liver, kidney, skin as well 
as blood and tears. Thus far, evidence of pulmonary involvement in AFD has 
been based on clinical parameters with obstructive changes in lung function in 
AFD subjects (236;237); and on the demonstration of storage material in lung-
derived samples histologically, both on light and electron microscopy (238;239). 
Quantification of α-galactosidase A activity from lung derived samples has not 
been performed. Hence there is no normal reference range with which to 
compare the values found in AFD subjects.  
To examine changes in the lung in AFD in more detail it was necessary to 
first establish that α-galactosidase A could be measured in sputum samples, and 
subsequently to build a reference range for sputum α-galactosidase A activity 
from non-AFD control subjects. For all non-AFD control subjects, plasma α-
galactosidase A activity made it highly unlikely that any had undiagnosed AFD. 
However, in some control subjects blood leucocyte α-galactosidase A activity was 
below the reference range used for this assay. Despite this, however, there was 
still a clear and significant difference between blood leucocyte enzyme activity in 
the AFD and control groups. Further confirmation was obtained that these 
subjects did not have AFD by genotyping for known AFD-related mutations 
(standard practice in AFD females).  
As outlined in Methods Section 2.3.6.1, experiments were performed to 
establish that generally accepted processing of sputum samples did not affect α-
galactosidase A enzyme activity measurements. It was then possible to 
investigate differences between sputum enzyme activity in AFD and controls.  
Taken as a whole, AFD results indicate that α-galactosidase A activity was 
similar in AFD subjects compared to non-AFD controls in both the fluid phase of 
sputum and induced sputum derived leucocytes. However, when divided by 
gender, it was clear that α-galactosidase A activity in AFD males was significantly 
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lower in both the fluid phase and cellular phase of sputum compared to non-AFD 
male controls, as well as being lower than in AFD females.  
Enzyme activity in sputum from AFD females was not significantly different 
to that of control females. This is similar to reported findings from both plasma 
and blood leucocyte enzyme activity in AFD, where lyonisation is thought to play 
a part in the differences in enzyme activity between AFD males and females; and 
enzyme activity in AFD female subjects sometimes falls within the normal 
reference range despite clinical features and genotyping pointing towards AFD 
(240).  
The relationship between plasma and sputum supernatant enzyme activity 
within AFD and non-AFD control subjects appeared to differ, with activity being 
higher in plasma than in the fluid phase of sputum in non-AFD control subjects, 
and the opposite in AFD subjects. This was statistically significant in the group as 
a whole and in AFD males, but not females. No gender differences were 
apparent in control subjects. 
Examining the relationship between sputum and blood-derived leucocyte 
enzyme activity, more consistency was present between AFD and non-AFD 
control groups. Sputum leucocyte derived α- galactosidase A activity was higher 
than that of paired samples of blood derived leucocytes for both groups as a 
whole, and when divided by gender. The sputum/blood enzyme ratio was 
consistently higher in AFD groups compared to the matched non-AFD control 
groups.  This was most marked in AFD males, implying that this group had the 
largest relative difference between sputum and blood enzyme activity. It is 
possible that enzyme replacement therapy may have an impact on 
sputum/blood leucocyte enzyme ratio in AFD subjects compared to non-AFD 
subjects, although this is unclear.  
It is likely that α-galactosidase A enzyme detected in the fluid phase of 
sputum derives from both plasma α-galactosidase A within the pulmonary 
circulation, and enzyme leaching out of sputum cells which are suspended within 
it. A possible explanation for the differences seen in plasma and sputum 
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supernatant activity between non-AFD controls and AFD subjects may be that it 
is the latter mechanism which is responsible for the majority of enzyme activity 
being evaluated in the fluid phase of sputum. Given that plasma enzyme activity 
in the AFD male group was very low, the relatively large difference in sputum 
leucocyte enzyme activity compared to blood evident in this group may have 
caused the enzyme activity in the sputum supernatant to surpass that of the 
plasma in the AFD subjects.  
As would be expected, the disease severity of AFD subjects on ERT was 
significantly greater than that of subjects who were enzyme naïve as assessed by 
both the Mainz severity score and the Age adjusted FOS-MSSI. However no 
significant difference was seen in α-galactosidase A activity in blood or sputum, 
although numbers of ERT naïve subject were small. Examination of the effect of 
ERT on plasma and blood leucocyte α-galactosidase A activity demonstrated that 
there is very little change from baseline activity at diagnosis, regardless of the 
duration of treatment or the time elapsed since the last enzyme infusion. This 
would be in keeping with pharmacokinetic data from clinical trials of enzyme 
replacement therapy which demonstrated the short half life of exogenous 
enzyme (241).  
It is not clear, however, whether the half life of ERT may be different within 
the lung milieu, where the longer life span of leucocytes compared to that of 
blood white cells might allow an accumulation of lung derived cells containing 
exogenous enzyme compared to blood which provides an additional explanation 
for the gradient between sputum/blood enzyme activity in AFD.  Clarification of 
this would only be possible by longitudinal assessment of sputum α-
galactosidase A activity in subjects commenced on ERT, who had been sampled 
at baseline. The ratio of sputum/blood α-galactosidase A activity was no different 
between AFD subjects with mild or severe disease.  
AFD subjects with evidence of airway obstruction had lower plasma and 
blood leucocyte α-galactosidase A activity compared to those AFD subjects with 
normal spirometry. This suggests that changes in spirometry may be related to 
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residual enzyme activity. Examination of sputum α-galactosidase A activity in 
these populations revealed that AFD subjects with airway obstruction also 
tended to have lower sputum leucocyte enzyme activity compared to those 
without airway obstruction, though this did not reach statistical significance 
(p=0.08), with the small numbers studied. The weak correlation between sputum 
supernatant/plasma ratio and FEV₁/FVC may imply that lung involvement in the 
form of airflow obstruction is more dependent on blood enzyme activity than 
that of sputum, but further sampling and work in this area would need to be 
done to clarify this.  
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4.10 Conclusions  
 The data collected and analysed in this chapter can be summarised as 
follows:  
1. α-galactosidase A activity can be measured in induced sputum supernatant 
and from induced sputum derived leucocytes  
2. α-galactosidase A activity is lower in induced sputum derived leucocytes 
from AFD males compared to non-AFD male controls 
3. α-galactosidase A activity is lower in induced sputum derived leucocytes 
from AFD males compared to AFD females  
4. Induced sputum α-galactosidase A activity is greater than blood α-
galactosidase A activity in AFD subjects (statistically significant in all 
compartments except sputum supernatant in AFD females) 
5. No demonstrable difference in α-galactosidase A activity in blood or 
induced sputum was seen in AFD subjects on ERT compared to those who 
were ERT naïve 
6. There is no demonstrable relationship between overall disease severity as 
measured by MSSI and sputum α-galactosidase A activity  
7. Blood and plasma α-galactosidase A activity are lower in AFD subjects with 
airway obstruction compared to those without 
8. There is a suggestion that induced sputum leucocyte α-galactosidase A 
activity is lower in AFD subjects with airway obstruction compared to those 
without 
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5.1 Introduction  
The mechanisms underlying the development of airway involvement in 
AFD are as yet unclear. However, there is some evidence that changes occur at a 
cellular level within the lungs with the demonstration of lamellar inclusion bodies 
in bronchial epithelial cells both from bronchoscopy samples including 
bronchoalveolar lavage and brushings (242), as well as from  induced sputum 
sampling (243). Additional studies have also examined induced sputum cell 
populations in normal individuals without underlying respiratory disease  
providing a point of reference for studies into other lung pathology (244)((245). 
To our knowledge, further examination of the sputum for the purposes of 
establishing the pulmonary impact of AFD has not been undertaken. Given that 
the changes noted in AFD have been related to the airways (246;247), sputum 
sampling is an appropriate method of further examining the AFD lungs. As the 
majority of subjects would be unable to produce spontaneous sputum, sputum 
induction would allow samples to be generated and to be standardised for 
comparison with those from control subjects.  
Given that it is NKT cells which are responsible for lipid antigen recognition, 
it has also been suggested that abnormalities in NKT cell populations may exist in 
AFD, (248).  A specific subset of invariant NKT cells (iNKT), are particularly 
responsible for glycolipid recognition. Indeed, studies in AFD mice, demonstrated 
increased tissue CD4+/CD8+ T cell ratios in the liver, and noted that lower 
numbers of invariant NKT cells were present, though did not see the same in the 
peripheral blood of human AFD subjects (249). It has also been demonstrated in 
mice that lipid accumulation reduces NKT cell numbers by impairing thymic 
selection and interferes with lipid antigen presentation in lysosomal storage 
disorders (132).  
We therefore aimed to use flow cytometry to examine induced sputum 
samples from AFD subjects with and without lung involvement, and to compare 
these to both a COPD and healthy control group in order to determine the 
proportions of different cells present. We sought in particular to examine 
lymphocyte numbers and subtypes, including NKT cells. Given the cell numbers 
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obtained in induced sputum and the general paucity of iNKT cells we felt it would 
be difficult to examine differences in iNKT cell populations in a meaningful way 
using this method.   
Pro-inflammatory cytokines such as interleukin-8 (IL-8) and interleukin-6 
(IL-6) have been strongly implicated in airways disease. IL-8 is produced by 
monocytes/macrophages and airway epithelial and smooth muscle cells, and is 
known to function as a neutrophil chemoattractor and activator (250). It has 
been measured in induced sputum samples from COPD subjects  and shown to 
be closely associated with the degree of airway obstruction present (251). IL-6, 
which is also produced by T cells and B cells, has  been found to be elevated in 
induced sputum samples from subjects with severe asthma (252) as well as in 
COPD where it too has been associated with lung function decline (253;254).  
Therefore, in order to gain further information on the inflammatory 
processes present in the airways of AFD patients, we also aimed to examine 
induced sputum concentrations of cytokines IL-8 and IL-6 in comparison to 
subjects with chronic airways disease and healthy individuals. Studies in airways 
disease have also noted that cytokine concentrations may be influenced by 
cigarette smoking (255) and given that existing studies in AFD subjects suggest 
that the degree of airway obstruction may be significantly worsened by smoking 
(256) and we therefore aimed to examine this also.  
5.2 Hypotheses 
Hypothesis 1:   
Induced sputum samples from AFD subjects with airways obstruction would 
have a greater proportion of CD8+ T cells than AFD subjects without airway 
obstruction 
Rationale:  
Increased proportions of CD8+ cells are seen in COPD patients, which has 
some similar features to the airway obstruction in AFD 
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Hypothesis 2: 
Induced sputum samples from AFD subjects with airways involvement would 
have a higher proportion of neutrophils than that of AFD subjects without 
airway obstruction 
Rationale:  
Neutrophilic inflammation is an important feature of airway inflammation in 
airways disease such as COPD 
Hypothesis 3: 
Higher concentrations of pro-inflammatory cytokines IL-8 and IL-6 would be 
present in the induced sputum of AFD subjects with airway obstruction 
compared to those without 
Rationale:  
Inflammatrory cytokines IL-8 and IL-6 are present in elevated concentrations 
in COPD subjects 
5.3 Objectives  
1. To delineate the cell populations present in the induced sputum of AFD 
subjects  
2. To compare cell populations in the induced sputum of AFD subjects to 
COPD and healthy control subjects 
2. To compare the cell populations present in the induced sputum of AFD 
subjects with airway obstruction and those without  
3. To examine the inflammatory processes in the lung in AFD by examining 
cytokine profiles 
4. To examine the impact of smoking on inflammatory cytokines in induced 
sputum in AFD  
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5.4 Methods 
All induced sputum sampling, processing of samples and flow cytometry 
data acquisition and analysis were performed by the same operator, Dr. Nadia 
Shafi. Induced sputum samples were obtained and processed within 2 hours as 
per the protocol outlined in Methods Section 2.3.6.2. Antibody staining and flow 
cytometry data acquisition were performed on the same day as sputum 
sampling. Samples for cytokine assays were frozen at -80°C and enzyme linked 
immunosorbent assays (ELISAs) performed as a batch at a later date as per the 
protocol outlined in Methods Section 2.3.10. 
Statistical analysis for comparison normally distributed data including of 
age and lung function data was performed using the unpaired t test. For non-
parametric data including cell numbers and percentages, statistical analysis was 
performed using the Mann Whitney U test.  
5.5 Study Population 
5.5.1 Demographics 
Flow cytometric examination was performed on induced sputum samples 
from 22 AFD, of whom 13 had evidence of airway obstruction with FEV₁/FVC 
<0.7, and 9 who did not. Alongside this were 12 COPD subjects matched as 
closely as possible to the AFD subjects with airway obstruction, and 7 healthy 
control subjects matched as closely as possible to AFD subjects without airway 
obstruction (Table 5.5.1). Priority for matching was given to spirometry and 
gender over age, and as a result of this the COPD group were significantly older 
than the AFD and healthy control groups with a mean age of 64.2 years (p<0.005, 
Table 5.5.1). There was no significant age difference between the AFD subjects 
and the healthy controls. Data were also included from 3 AFD subjects who were 
not matched to a control subject. 
The AFD group with airway obstruction had a mean FEV₁/FVC  and FEV₁ 
%predicted which was significantly lower than that of both the AFD group 
without airway obstruction and the healthy control group (p<0.05 and p<0.001, 
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Table 5.5.1), but not significantly different to the COPD group. However, when 
assessed by GOLD criteria, the AFD obstructed group as a whole had a milder 
degree of airway obstruction than the COPD group. 
On assessment of the small airways, both the AFD obstructed group and 
COPD group had significantly lower MEF50 %predicted than the AFD 
unobstructed group and healthy control group though on comparison of RV/TLC 
as a measure of small airways disease, only a difference between the COPD 
group and these groups was seen (Table 5.5.1). 
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Table 5.5.1 Demographics of AFD, COPD and healthy control 
subjects used for flow cytometric analysis of induced sputum cell 
populations 
*p<0.05, **p<0.0001 compared to AFD without airway obstruction 
#p<0.0001 compared to Healthy Controls, § p<0.005 compared to all groups 
 
5.5.2 Flow cytometry data plots  
Populations of T lymphocytes, NKT cells, B lymphocytes, neutrophils and 
monocytes/macrophages were identified using flow cytometry as described in 
Methods Section 2.3.9. The number of events captured on the flow cytometry 
plots used for the comparison of cell populations was similar for each group 
(Table 5.5.2).   
Parameter 
(mean  
+/-SD) 
AFD with 
airway 
obstruction 
COPD AFD without 
airway 
obstruction 
Healthy 
Control 
n 13 12 9 7 
Age,           
years 
49.5 
(+/- 14.5) 
64.3§            
(+/- 9.5) 
44.2 
(+/- 13.7) 
44.3            
 (+/- 10.3) 
Male, 
Female 
8, 5 8, 4 1, 8 3, 4 
FEV₁/FVC 0.65**# 
(+/-0.04) 
0.62**#        
 (+/-0.05) 
0.76 
(+/-0.04) 
0.77 
(+/-0.09) 
FEV₁ 
% predicted 
82.2*# 
(+/- 8.0) 
69.2**#         
(+/-11.7) 
95.3 
(+/-15.2) 
111.6          
 (+/-18.0) 
MEF50 
% predicted 
43.7* 
(+/- 9.8) 
24.9**#        
(+/- 13.8) 
63.8 
(+/- 18.4) 
68.6 
(+/- 25.4) 
RV/TLC          
% predicted 
89.7         
(+/- 17.5) 
117.7**#     
(+/- 18.1) 
77.2          
(+/- 6.5) 
81.3          
 (+/- 11.1) 
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For the purposes of comparison between groups, data for each population 
examined was expressed as a percentage of the relevant total population, as 
described in each section to follow. This was to enable the proportion of cells 
representing each cell sub-type in the different conditions to be compared.  
Table 5.5.2 Total number of events captured on flow cytometry plots 
used for analysis of cell populations in induced sputum of AFD, 
COPD and healthy control subjects 
 
  
Flow plot event number x10³ 
Median (range) 
Flow plot n AFD n COPD n Healthy  
Control 
T 
lymphocyte 
18 137.7 
(45.7- 819.9) 
12 251.2 
(105.6- 690.4) 
7 252.9 
(66.8 – 454.5) 
NKT cell 21 162.6 
(17.4 – 711.0) 
12 242.8 
(89.2 – 718.5) 
8 234.1 
(101.5–559.4) 
B 
lymphocyte 
8 229.9 
(14.8- 574.6) 
6 194.5 
(146.2 -362.2) 
5 235.1 
(163.2 -363.9) 
Neutrophil, 
Monocyte/ 
Macrophage 
19 100.0 
(14.6- 650.0) 
13 171.1 
(38.8 – 404.3) 
6 210.7 
(12.9 – 265.9) 
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5.6 Lymphocytes  
5.6.1 T lymphocyte populations  
Induced sputum samples were stained with antibodies for CD3, CD4, CD8 
after processing, using the method previously outlined in Methods Section 2.3.9.  
A standardised lymphocyte gate was applied to the samples analysed, whose 
position was established using peripheral blood samples on forward scatter vs 
side scatter plots (Figure 5.6.1i). T lymphocytes were defined as CD3 positive 
(CD3+) events falling within the lymphocyte gate, and CD3+CD4+ and CD3+CD8+ 
events were identified from events within this gate (Figure 5.6.1ii).   
From what is known about induced sputum cell populations, it was likely 
that lymphocytes would only make up a very small proportion of total cell 
numbers (257;258), only induced sputum samples with a minimum of 2000 
events in the lymphocyte gate were included in the data analysis for lymphocyte 
populations. This enabled data from 15 AFD subjects, 12 COPD subjects and 7 
healthy controls to be compared. On analysis of the flow plots, the percentage of 
the total events that fell inside the defined lymphocyte gate for each sample was 
not significantly different for each of the group (Table 5.6.1).  
Comparing the groups, the COPD subjects had the highest percentage of 
CD3+ T cells. This was significantly higher than that of the AFD and healthy 
control subjects (p<0.05, Table 5.6.1). No difference was seen in T cell 
percentage between AFD and healthy control subjects. 
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Table 5.6.1 T cell populations in induced sputum of AFD, COPD and 
Healthy control subjects           
*p<0.05 compared to AFD and Healthy control 
 Sub-populations of T lymphocytes were analysed, with CD4+ and CD8+ 
lymphocyte populations expressed as a percentage of the total CD3+ T cells 
within the lymphocyte gate. The percentages of CD4+ T lymphocytes and CD8+ T 
lymphocytes were not significantly different in the AFD, COPD and healthy 
control groups, with the CD4/CD8 ratio also consistent between the groups 
(Table 5.6.1).  
 
Lymphocyte cell 
type 
AFD COPD Healthy control 
Median (range) 
n 15 12 7 
% of total events 
falling within 
lymphocyte gate 
2.30 
(0.52 – 7.26) 
1.54 
(0.42 – 3.19) 
1.79 
(0.59 – 3.50) 
CD3+ T cells 
% of lymphocyte 
gate 
64.7 
(15.4 – 89.9) 
74.5* 
(53.5 – 92.5) 
40.1 
(21.3 – 85.3) 
CD3+CD4 + 
% of T cells 
68.6 
(30.8 – 86.1) 
77.90 
(27.0 – 93.1) 
73.22 
(39.8 – 86.8) 
CD3+CD8+ 
% of T cells 
31.4 
(13.9 – 69.9) 
22.10 
(6.9 – 73.0) 
26.78 
(13.3 – 60.2) 
CD4+/CD8+ 
T cell ratio 
2.2 
(0.43 – 6.2) 
3.54 
(0.37 – 13.52) 
2.73 
(0.66 – 6.56) 
NKT cell 
% of T cells 
1.60              
(0.72– 5.3) 
0.94 
(0.1 –  3.0) 
1.2 
(0.1 – 2.2) 
Chapter 5 – Cell populations and cytokines in induced sputum 
153 
 
Figure 5.6.1 Example flow cytometry cell plot for lymphocytes in 
induced sputum 
Induced sputum flow cytometry cell plot of forward scatter vs side scatter, 
with i) gate used for lymphocyte population analysis of all samples and ii) 
example of CD3+CD4+ and CD3+CD8 T cell populations generated from the 
lymphocyte gate events and shown as a percentage of events from that gate 
(here CD4+ 34.19% and CD8+ 7.88%) 
i)  
      
ii)       
CD4+ 
CD8
+ 
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5.6.2 NKT cell populations  
NKT cells were defined as CD3+CD16+CD56+ events within the lymphocyte 
gate previously described. Again, the percentage of the total events falling within 
the lymphocyte gate was similar between all three groups, and no significant 
difference was seen in the percentage of NKT cells found in the induced sputum 
of AFD, COPD and healthy control subjects (Table 5.6.1). 
5.6.3 B lymphocytes  
Induced sputum samples for B lymphocyte populations were analysed from 
8 AFD, 6 COPD and 5 healthy control subjects having been stained with 
antibodies to CD45 and CD19. The same lymphocyte gate as seen in Figure 5.6.1i) 
was applied to all the flow cytometry plots of only CD45+ events.  B lymphocytes 
were defined as all CD45+CD19+ events falling within the lymphocyte gate.  
The percentage of the total events from each sample contained within the 
lymphocyte gate was similar between the groups. No significant differences in 
the B cell populations were seen between the groups (Table 5.6.3).  
 
Table 5.6.3 B lymphocyte populations in induced sputum of AFD, 
COPD and healthy control subjects  
Cell type AFD COPD Healthy Control 
Median (range) 
n 8 6 5 
% of CD45+ 
events 
within 
lymphocyte gate 
1.94 
(0.39 – 2.62) 
1.95 
(0.64 – 2.74) 
1.47 
(0.68 – 2.71) 
B cell % of 
lymphocyte gate 
0.37 
(0.12 – 1.37) 
0.71 
(0.13 – 1.42) 
0.33 
(0.24 – 2.06) 
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5.7 Neutrophils and Monocytes/macrophages 
 Induced sputum samples from 19 AFD, 12 COPD and 6 healthy control 
subjects were stained with CD45, CD14 and CD15 antibodies to examine the 
neutrophil and monocyte/macrophage populations. From CD45 vs side scatter 
plots, CD45+ events were identified and used to delineate neutrophil and 
monocyte/macrophage populations.  
 Analysis of the flow plots revealed that the total percentage of the CD45+ 
cells within the groups was similar (Table 5.6.1).  Neutrophil and 
monocyte/macrophage cell populations were expressed as a percentage of all 
the CD45+ events. Statistical analysis was performed using Mann Whitney U test 
for non-parametric data.  
5.7.1 Neutrophil populations 
Neutrophil populations were identified from the CD45+ cells by their 
strongly CD15+ properties (Figure 5.7.1ii). On statistical analysis neutrophil 
populations were not significantly different between the groups, with only 
trends towards significant differences between AFD group and healthy control 
groups with the percentage of neutrophils being lower in AFD (p = 0.09, power 
66%,  (Table 5.7.1).  
5.7.2 Monocyte/macrophage populations  
Monocyte/macrophages percentages were quantified by identification of 
CD14+ events after the subtraction of neutrophil and lymphocyte populations 
from the total CD45+ population, with the lymphocytes being identified by their 
position on the CD45 vs side scatter plots (Figure 5.7.1i) (259). In AFD subjects 
and COPD subjects the monocyte/macrophage population appeared to be the 
predominant cell population in induced sputum, though this was not the case for 
healthy controls where neutrophil and macrophage numbers appeared more 
even. However although monocyte/macrophage populations were not 
statistically significantly different between the groups, there was a trend towards 
significance between the AFD and healthy control groups (p = 0.07, power 79%, 
Table 5.7.1). Further differentiation of monocytes and macrophages was not 
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possible due to the degree of auto-fluorescence generated by alveolar 
macrophages.   
Figure 5.7.1 Example flow cytometry cell plot for neutrophils and 
monocytes/macrophages in induced sputum 
Induced sputum flow cytometry plot with CD45, CD15 staining used to 
identify i)  CD45+ cells above line 44.2% of events on plot,  and lymphocyte 
population (outlined) and ii) neutrophil population identified as CD45+CD15+ 
cells, here 65.6.1% of CD45+ population (outlined) 
                  
 
 
 
 
 
i) 
 
ii)  
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Table 5.7.1 Neutrophil and monocyte/macrophage populations in 
induced sputum from AFD, COPD and healthy control subjects 
5.8 Sputum cell populations compared to blood  
The percentage populations of lymphocytes, neutrophils and 
monocytes/macrophages in AFD subjects were compared between the induced 
sputum and peripheral blood. Peripheral blood differential white cell 
percentages were taken from the results of full blood count samples taken on 
the day of the AFD subjects study visit. Samples were processed by the Royal 
Free Hospital Heamatology Laboratory as per standard protocol.  
Comparison of blood and sputum lecuocyte populations revealed that the 
predominant leucocyte population in peripheral blood was that of neutrophils, 
which were present at significantly higher percentage than that of induced 
sputum (p<0.0001), whilst the percentage of lymphocytes in the peripheral blood 
was also significantly higher than that of sputum (p<0.0001). However, the 
percentage monocyte population was found to be significantly higher in induced 
sputum samples compared to peripheral blood (p<0.0001) (Table 5.8) 
 
Cell type AFD COPD Healthy 
control 
Median (range) 
n 19 12 6 
CD45+ % 
of total events 
47.1 
(36.92– 76.44) 
51.5 
(26.7 – 74.5) 
51.3 
(37.3 – 62.5) 
Neutrophil % 
of CD45+ events 
21.7 
(7.6 – 40.7) 
18.3 
(3.5 – 80.3) 
43.3 
(15.9 – 88.0) 
Monocyte /macropha
ge % of CD45+ 
events 
76.4 
(53.1 – 88.2) 
76.4 
(17.3 – 95.6) 
49.4 
(11.0 – 80.9) 
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Table 5.8 Comparison of peripheral blood and induced sputum 
percentage lymphocyte, neutrophil and monocyte populations in 
AFD subjects  
 
5. 9 Airway Obstruction in AFD and cell populations 
Airway obstruction was defined as FEV₁ /FVC <0.7. T cell populations in 10 
AFD subjects with airway obstruction were compared to 5 AFD subjects without 
airways obstruction alongside the 12 COPD and 7 healthy control subjects.   
5.9.1 Lymphocytes in relation to airflow obstruction  
Comparison of T cell percentages revealed a trend towards higher 
percentages of T cells within the lymphocyte gate in AFD subjects with airway 
obstruction compared to AFD subjects without airway obstruction, though this 
did not reach significance (p=0.07, Table 5.9.1). No significant differences were 
seen in T cell populations between AFD subjects in either group and healthy 
controls. The COPD group had significantly higher T cell percentages than both 
the unobstructed AFD subjects and the healthy control group (p<0.05, Table 
5.9.1).  
On further analysis, the percentage of CD3+CD4+ T cells and CD3+CD8+ T 
cell were similar in each group, as were the CD4+/CD8+ ratios (Table 5.9.1) No 
significant differences were seen in the NKT cell population between the groups 
(Table 5.9.1). 
% population 
Median (range) 
Peripheral blood Induced sputum p value 
Lymphocytes 29.8 
(19.2 – 40.8) 
2.3 
(0.5 – 7.3) 
<0.0001 
Neutrophils 60.8  
(47.7 – 73.6) 
21.7 
(7.6 – 40.7) 
<0.0001 
Monocytes 7.0 
(4.8 – 11.9) 
76.4 
(53.1 – 88.2) 
<0.0001 
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5.9.2 Neutrophil and monocyte/macrophages in relation to airflow 
obstruction  
Neutrophil and monocyte/macrophage populations from 10 AFD subjects 
with airway obstruction were compared to the 9 AFD subjects without airway 
obstruction alongside the COPD subjects and healthy control subjects. 
Comparison of the neutrophil and monocyte/macrophage populations between 
the groups did not reveal any significant differences (Table 5.9.2).  
Table 5.9.1 T lymphocyte populations in relation to airflow 
obstruction  
Group 
 
AFD with 
airway 
obstruction 
AFD without 
airway 
obstruction 
COPD Healthy control 
Median (range) 
n 10 5 12 7 
FEV1/FVC 
Mean (+/- SD) 
0.65* 
(+/- 0.04) 
0.74 
(+/- 0.04) 
0.62* 
(+/- 0.05) 
0.77 
(+/- 0.09) 
CD3+ T cells 
% lymphocyte gate 
69.6 # 
(18.8 – 89.9) 
30.9 
(15.2 – 64.7) 
74.5* 
(53.5 – 92.5) 
40.1 
(21.3 – 85.3) 
CD3+CD4 + 
% of T cells 
68.4 
(30.8 – 80.5) 
80.1 
(59.1 – 86.1) 
77.9 
(27.0 – 93.1) 
73.2 
(39.8 – 86.8) 
CD3+CD8+ 
% of T cells 
31.6                      
(19.5 – 69.9) 
19.9                 
(13.9 – 40.9) 
22.10 
(6.9 – 73.0) 
26.8 
(13.3 – 60.2) 
CD4+/CD8+ 
T cell ratio 
2.2                         
(0.4 – 4.1) 
4.0                         
(1.1 – 9.2) 
3.5               
(0.4– 13.5) 
2.7                               
(0.7 – 6.6) 
NKT cell 
% of T cells 
1.0                            
( 0.7 – 3.0) 
1.7                   
(0.8 – 5.3) 
0.9                       
(0.1 – 3.0) 
1.2                         
(0.1 – 2.2) 
* p<0.05 compared to AFD without obstruction and healthy controls, # p = 0.07 
compared to AFD without airway obstruction  
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Table 5.9.2 Neutrophil and monocyte/macrophage populations in 
relation to airflow obstruction 
 
  
Group AFD with airway 
obstruction 
AFD without 
airway 
obstruction 
COPD Healthy 
control 
Median (range) 
n 10 9 12 6 
FEV1/FVC 
Mean(+/-SD) 
0.65 
(+/- 0.04) 
0.76 
(+/- 0.04) 
0.62 
(+/- 0.05) 
0.77 
(+/- 0.09 ) 
Neutrophil % 
of CD45+ 
events 
19.5 
(7.64 – 34.9) 
21.0 
(0.58 – 40.7) 
18.3 
(3.47 – 80.3) 
43.3 
(15.9 – 88.0) 
Monocyte / 
macrophage 
% of CD45+ 
events 
74.3 
(60.4 – 88.2) 
76.71 
(53.1 – 88.2) 
76.35 
(17.3 – 95.6) 
49.38 
(11.0 – 80.9) 
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5.10 Sputum Cytokine assays  
Pro-inflammatory cytokine interleukin-8 (IL-8) and interleukin-6 (IL-6) 
concentrations were measured in sputum derived leucocyte lysate samples from 
10 AFD subjects, 5 COPD subjects and 5 healthy control subjects using the 
procedure described in Methods Section 2.3.6. These groups were not matched 
at recruitment. Cytokine assays were performed using standard ELISA kits as 
described in Methods Section 2.3.10.  
In the groups tested for cytokines as a whole, COPD subjects were 
significantly older than both the AFD subjects and healthy control subjects (Table 
5.10.1). Lung function parameters for both large and small airways including  
FEV₁ /FVC, FEV₁, RV/TLC and MEF50 % predicted were all significantly lower in the 
COPD group compared to both the AFD group as a whole and the healthy control 
group (Table 5.10.1). There were no differences in lung function parameters 
between the AFD group and the healthy control group.  
5.10.1 Induced sputum leucocyte lysate IL-8 and IL-6 concentrations 
in AFD, COPD and healthy Control subjects  
Induced sputum leucocyte lysate IL-8 concentration was found to 
be significantly higher in both AFD subjects and COPD subjects compared 
to healthy controls (p<0.01, Table 5.10.1). No significant differences were 
seen in IL-6 concentrations between the AFD, COPD and healthy control 
groups (Table 5.10.1).  
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Table 5.10.1 Sputum IL-8 and IL-6 concentrations in AFD, COPD and 
Healthy Control subjects  
Parameter 
Mean (+/- SD) 
AFD COPD Healthy 
Control 
n 10 5 5 
Age [years] 47.2* 
(+/- 15.5) 
68.1 
(+/- 10.9) 
42.2*** 
(+/- 8.6) 
Pack year smoking 
history 
Median (range) 
1.0* 
(0 – 20.0) 
17.1 
(0 – 75.0) 
0 
(0 – 16.0) 
FEV₁/FVC  0.73** 
(+/- 0.07) 
0.59 
(+/- 0.06) 
0.75** 
(+/- 0.08) 
FEV₁ %predicted 92.0* 
(+/- 12.6) 
78.6 
(+/- 10.4) 
103.2* 
(+/- 13.5) 
RV/TLC 81.2** 
(+/- 12.0) 
107.4 
(+/- 17.9) 
85.8** 
(+/- 6.9) 
MEF 50 % predicted 60.8* 
(+/- 19.8) 
30.1 
(+/- 17.7) 
72.1* 
(+/- 23.1) 
Sputum leucocyte  
lysate IL-8 
pg/ml/mg protein 
Median (range) 
1764 # 
(519.6 – 11,409) 
1166 # 
(334.4 – 9764) 
200.6 
(94.3 – 333.1) 
Sputum leucocyte  
lysate IL-6 
pg/ml/mg protein 
Median (range) 
21.4 
(6.2 – 132.4) 
15.1 
(4.8 –19.5) 
13.8 
(9.6 –28.2) 
* p<0.05, ** p<0.01, *** p<0.005 compared to COPD group  
 # p<0.01 compared to healthy control group 
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5.10.2 Induced sputum leucocyte lysate IL-8 and IL-6 concentration in 
relation to airway obstruction 
Of the 10 AFD subjects in this group, 4 had evidence of airway obstruction 
as defined by FEV₁/FVC<0.7. However, the differences in lung function 
parameters between the AFD group with and without obstruction did not reach 
statistical significance (Table 5.10.2). The COPD group had significantly lower 
FEV₁/FVC, RV/TLC and MEF50 %predicted compared to the unobstructed AFD 
group and healthy controls, and a significantly lower FEV₁ %predicted compared 
to healthy controls (Table 5.10.2).  
The sputum leucocyte lysate IL-8 concentration was found to be 
significantly higher in both the obstructed and unobstructed AFD groups and the 
COPD group compared to healthy controls (p<0.05 for AFD obstructed and COPD, 
p<0.01 for AFD unobstructed, Table 5.10.2). IL-6 concentrations were not found 
to be significantly different between any of the groups (Table 5.10.2).  
Analysis of IL-8 and IL-6 concentration in sputum leucocyte lysate of AFD 
subjects in relation to FEV₁/FVC as continuous variables did not reveal any 
significant correlations (not shown). 
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Table 5.10.2 Sputum IL-8 and IL-6 concentration in leucocyte cell 
lysate in relation to airflow obstruction 
 *p<0.05 compared to COPD 
**p<0.01 compared to healthy control  
Parameter 
median 
(range) 
AFD 
obstructed 
AFD 
unobstructed 
COPD Healthy 
control 
n 4 6 5 5 
FEV₁/FVC 0.67 
(+/- 0.03) 
0.78* 
(+/- 0.05) 
0.58 
(+/- 0.06) 
0.75* 
(+/- 0.08) 
FEV₁  
% predicted 
86.5 
(+/- 9.5) 
95.7 
(+/- 13.9) 
78.6 
(+/- 10.4) 
103.2* 
(+/- 13.5) 
RV/TLC 92.0 
(+/- 10.9) 
74.1* 
(+/- 5.8) 
107.4 
(+/- 17.9) 
85.8* 
(+/- 6.9) 
MEF50% 
predicted 
45.8 
(+/- 6.9) 
70.8* 
(+/- 19.4) 
30.6 
(+/- 17.7) 
72.1* 
(+/- 23.1) 
Sputum 
leucocyte  lysate 
IL-8 
pg/ml/mg 
protein 
Median (range) 
 
761.0* 
 
(585.3 –  2341) 
 
2497** 
 
(519.6 - 11,409) 
 
1166* 
 
(334.4 – 9764) 
 
200.6 
 
(94.3 – 333.1) 
Sputum 
leucocyte  lysate 
IL-6 
pg/ml/mg 
protein 
Median (range) 
 
6.7 
 
(6.2  – 37.7) 
 
23.5 
 
(7.7  – 132.4) 
 
15.1 
 
(4.8 – 19.5) 
 
13.8 
 
(9.6 – 28.2) 
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5.10.3 Influence of smoking history on induced sputum IL-8 and IL-6 
concentration in AFD 
Of the AFD subjects, only 2 had a smoking history of greater than 10 pack 
years, and none were current smokers. There was a significant difference 
between sputum leucocyte lysate IL-8 concentration in the 8 AFD subjects with 
<10 pack years of smoking compared to the 5 healthy controls; and also between 
the 5 COPD subjects and healthy controls, with the lowest values found in the 
healthy control group.  
There were no significant differences in sputum IL-6 concentration in AFD 
subjects with greater than or less than 10 pack years of smoking compared to 
each other or to COPD or healthy control subjects.  
Table 5.10.3 Induced sputum cell lysate IL-8 and IL-6 concentration in 
relation to smoking history 
Sputum 
leucocyte 
lysate 
Median 
(range) 
AFD >10 pack 
years 
AFD <10 pack 
years 
COPD Healthy 
controls 
n 2 8 5 5 
IL-8 pg/ml/mg 
protein 
1431 
(519.6 – 2341) 
1764*** 
(677.2 – 5176) 
1166** 
(593.8 – 5736) 
200.6 
(95.26 – 331.8) 
IL-6 pg/ml/mg 
protein 
7.04 
(6.35 – 7.72) 
23.45 
(10.49 – 83.54) 
15.09 
(8.35 – 18.79) 
13.81 
(9.72 – 21.44) 
** p<0.05, *** p<0.005 compared to healthy controls  
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5.11 Discussion 
 Induced sputum sampling provides an additional method for examining 
the lungs that is non-invasive, tolerable and repeatable. In the context of 
Anderson Fabry Disease, with a group of patients who undergo multiple regular 
routine investigations of varying complexity already, it provided a suitable, 
straightforward alternative to more invasive methods of sampling the lung, such 
as bronchoscopy. In light of what we know about the changes in the lungs in AFD 
thus far being mainly changes that are airway related, the origin of induced 
sputum samples was also well suited to this purpose.  
Samples obtained for the investigation of specific cell populations in each 
group were generally adequate in terms of cell yield. The number of events 
captured from each sample in the different groups was similar overall. However, 
for the purposes of examining the lymphocyte population, it was important that 
enough events within the set lymphocyte gate were captured in order to enable 
further dissection of the lymphocyte populations present. This resulted in 3 of 
the AFD samples obtained being unsuitable for use for this purpose.  
Examination of the lymphocyte populations in the induced sputum of AFD 
subjects compared to healthy control subjects did not reveal any significant 
differences in T cell populations in the group as a whole. The COPD subjects 
demonstrated a higher percentage of T cells overall in induced sputum compared 
to AFD subjects and healthy controls. However, AFD subjects with airways 
obstruction appeared to have a higher percentage of T cells in induced sputum 
when compared to AFD subjects without airway obstruction though this did not 
reach statistical significance,  
  Further examination of T cell subsets did not reveal any differences 
between the CD4+ and CD8+ T cell percentages between the three groups.  It has 
been previously shown by others that there may be a predominance of CD8+ T 
cells in the sputum of COPD subjects (260), but this did not appear to be the case 
in our cohort. The relatively small sample size may be a factor here; and with 
further sampling, differences in T cell subsets in the AFD subjects may become 
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apparent. An additional explanation for this is that the COPD subjects recruited 
for this study were from a COPD study cohort who are carefully and optimally 
monitored and managed and therefore may not be entirely representative of a 
typical COPD population. It was also ensured that all COPD subjects were 
sampled at baseline, at least 6 weeks away from their last exacerbation, which 
may also have influenced the sputum cell profiles obtained.  
Examination of NKT cell populations did not reveal any differences 
between the groups, with the percentage of NKT cells in each of the groups 
being similar and small in number (0.94 -1.6% of the lymphocyte gate). Given 
this, it is likely that identification of specific invariant NKT cells would have been 
difficult. It would however be of interest to try and explore changes in iNKT cell 
populations at a cellular level within the lung, given the documentation of 
accumulated storage material within lung derived cells in previous studies (261).  
Assessment of B lymphocyte populations did not reveal any differences 
between AFD subjects and healthy controls or COPD subjects. This would be 
consistent with the evidence that AFD has not been shown to particularly affect 
B cell populations. In contrast, there has been some suggestion that B cells may 
be relevant in the pathophysiology of COPD, with findings of increased B cell 
numbers in bronchial biopsies (262).   
Overall, from the examination of lymphocyte populations in these groups 
there is some evidence to suggest that changes in lymphocyte cell numbers 
warrant further investigation in the context of lung involvement in AFD, and that 
changes seen in COPD airways may be relevant. Overlap with pathophysiology of 
COPD may guide potential treatments of value to AFD subjects who are 
symptomatic as a result of their pulmonary involvement.  
The examination of neutrophil populations did not reveal any significant 
differences between AFD, COPD and healthy control subjects. However, on 
calculating the power of this part of the study, it is apparent that it was under-
powered with the sample size recruited. From this analysis the healthy control 
group had the highest percentage of neutrophils in their induced sputum at 
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43.3%.  This is similar to other studies in healthy populations (263;264). In 
comparison, the AFD subjects had lower percentages of neutrophils, coming 
close to statistical significance (p=0.09), though with no difference between AFD 
subjects with and without airway obstruction, implying that perhaps in AFD 
neutrophilic inflammation does not play a big part in the underlying 
pathophysiology.  
For monocytes/macrophage populations there was a strong suggestion 
that the percentage populations in AFD and COPD subjects were greater than 
that of healthy control subjects (p=0.07).  Here, too, larger numbers of study 
subjects may help to clarify this point.  The median percentage macrophage 
population of 49.3% in healthy control subjects is not dissimilar to previous 
studies examining induced sputum cell populations (265;266), though was 
slightly lower than seen in others (267).  
Comparison of sputum populations with those seen in the peripheral blood 
revealed significant differences, with as expected the percentages of 
lymphocytes and neutrophils much higher in blood compared to sputum, and 
that of monocytes significantly higher in sputum. This finding supports the idea 
that the differences demonstrated in induced sputum leucocyte and peripheral 
blood leucocyte α-galactosidase A activity may be due to differences in the 
leucocyte populations present.  
The most significant limitation to this aspect of the study is the number of 
samples obtained from study subjects for the purpose of examining cell 
populations. This was limited by the yield from one sputum induction procedure 
being insufficient to consistently provide enough cells for the purposes of both 
enzyme activity assessment and examination of cell populations. Therefore 
subjects had to be sampled on consecutive study visits to achieve both. In 
addition to this, the yield from induced sputum sampling from subjects who are 
largely non-producers of sputum, such as healthy controls and AFD subjects, was 
on occasion insufficiently low in cell number for the population under 
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investigation, and therefore not suitable for use. In practice this was only the 
case in the lymphocyte plots in this study.  
Analysis of cytokines in the induced sputum of AFD subjects revealed 
elevated concentrations of IL-8 when compared to healthy control subjects. This 
increase was present in both AFD subjects with and those without airway 
obstruction, suggesting that the trigger for this is related to AFD. Given that IL-8 
is produced by alveolar macrophages, this is also in keeping with our finding that 
AFD subjects had a greater percentage population of macrophages in induced 
sputum compared to healthy controls. The same was true for the COPD group in 
this study, where IL-8 concentrations were also greater than in healthy controls, 
(as were increases in monocyte/macrophage populations). No difference was 
seen in IL-6 concentration between the groups.  
The role of cytokines in the pathophysiology of AFD is as yet unclear, 
though there are suggestions that cytokines may play a role in the presentation 
and severity of changes seen in AFD (268). One study has raised the question as 
to whether genetic polymorphisms of IL-6 may influence the severity of 
ischaemic events in AFD subjects (269).  
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5.12 Conclusions 
The new findings from this chapter can be summarised in the following 
points:  
1. No significant differences were seen in T lymphocyte populations or T cell 
subsets between AFD subjects and healthy controls  
2. There was a suggestion that AFD subjects with airway obstruction have a 
higher percentage of T lymphocytes in induced sputum compared to AFD 
subjects without airway obstruction, as noted in the COPD group 
3. No significant differences were seen in neutrophil populations between 
AFD and healthy control subjects 
4. There was the suggestion of increased monocyte/macrophage percentages 
in the induced sputum of AFD subjects and COPD subjects compared to 
healthy controls 
5. There was an elevated concentration of interleukin-8 in the induced 
sputum of AFD subjects compared to healthy controls 
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6.1 Summary of study findings  
 
 This study has demonstrated that both respiratory symptoms and airways 
disease are common in patients with Anderson Fabry Disease. We have shown 
that it is generally mild in nature, and has features of small airways airflow 
limitation on lung function testing. However, we have also found evidence of 
more marked airway involvement in almost half the AFD subjects recruited. This 
was most frequent in males though was also present in a significant proportion 
of females (32%). We have demonstrated that the majority of this airflow 
limitation appears to be fixed, with little reversibility to bronchodilators, and is 
not seen to progress significantly over a 12 month period. We did not find any 
specific changes in measures of diffusion capacity in AFD subjects, other than in 
the context of a significant smoking history. In addition we did not demonstrate 
any consistent radiological changes in AFD subjects on CXR or CT scanning of the 
chest.  
 Our study showed that AFD subjects with worse overall disease as 
measured by MSSI were more likely to suffer from pulmonary involvement, and 
demonstrated weak negative correlations between both MSSI and Age adjusted 
Severity Score with airway obstruction. We have also demonstrated that the 
changes in airflow limitation seen in our cohort of AFD subjects could not be 
explained by smoking alone, with subjects who had minimal smoking history 
showing significant evidence of airway obstruction compared to healthy controls. 
We did not reveal any differences in lung function in AFD subjects on ERT 
compared to those who were naïve of ERT. Comparison of lung function data of 
some of the more frequent genotypes in this cohort indicated that the most 
obstructed subjects had the genotype R227X, whilst the least obstructed had an 
exon 1 deletion, though the numbers of subjects were too small to analyse this 
statistically for the purpose of exploring genotype-phenotype correlation.   
 In our study we established a method for measuring α-galactosidase A 
activity in induced sputum samples, and showed that activity of the enzyme was 
low in AFD males compared to controls and AFD females. We demonstrated that 
Chapter 6 – Discussion 
173 
 
for the most part, α-galactosidase A activity was greater in the sputum than in 
the blood in both AFD and non-AFD subjects, apart from in the plasma and fluid 
phase of the sputum where the opposite appeared to be true in non-AFD 
subjects only.  
 Measurements of α-galactosidase A activity in blood or sputum were 
found to be no different in AFD subjects on ERT when compared to those who 
were enzyme naïve. In addition, we found no differences in sputum enzyme 
activity in subjects with mild compared to more severe disease as measured by 
an MSSI of less or more than 20. Whilst we were able to demonstrate that 
plasma and blood leucocyte α-galactosidase A activity was significantly lower in 
AFD subjects with airway obstruction compared to those without, sputum α-
galactosidase A activity was also lower in this group but this did not reach 
statistical significance (p=0.08).  
Examination of induced sputum samples from one AFD male subject out of 
3 examined revealed the presence of inclusion bodies in keeping with those 
reported previously in AFD subjects (270), indicating detectable storage material 
in sputum derived cells.  
This study also sought to investigate cell populations in the induced 
sputum of AFD subjects, and demonstrated that the predominant cell population 
in the induced sputum of AFD subjects was monocytes and macrophages 
followed by neutrophils, in similar percentages to that seen in the COPD subjects 
in this study. We did not find any differences in the populations of these cells in 
AFD subjects with airways disease compared to those without.  
Examination of populations of T lymphocytes in AFD subjects compared to 
healthy controls revealed no difference. T lymphocytes were proportionally 
higher in the sputum of COPD subjects compared to both AFD subjects and 
controls. On examining sputum T lymphocyte populations in AFD subjects with 
airway obstruction there was a suggestion that this population was greater than 
that seen in sputum from AFD subjects without airway obstruction, though this 
did not reach statistical significance (p=0.07). No differences in the populations 
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of T cell CD4+ and CD8+ subsets were found between AFD, COPD and healthy 
control subjects. No differences in NKT cell populations were revealed between 
the groups.  
On examining cytokines in the induced sputum from AFD subjects we 
found elevated concentrations of IL-8 in sputum in AFD subjects, both in those 
with and without airway obstruction, compared to healthy controls. COPD 
subjects also had demonstrably high IL-8 concentrations in comparison to 
healthy controls. No differences were noted in IL-6 concentrations between the 
groups studied.  
6.2 Possible Model of AFD lung disease  
From what is known about AFD as a whole, and from the limited evidence 
that has been gathered regarding how AFD affects the lungs, one could propose 
the following model of AFD pathophysiology in the lungs:  
 
As in other organ systems, there is a gradually increasing accumulation of 
substrate throughout the lung in AFD over time. This is deposited in airway wall 
and in the airway and vascular epithelium as well as in pneumocytes, as has been 
demonstrated on bronchoscopy and lung biopsy samples (271;272). The impact 
of this is first noted in testing the small airways as they are of the smallest calibre 
and contribute most to airway resistance (273). The deposition and accumulation 
of Gb3 results in hypertrophy of the smooth muscle in the airway wall, as seen in 
the smooth muscle of the vascular wall in AFD vasculopathy (274) which triggers 
an ongoing low grade inflammatory process, in turn driving further 
immunopathology, including pro-inflammatory cytokines (275).  At this stage in 
the presence of airway smooth muscle hypertrophy, changes in airway calibre are 
reversible and there is a measurable response to bronchodilators. However, with 
ongoing tissue activity, local cell death and necrosis from sphingolipid-driven 
apoptosis and abnormalities in iNKT cells and lipid antigen processing (276;277) 
plus cytokine production, more established and irreversible change in the airway 
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wall develop such as peribronchial and peribronchiolar fibrosis.  These have  been 
reported in open lung biopsy samples from an AFD patient with significant 
respiratory symptoms (278). Over time, with the ongoing accumulation of 
substrate and the responses that this triggers, this process reaches a threshold 
where its effects becomes evident in the larger calibre airways also, thereby 
being detectable on lung function testing. The slow, chronicity of the process 
means that it presents in older AFD subjects, and correlates with other factors 
that would indicate worsening disease. 
 
Whilst some of the work from this study has provided support for this 
proposed model, there remain gaps which require further investigation to 
determine just how closely this reflects the pathophysiology of AFD lung 
involvement.    
6.3 Changes seen with pulmonary involvement 
6.3.1 Small airways 
The findings from this study and from the majority of the previous 
literature on pulmonary involvement in Anderson Fabry Disease, point towards 
lung pathology that is mainly airway-related. We documented in our cohort mild 
airway obstruction, with widespread changes in particular in the calibre of the 
smaller airways affecting 80% of the subjects. More global measures of both 
large and small airways involvement were present in almost half of those 
assessed.  
It is recognized that the assessment of small airway pathology is difficult 
using spirometry given the degree of variability that can occur with measures 
such as MEF25-75 (279;280). However, on the basis of these findings it is important 
to investigate this further in AFD. It has been documented in respiratory diseases 
such as cystic fibrosis that early changes occur in the smaller airways, with 
considerable damage often present at this site prior to a detectable fall in FEV₁ 
(281). In view of this there has been some focus recently on the use of lung 
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clearance index (LCI), a technique based on multi-breath washout of tracer, to 
examine small airway function in more detail and to detect early changes in the 
airways (282). This may be useful in AFD to test out the hypothesis, to ascertain 
the extent of changes in airway calibre more accurately, and to document its 
possible progression.  
6.3.2 Progression of airway involvement  
Our study findings support the concept that gradual progression of lung 
involvement occurs over time, involving the small airways first before affecting 
the larger caliber airways.  Those subjects with lower FEV₁/FVC <0.7 were older, 
though this did not reach significance in the number of subjects investigated 
here.  This is in line with previous work (283). Whilst we did not demonstrate 
changes in lung function parameters over time, it is acknowledged that the 
period of 12 months in the context of AFD is perhaps not long enough to assess 
this accurately. With more sensitive measures of airway function such as LCI, it is 
possible that even small but genuine changes may be detected. If this were the 
case it may assist with determining the rate of change of lung function over time, 
and enable one to predict individual projection of lung function decline. Any 
alterations to this in subjects subsequently commenced on ERT would also be of 
interest.  
6.3.3 Reversibility 
Of note in AFD is the lack of reversibility, for the most part, to 
bronchodilators.  This suggests that the airway obstruction in AFD is largely fixed.  
Considering the model outlined above, this irreversibility may result from 
peribronchial fibrosis. If this were the case it would raise the question whether 
ERT if started early, may prevent the development of fixed airway obstruction in 
AFD through reducing substrate accumulation and thus limiting the process that 
results in fibrotic change.  
Similar concepts have been postulated in heart disease, where autopsy 
findings of AFD subjects diagnosed relatively late, but who had received ERT, 
showed ongoing evidence of substrate within the myocardium and significant 
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fibrosis (284). It was suggested that once established fibrotic change is present, 
the comparative effectiveness of ERT on clearing substrate from the myocardium 
may be diminished (285). This theory is supported by studies involving serial 
myocardial biopsies to examine the effectiveness of ERT in clearing substrate 
from the heart, which found that although there is clearance of Gb3 from the 
coronary vasculature, persistence of substrate in cardiomyocytes is seen (286). 
This implies that the persistence of substrate in muscle cells can result in fibrosis.  
In the kidney, differences in the degree of substrate clearance from different cell 
types has also been reported on serial biopsy findings after receiving ERT for less 
than  a year.  Substrate persists predominantly in podocytes and the distal 
tubular epithelium  (287).  
From a clinical perspective one might question whether AFD subjects with 
airway obstruction would benefit from regular inhaled bronchodilator therapy 
for symptoms of cough and wheeze. This warrants further investigation using 
trials of treatment and validated respiratory questionnaires to assess the efficacy 
of such drugs.  
6.3.4 Radiology 
The physiological changes present in the airway were not demonstrable on 
radiological examination, despite the use of CT imaging protocols that should 
highlight changes in small airways, where the most widespread changes were 
seen. The knowledge that plain CXRs are likely to yield as much information in 
most cases as a CT scan is helpful in that it may avoid unnecessary radiation in a 
patient group who already acquire a significant cumulative exposure to radiation, 
as they undergo a large number of radiological investigations. However, for the 
purposes of further exploration into the airway changes seen in AFD, recent 
studies in airways disease have used new advances in CT imaging techniques and 
software to examine the airway wall, providing detailed assessments of airway 
dimensions and wall thickness, and their relationship to airflow limitation (288-
290). In AFD the use of CT imaging may help to assess the degree of smooth 
muscle hypertrophy in the airway wall and to compare the pattern of airflow 
limitation in more detail to that seen airways disease.  
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6.4 Pattern of disease in the lungs  
6.4.1 Gender 
As with other aspects of AFD, we showed that lung involvement in AFD was 
worse in males, though spirometric abnormalities were also evident in females. 
Interestingly there was no difference in the average age of male and female AFD 
subjects with airway obstruction. One might have expected the females with 
evidence of lung involvement to have been older, as is the case in other AFD 
pathology (291). This raises the question whether other factors such as smoking 
are relevant. In our study the majority of spirometric changes appeared to be 
independent of smoking, though it did impact on diffusion capacity in AFD 
subjects with >10 pack years of smoking. Indeed, the results of the multivariable 
analysis suggest that smoking was not associated with FEV₁/FVC and MEF50 
%predicted. AFD itself appeared to have little effect on diffusion capacity.  
6.4.2 Disease severity 
Some of the data from our study suggested that AFD subjects with worse 
generalised systemic disease as measured by MSSI, were more likely to have 
evidence of airway obstruction. This would also fit with our proposed model, in 
that changes in the lung are related to the same factors influencing severity of 
disease in other organs in AFD. When other possible confounders were 
controlled for within a multivariable analysis, however, the effect of MSSI on 
FEV₁/FVC did not reach statistical significance - even though the data suggest that 
with larger numbers of subjects this may have been the case. From a clinical 
perspective, this has relevance in the context of symptoms and well being, as it is 
the AFD subjects already suffering from the most marked disease who are likely 
to also be affected by the respiratory component of AFD. Obviously in the case of 
significant cardiac involvement symptoms such as shortness of breath and 
reductions in exercise tolerance may be compounded; though this highlights the 
need for further investigation into the response of such symptoms to respiratory 
interventions.   
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6.4.3 Genotype 
As with other aspects of AFD, it was not possible to establish any firm 
association between genotype and lung involvement in AFD. It has been 
previously noted in AFD that relationships do exist between phenotype and the 
residual enzyme activity associated with different types of mutations, particularly 
in renal disease where the presence of detectable residual α-galactosidase A 
activity  is linked to later onset renal disease, lower Gb3 content in renal cells and 
lower scores for histological damage (292). However we did not find any 
relationship between residual enzyme activity in plasma and airway obstruction, 
measured by FEV₁/FVC or MEF50 %predicted.  
6.5 α-galactosidase A activity  
6.5.1 Induced sputum enzyme activity  
In our investigation into α-galactosidase A activity in the lung we were able 
to determine that one can measure enzyme activity in lung derived samples 
using similar methods to that in blood. The pattern in sputum, as hypothesised, 
was lower in AFD males than control males and AFD females.  This was seen to 
be true for both the fluid phase and the cellular phase of the sputum.  
In the context of our hypothesed model of lung involvement in AFD, this 
pattern of α-galactosidase A activity would be consistent, as it is the same group 
of subjects with low enzyme activity compared to controls who demonstrate 
lung involvement, which would have occurred as a result of greater Gb3 
accumulation in the airways and the processes that this triggers.   
6.5.2 Induced sputum and blood enzyme activity 
In paired samples from the same subject α-galactosidase A activity in 
induced sputum in both controls and AFD subjects was higher than in blood, with 
the exception of the sputum supernatant compared to the plasma in non-AFD 
controls. It is possible that this may in part explain why the lungs in AFD are not a 
major cause of morbidity; and why overall pulmonary involvement is not a 
prominent feature of AFD presentation.  
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The finding that α-galactosidase A activity in induced sputum leucocytes 
was greater than that of blood leucocytes in the control population as well as in 
the AFD population was interesting as it suggests that this may be related to 
differences in the composition of lung derived samples compared to blood. In 
peripheral blood, the predominant white cell populations are generally 
neutrophils, followed by lymphocytes and then monocytes, which was shown to 
be true for our cohort by their differential white cell counts. In induced sputum, 
however, there is evidence to suggest that the main cell populations from 
healthy subjects are macrophages and neutrophils (293;294). This was verified in 
our study, with the monocyte/macrophage population predominant in sputum 
samples from all the groups, followed by neutrophils, both of which were 
significantly higher than the percentage populations in blood. In AFD there has 
been work showing that α-galactosidase A activity varies between different 
leucocyte cell types, being greatest in monocytes, Thus the presence of a 
predominant macrophage population in the sputum of AFD and healthy control 
subjects may explain the difference in enzyme activity seen (295).   
Cell populations from bronchoalveolar lavage samples have been shown to 
differ from induced sputum, with the finding of much lower numbers of 
neutrophils in BAL (296). This raises the question whether the induced sputum 
process itself contributes to airway neutrophil recruitment. To examine the 
enzyme changes in the lung in AFD further, it may be useful to analyse BAL 
samples and determine the relationship between cell populations and α-
galactosidase A activity. Although the majority of changes so far evident in the 
lung in AFD have been related to the airways rather than at alveolar level, 
storage material has also been demonstrated in pneumocytes (226;297), 
therefore this may be of great relevance.  
α-galactosidase A activity has been quantified in a number of different sites 
in subjects with Anderson Fabry Disease, including liver, kidney, skin as well as 
blood and tears. We have been able to demonstrate activity from induced 
sputum samples, which in the main comprise lung derived leucocytes. However it 
is not known what is the enzyme activity in other cell types derived from the 
Chapter 6 – Discussion 
181 
 
lung, and whether this differs. This would clearly be relevant to further lung 
based work.  
It was notable that the range for sputum leucocyte-derived enzyme activity 
was wide in both controls and AFD subjects, with the highest measures in 
sputum being much greater than those in blood. Whilst this again may result 
from the different cell populations present in sputum, it could also reflect the 
quality of the sample acquired. As, whilst all the samples processed for the 
purpose of measuring α-galactosidase A activity had a minimum of 1x10^6 
leucocytes with a cell viability of >80%, some samples may have been more 
cellular than others.  Furthermore the extent of salivary contamination differed 
from sample to sample, though all samples contained <20% squamous cells. 
Sampling the lung by bronchoscopy may be one way of avoiding salivary 
contamination, though this is more invasive.  
6.5.3 Enzyme replacement therapy 
It was difficult to assess the impact of ERT on the lung from this study, as 
the majority of subjects were already receiving it, resulting in a small enzyme 
naïve population. There were no significant differences noted in the sputum or 
blood enzyme activity of AFD subjects who were receiving ERT and those who 
were not. This is most likely due to the pharmacokinetcs of ERT, which have 
demonstrated that at doses similar to that administered for treatment over a 2 
hour infusion period,  80% of peak concentration was 60 minutes into the  
infusion, and plasma concentration fell back to half peak 15 minutes after the 
infusion had been completed (298). 
It is difficult to estimate penetration of ERT into the lung. Dosing studies in 
a mouse model prior to the clinical trials of ERT did demonstrate some recovery 
of human α galactosidase A glycoforms from the lungs after intravenous 
administration of enzyme, though at lower levels than was evident from the 
liver, heart and kidneys (299). However there has been no demonstration of Gb3 
clearance from the lung with ERT, as shown in the liver, kidney, heart and skin 
(300), though such examination may be helpful.   
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The lack of difference in sputum enzyme activity between those on ERT 
and those who are enzyme naïve may also reflect higher residual α-galactosidase 
A activity in enzyme naïve subjects. However, when tested in blood no significant 
difference between the two groups was found. In our study almost all AFD 
subjects on ERT were receiving fortnightly Replagal®, with only 3 using 
Fabrazyme®. It is therefore not possible to comment on the effect of different 
enzyme preparations when interpreting these results, though clearly this and the 
differences in dosing may be relevant.  
 
6.6 Sputum cell populations and cytokines 
6.6.1 Lymphocytes 
The examination of cell populations by flow cytometry suggest that further 
investigation into lymphocyte populations may of value in AFD subjects. AFD 
subjects with airway obstruction seemed to have a higher T cell percentage in 
their sputum than those without documented airway obstruction, though this 
did not reach statistical significance (p=0.07, power 72%).  This is similar to that 
seen in the COPD control group. It may be proposed therefore that with a larger 
sample size a significant difference in T lymphocyte populations may be evident 
between AFD subjects with and without airways disease.  
The finding of changes in CD3+ T cell population has been demonstrated in 
AFD mouse models by Balreira et al who reported lower numbers of hepatic T 
cells in the liver of Fabry mice, and were able to demonstrate that this was 
largely due to reduced numbers of CD3int T relative to CD3high T cells, and a 
subsequent reduction in the percentage CD3+CD4+ population (301). There is 
therefore an implication that T cells may play a part in the cascade that occurs as 
a result of the presence of lipid antigen.  
 In airways disease it has been shown that the percentage lymphocyte 
population present in bronchoalveolar lavage is significantly greater than that of 
induced sputum from both COPD and control subjects (302). This may therefore 
Chapter 6 – Discussion 
183 
 
be one way of examining the influence of lymphocytes in the AFD lung changes 
in greater detail. Sampling the lung in this way would potentially allow further 
examination of the lymphocyte subsets present, as with larger numbers of 
lymphocytes it would be easier to delineate CD4+ and CD8+ T cell populations.  
6.6.2 NKT cells  
In our study we did not demonstrate any difference in NKT cell populations 
in the induced sputum of AFD subjects compared to COPD subjects or healthy 
controls. However, when examining this population it must be acknowledged 
that the number of cells being analysed becomes very small, and that therefore 
results must be interpreted in light of this. By the same token it would have been 
unfeasible to further examine the flow cytometry plots for an iNKT cell 
population using CD markers for the invariant chain as these are likely to be an 
even smaller subset on the overall T cell population. 
Given its higher yield of lymphocytes, sampling by BAL may allow better 
assessment of the invariant NKT cell population. This would  be of interest given 
the anomalies in iNKT cells that have been described in regards to AFD, with 
reports of reduced numbers due to impaired thymic selection (133). Studies have 
been performed in airways disease to examine the prevalence of iNKT cells in 
BAL samples and shown that iNKT cells are present in low numbers in COPD, 
asthma and control subjects (303). In addition, peripheral blood iNKT cell 
percentages have been found to be low in COPD subjects, with further 
reductions seen at exacerbation (304).  
6.6.3 Monocytes/macrophages  
We found that the predominant cell population in the induced sputum of 
AFD subjects was the monocytes/macrophage population. This was also the case 
in our COPD and healthy control cohorts, though there was perhaps a lower 
percentage in the healthy control group. In COPD, increased numbers of alveolar 
macrophages are of significance in the pathophysiology of the inflammatory 
process due to their production of cytokines and chemokines, including IL-8, 
particularly on activation by cigarette smoke (305;306). Given that our data point 
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towards increased numbers of monocyte/macrophages in AFD sputum, this may 
be of relevance as it has been suggested that the impact of smoking on the lungs 
in AFD is disproportionate to smoking history alone (307).  
Macrophage numbers have also been shown to correlate with worsening 
lung function in COPD (308). Here, no difference was seen in 
monocyte/macrophage populations between the AFD subjects with and without 
airways disease, suggesting that the cause for a higher proportion of 
macrophages in sputum may be inherent to AFD. Again the examination of 
induced sputum in more subjects in both groups is necessary to determine any 
differences in the AFD populations. Longitudinal follow up would allow us to 
assess whether subjects with higher macrophage numbers were more likely to 
develop airway obstruction over time.  
6.6.4 Neutrophils  
The neutrophil populations in induced sputum were also similar between 
the groups.  However, when calculating the power of this part of the study to 
detect a difference, it is apparent that it was under-powered with the sample 
size recruited. Sputum neutrophilia has been documented in COPD; with 
increasing numbers found to correlate with decline in lung function (309;310). 
The recruitment of neutrophils to the airways in COPD has also been related to 
current smoking and exacerbations (311;312). In our COPD cohort the low 
percentages of neutrophils may be explained by the mild degree of airway 
obstruction recruited to the cohort, with the subjects being GOLD Stage I or II 
only, with no current smokers and sampling being performed in a stable state 
outside of an exacerbation.  
An additional limitation when delineating sputum populations of 
monocytes and macrophages is the autofluorescence associated in particular 
with alveolar macrophages. This is a common problem, and is present with 
several CD antibody markers (313;314).  Proposed methods to overcome this 
difficulty include using alternative antibodies. We did not pursue this here as we 
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felt it was beyond our particular study where the focus was the relative size of 
the populations  (315;316).  
6.6.5 Cytokines  
The sputum cytokine measurements performed in our study revealed 
elevated concentrations of IL-8 in AFD and COPD subjects when compared to 
healthy controls, but no difference in IL-6 concentrations. Elevated 
concentrations of IL-8 have been demonstrated in the sputum in the sputum of 
both subjects with COPD and asthma in the past, and shown to have a negative 
correlation with FEV₁/FVC in COPD subjects (317). IL-8 is associated with 
neutrophil activation and chemotaxis, and has been shown to be elevated in 
smokers compared to non-smokers (318), though we did not see any difference 
in neutrophil populations between our groups.  In our study it was difficult to 
draw any conclusions regarding the influence of smoking on the IL-8 
concentrations in AFD as numbers were small. However there appeared to be a 
trend towards a significant difference in IL-8 in AFD subjects with >10 pack years 
of smoking compared to healthy controls (p=0.09, power 52%), suggesting that 
more data may be required to examine this.   
IL-8 may be relevant, regardless of smoking, in that sputum concentrations 
were elevated in non-obstructed AFD subjects as well as those with airway 
obstruction. It is important to note that there are significant concentrations of IL-
8 present in saliva, and this could have influenced our findings. The effect of this 
should have been minimized by the sputum processing method, which sought to 
minimise salivary contamination of the samples. Given that all the samples from 
each of the groups were obtained and processed in the same way, this should 
not be a significant factor. However sampling by BAL may further bypass salivary 
contamination and so help to clarify this. 
Previous studies in AFD have demonstrated elevated plasma 
concentrations of IL-10, IL-1β and IL-1α (319). We did not, in our study measure 
concentrations of cytokines in paired lung and plasma samples, though this may 
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be of some value in determining whether IL-8 has a possible role in systemic AFD, 
or whether this finding is only evident in the lungs.   
6.7 Clinical relevance  
From a clinical perspective our study demonstrates that greater emphasis 
should be placed on respiratory aspects of AFD, as symptoms are common, and 
more frequent in those with more severe overall disease, in males and smokers. 
It is possible that symptoms including shortness of breath and reductions in 
exercise tolerance are being attributed solely to cardiac involvement, whereas 
there may be a significant contribution from the lungs in some cases. Certainly 
smoking cessation should be emphasized.  
Given that there appears to be some overlap with airways diseases such as 
COPD, further investigation into the benefit of airway treatments such as 
inhalers is warranted to assess whether these might have a role in improving 
symptoms. Although little reversibility to bronchodilators was evident, one could 
propose that inhaled corticosteroids may be of potential benefit if the basis of 
the changes seen are inflammatory and due to processes affecting the bronchial 
epithelium and airway wall. When considering this it would be important to 
remember the distribution of the airways abnormalities noted in AFD, with the 
small airways perhaps being the largest contributing component.  Therefore the 
choice of agents and delivery device used should allow particles sized small 
enough to reach this part of the lungs (320).  
Certainly it may be also important to consider the choice of drugs used in 
the treatment of cardiac aspects of AFD, which may impact on the airways in a 
detrimental manner in subjects with possible reversible airway obstruction, such 
as β-blockers. 
The role of ERT in respiratory aspects of AFD requires further evaluation. 
Whilst it is unlikely that respiratory involvement per se in AFD would commonly 
drive the need to commence ERT, it is possible that in the long term it may have 
a role in preventing the progression of airflow limitation becoming clinically 
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relevant.  This may be helpful given that it appears to be those with overall 
worse disease severity who are more likely to have airway obstruction as a result 
of AFD.  
6.8 Limitations  
6.8.1 Numbers and demographics of subjects  
As with all studies investigating rare diseases, one of the drawbacks of this 
work is the limited number of study subjects assessed. A total of 45 AFD patients 
were prospectively recruited, as described in Methods Section 2.2.1. They were 
therefore not subject to selection bias based on symptoms or signs suggestive of 
respiratory involvement but were a pragmatically-recruited group attending our 
service.   
Given that all study subjects were clinically assessed and all sampling and 
processing was performed by the same operator, the number of subjects seen 
per day was limited by the practicalities of this in the time available. Study 
subjects often lived some distance from the hospital and were therefore only 
able to perform study investigations at their scheduled 6 monthly appointment. 
Hence all investigations had to be co-ordinated to have minimal impact on their 
clinical care.  
The COPD cohort recruited consisted of 14 subjects matched to AFD 
subjects with evidence of airflow obstruction first by gender and then GOLD 
stage. The COPD control population was significantly older than the AFD 
subjects; however, as lung function data were reported and compared adjusted 
for age, this is likely to have had little impact on the results. However the 
evaluation of cell populations in sputum may have been affected by the changes 
to cellular immunity that occurs with age. This may have therefore been 
relevant.   
Differences were present in the individual lung function parameters in the 
COPD cohort as despite being matched on GOLD stage these were significantly 
lower in the COPD group when compared to the AFD group. This is because each 
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stage of the GOLD criteria encompasses a range for the percentage predicted 
value of FEV₁. Therefore despite being classified in the same GOLD stage, the 
absolute value of an FEV₁ towards the higher end of the category can be up to 
29% more than one at the lower end.  
The healthy control cohort was small though these subjects were closely 
matched to a subset of the AFD cohort. The study would benefit from a larger 
healthy control cohort, particularly as the nature of AFD’s genetic inheritance 
demands that affected males and females are analysed separately. 
6.8.2 The nature of sputum and cell yield  
Whilst induced sputum sampling is quick and non-invasive, it must be 
recognised that the yield from induced sputum sampling may be variable 
depending on the population being sampled. In sputum producers such as COPD 
subjects the cellularity of samples produced was much greater than in the non-
sputum producing groups of AFD subjects and healthy controls. Whilst it was 
ensured that adequate numbers of cells were used for each aspect of sputum 
analysis, this did on occasion limit the number of investigations that could be 
performed on an obtained sample.  
In addition, it is not known what the contribution of other lung derived 
cells is to the measurements of α-galactosidase A activity performed on sputum 
samples. Although the majority of cells within samples were leucocytes, the 
presence of squamous cells, bronchial epithelial cells and their contribution to 
measured enzyme activity is unknown. It is possible that this contribution is 
minimal, however the cellular protein from these cell types would be having an 
effect on the calculation of enzyme activity with the fluorometric assay used in 
this study at the very least. Alternative methods of measuring enzyme such as 
mass spectrometry may provide a way around this for future research.  
6.8.3 Freeze/thawing of samples  
Samples of blood and sputum were processed whilst fresh on the day of 
obtaining them and then stored at - 80°C prior to being thawed for enzyme and 
cytokine measurement. It is possible that there may have been some impact on 
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samples from this process and from the duration stored, which may be one 
explanation for findings outside of the normal range on α-galactosidase A 
samples from non-AFD control subjects.  
6.8.4 Flow cytometry 
 The majority of the flow cytometry performed in this study was on a 3 
colour Beckton Dickinson (BD) FACScan flow cytometer. When combined with 
limitations of cell yield from samples, this meant that the combinations of 
antibodies used were dictated by these factors, and therefore although able to 
identify cells adequately were limited in precision to delineate cell populations in 
more detail. The difficulty of autofluorescence in samples as a result of cellular 
debris and from macrophages was also a limiting factor in this. It is possible that 
the use of 4 colour machine for the addition of other antibodies may assist in 
further description of cell populations in AFD sputum samples.  
6.9 Potential areas for ongoing work from this study  
6.9.1 Additional recruitment and follow up 
Clearly the examination of larger numbers of AFD subjects would help to 
further dissect out the impact of the potential cofounders such as smoking, 
gender and age. It would provide further data on the relationship between lung 
involvement and disease severity. The impact of ERT would also be better 
assessed with a larger cohort of enzyme naïve subjects, and ideally with the 
longitudinal assessment of subjects before and after the commencement of ERT, 
with sampling of the lungs in those subjects for changes in enzyme activity. 
Further follow up over a longer period of time would also be useful to examine 
ongoing changes in lung function which may progress at a slower rate compared 
to changes in other organ systems.  
6.9.2 Cardiopulmonary exercise testing  
Having delineated their lung function in detail, to further determine the 
relative contribution of the lungs and heart to symptoms in our cohort of AFD 
subjects the additional examination of data from cardiopulmonary exercise 
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testing would be of use.  It would provide more information on the functional 
contribution of pulmonary aspects of AFD alongside cardiac involvement.   
6.9.3 Detailed examination of lung derived cells  
Whilst so far we have examined cell populations by flow cytometry, during 
this study, cytospins of each sputum sample obtained were made and fixed, with 
a view to further examination of lung derived cells. Further work examining lipid 
storage in lung derived cells may be performed by immunohistochemical staining 
with anti-CD77, as used to examine urinary sediment (321). This may help to 
clarify which cell types from the lung are most affected by storage material, and 
perhaps if examined longitudinally in subjects commenced on ERT may give 
some indication of ERT penetration and effect on the lung. It would also be of 
value to examine these in the context of the proportions of other less prominent 
cell populations which have not been examined, such as eosinophils and 
basophils.  
6.10 Further work in the field of pulmonary involvement in 
AFD 
6.10.1 Pulmonary sampling by bronchoalveolar lavage  
It is possible that more precise information could be gained from 
pulmonary cells by obtaining samples using bronchoalveolar lavage - though with 
the recognition that such samples would be from a different lung compartment. 
Sampling the lung in this manner would provide a bigger and more consistent 
cell yield than induced sputum sampling, with less contamination by cellular 
debris and squamous cells. Given that in the alveolar compartment a higher yield 
of lymphocytes would be expected this may also further assist in future research 
into the lungs in AFD given the similarities to COPD that have been highlighted in 
this study.  
Flow cytometric examination of BAL samples is generally easier and 
cleaner, though autofluorescence is still problematic, particularly when 
examining macrophage populations (259).  A more cellular sample would also 
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allow the use of additional CD markers that might help to further differentiate 
cell populations, such as CD68 to delineate macrophages as distinct from the 
monocyte population (322).  
6.10.2 Airway smooth muscle 
Further evaluation of the changes in airway smooth muscle should be 
pursued. It is likely as we have suggested in our model of airway involvement, 
and based on the demonstration of storage material in airway smooth muscle 
cells in previous studies (323) that changes in airway smooth muscle are key to 
the pathogenesis of the lung changes observed in AFD. It is possible that 
exploring the inflammatory cytokines involved in airway smooth muscle 
hypertrophy in asthma such as IL-1β and TNF-α may provide insight as to 
changes that ensue from Gb3 deposition in AFD (324).  
Evaluating airway wall thickness and the smooth muscle component of this 
by radiological means may also be useful as previously discussed. However it 
may also be of interest to explore whether ERT has an effect on clearance of Gb3 
in airway smooth muscle cells histologically by serial bronchial biopsy.  
6.10.3 Differential enzyme activity in sputum and blood  
This study has highlighted that the α-galactosidase A activity in lung-
derived samples appears to be higher than that of blood in paired samples from 
the same subjects, and raises the question as to what the cause of this 
differential in enzyme activity is. It may be of interest to look into this further as 
to whether there is a factor in the lung milieu which causes enzyme to 
accumulate, and if so if this could be exploited in some way to improve tissue 
activity of exogenous enzyme.  
6.10.4 Future therapies 
Research is ongoing into oral small molecules such as  
1-Deoxygalactonojirymicin (DGJ), which has been shown to assist with the 
folding and trafficking of enzyme in AFD resulting from missense mutations (325) 
as well as other site specific chaperones that may enhance the efficacy of ERT by 
similar mechanisms (326). For such therapies that are currently under 
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development, their impact on lung aspects of the condition should be evaluated 
alongside their other effects. Small molecule therapies which have been 
introduced in other genetic disorders, such as cystic fibrosis, are proving to be 
revolutionary in subjects where specific gene mutations result in protein 
abnormalities. Some of these have been shown to be amenable to correction, 
such as the G551D mutation of the CF gene with the drug Ivacaftor in cystic 
fibrosis patients who carry least one copy of this mutation (327).   
 The use of agents which may cause reduced accumulation of Gb3 are 
being investigated in mouse models (328) either alone or potentially co-
administered with chaperone therapy  to increase effectiveness (329).  
 The possibility of gene transfer via viral vectors continues to be explored 
in AFD murine models, and show promising results in the context of LSDs, where 
it has been demonstrated that even modest increases in enzyme actitivity may 
be sufficient to significantly improve disease severity (330;331). Research is 
ongoing into the possibility of haemopeitic stem cell transplants in LSDs, as well 
as gene therapy as potential future therapies that may be of significant impact 
(332).  
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6.11 Conclusions  
The findings from this study suggest that lung involvement in AFD is 
common, though relatively mild, slowly progressive and follows a similar pattern 
of involvement to that seen in other organ systems with regards to gender. The 
changes appear to mainly involve the development of airflow limitation, which is 
for the most part fixed, and appears to be independent of smoking. Involvement 
of the lung is more likely to be present in those with worse overall disease 
severity.  
We have shown it is possible to measure α-galactosidase A activity in lung 
derived samples, and this is lower in AFD males than control males and AFD 
females. There is a suggestion that it is lower in AFD subjects with airway 
obstruction compared to those without, though this did not reach statistical 
significance. We have also shown that α-galactosidase A activity is for the most 
part greater in sputum-derived samples than blood; and that this may result 
from the difference in the predominant cell population in these samples. We 
have not shown any difference in sputum α-galactosidase A activity associated 
with ERT use.  
The cell populations present in the induced sputum of AFD subjects with 
airway obstruction demonstrated similarities to those in COPD subjects. There 
were increases in total T cell percentage and a predominance of 
monocytes/macrophages though these did not reach significance when 
compared to healthy controls. No differences were seen in B cell, neutrophil or 
NKT cell populations between the AFD, COPD and healthy control groups.  We 
also showed that sputum IL-8 concentrations were elevated in AFD, similar to 
that seen in the COPD group.  
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Appendix 1 
 
1.0 Participant Invitation Letter  
 
Dear  
I would like to invite you to participate in the study: 
“Investigation of pulmonary involvement in patients with 
Anderson-Fabry Disease” 
This is a 12 month prospective study, at the Lysosomal Storage Disease Unit, Royal 
Free Hospital. The aims of this study are: 
1. To investigate the causative factors in the development of lung involvement 
in Anderson Fabry’s disease 
2. To assess the impact of Enzyme Replacement Therapy on lung 
involvement in Anderson Fabry’s Disease 
3. To investigate if lung involvement correlates with cardiac and renal 
involvement in AFD patients 
4. To elucidate the processes responsible for the pulmonary changes in 
Anderson-Fabry Disease, and how these compare to other lung diseases 
I have enclosed a copy of the patient information sheet regarding this study. 
If you would like more information please do not hesitate to contact us. 
Yours sincerely 
Dr. Nadia Shafi, MBBS, MRCP. 
Clinical Research Fellow 
Lysosomal Storage Disorders Unit 
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2.0 Patient Information Sheet: Anderson Fabry Disease (AFD) group 
  
Re:   Investigation of pulmonary involvement in patients with 
Anderson-Fabry Disease 
You are being asked to take part in a study which is to investigate the effect 
of Anderson-Fabry disease on the lungs and airways. Before you decide to take 
part, it is important for you to understand why this study is being done and what 
it will involve. Please take time to read the following information carefully and 
discuss it with others if you wish. Ask your doctor or people listed at the end of 
this sheet if there is anything that is not clear or if you would like more 
information. 
Why have I been chosen? 
You have been asked to participate in this study because you have been 
diagnosed with Anderson-Fabry Disease. 
What is the purpose of this study? 
Lung involvement and airways disease in Anderson-Fabry patients has not 
been studied much. The purpose of this study is to try and investigate who out of 
the patients with Anderson-Fabry Disease is likely to develop lung involvement, 
and how and what causes this. This study should provide information that may 
be used to assess and monitor Anderson-Fabry patients, and to see if there is 
benefit from enzyme replacement therapy in this aspect of the disease. The lung 
findings will be compared to those in patients with Chronic Obstructive 
Pulmonary Disease (COPD), a condition with affects the lungs and causes 
narrowing of the airways, and with healthy volunteers with no lung disease.  
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Do I have to take part? 
It is up to you whether or not to take part. If you decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. 
If you decide to take part you are free to withdraw at any time and without 
giving a reason. 
What will happen to me if I take part? 
At the moment it is routine for you to have 6 monthly blood and urine 
tests, 6 monthly nuclear medicine kidney assessments and annual heart 
assessments. For this study the extra tests would be: 
1) Two extra blood samples taken at each 6 monthly assessment 
2) Lung function testing at each 6 monthly assessment 
- this takes approximately 30mins, and is done on site at RFH 
3) Induced sputum sample at each 6 monthly assessment - this takes 
30minutes 
4) Additional blood samples on days 1, 4, 7 and 10 after your first ever 
enzyme infusion, for a few patients participating in an additional study 
(tick if participating in enzyme profiling) 
5) A chest CT scan – we are offering this to all AFD patients to try and 
further clarify the changes the condition may have on the lung, by looking 
at the appearances of the lung tissue and airways.  
What are the possible disadvantages and risks of taking part? 
We do not envisage any significant risk to you if you decide to participate in 
this study, though if you have a CT scan of your chest this will obviously involve 
exposure to a small amount of radiation.  
What are the possible benefits of taking part? 
As an individual you may not benefit directly from the research carried out. 
However research from this type of study will help us understand how the 
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respiratory system is affected in Anderson-Fabry Disease and how to better 
assess and monitor the signs and symptoms of the disease. In addition, these 
tests may provide extra information on your own response to therapy. 
What will happen to the results of the research study? 
Results of your tests will be communicated to your doctor at the Lysosomal 
Storage Disease Unit, Royal Free Hospital.  
Will any additional information be collected? 
To enable us to accurately interpret the results we would like to collect 
information about your treatment details and progress, and any additional 
information particularly in relation to your lungs.   
Who will have access to information about me? 
All data collected will be held at a database at the Royal Free Hospital. Only 
the doctors, nurses and technicians involved in running this study will have 
access to it. Your GP will be informed (with your consent) about your 
participation in the study.    
Who is organising and funding the research? 
The study is being organised by the team at the Lysosomal Storage Disease 
Unit, here at the Royal Free Hospital. It is being funded by an educational grant 
from Shire Human Genetic Therapies Inc  
Who has reviewed the study? 
Dr Derralynn Hughes, Dr. Marc Lipman, Dr. Atul Mehta, Dr. J. Hurst 
Contacts for further information? 
If you require any further information regarding the study at any stage, or 
in the event of an emergency please contact the following doctor or nurse. 
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Dr Nadia Shafi Tel: 020 7472 6409 
OR 
Nurses: Linda Richfield/ Alan Milligan Tel: 020 7472 6409 
What if I have any other concerns or wish to seek independent advice 
about the study? 
If you have any complaints about the way the investigator has carried the 
study please contact the Patient Advocacy Liason Service at the Royal Free 
Hospital; telephone number 0207 4726447  
Thank you for taking the time to read this information sheet. 
You will be given a copy of this information sheet and a signed consent 
form to keep. 
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3.0 Patient Information Sheet: COPD group 
 
Re:   Investigation of pulmonary involvement in patients with 
Anderson-Fabry Disease 
Anderson-Fabry Disease is a genetic condition, which belongs to a group of 
conditions known as Lysosomal Storage Disorders. It affects both men and 
women, and causes disease in multiple organ systems, including the lungs and 
airways. You are being asked to take part in a study which is going to investigate 
this further, by comparing the changes in the lung in AFD with those seen in 
Chronic Obstructive Pulmonary Disease (COPD), and people without any 
evidence of lung disease. Before you decide to take part, it is important for you 
to understand why this study is being done and what it will involve. Please take 
time to read the following information carefully and discuss it with others if you 
wish. Ask your doctor or people listed at the end of this sheet if there is anything 
that is not clear or if you would like more information. 
Why have I been chosen? 
You have been asked to participate in this study because you have been 
diagnosed with COPD, which is one of the groups we have chosen for 
comparison in the study.  
What is the purpose of this study? 
Lung involvement and airways disease in Anderson-Fabry patients has not 
been studied much. The purpose of this study is to try and investigate who out of 
the patients with Anderson-Fabry Disease is likely to develop lung involvement, 
and how and what causes this. We aim to do this by looking at the processes of 
inflammation and different cells found in the lungs, and comparing it to more 
common conditions where more is known, such as COPD.  
Do I have to take part? 
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It is up to you whether or not to take part. If you decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. 
If you decide to take part you are free to withdraw at any time and without 
giving a reason.  
What will happen to me if I take part? 
If you choose to take part, we will need to confirm that you definitely do 
not have AFD by doing blood tests to check your plasma enzyme levels and 
genetics. Obviously, if we were to find that you do have AFD there may be 
implications for your future medical health, and that of your family, and 
potentially an impact on any future financial/insurance undertakings, which 
would be addressed with the help of the LSDU at the Royal Free. However, we 
will not exclude you from taking part if you do not wish to have this genetic test, 
if we think it is very unlikely that you have undiagnosed AFD. 
At the moment it is routine for you to have regular follow up and lung 
function tests. We would aim to do the tests for the study when you come for 
your routine appointments, so avoiding any extra trips to the hospital. For this 
study the extra tests would be: 
1) Blood tests for: Haematology, biochemistry, cytokine profiles, plasma 
enzyme  levels, genotyping  
2) Induced sputum sample  
3) A chest Xray if you have not had one in the last 3 months  
What are the possible disadvantages and risks of taking part? 
We do not envisage any additional risk to you if you decide to participate in 
this study.  
What are the possible benefits of taking part? 
As an individual you are unlikely to benefit directly from the research 
carried out.  
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What will happen to the results of the research study? 
Results of your tests will be communicated to your doctor at the Royal Free 
Hospital, and the results of the research will be published once it is completed.  
Will any additional information be collected? 
To enable us to accurately interpret the results we would like to collect 
information about your treatment details and progress, and any additional 
information particularly in relation to your lungs.  
Who will have access to information about me? 
All data collected will be held at a database at the Royal Free Hospital. Only 
the doctors, nurses and technicians involved in running this study will have 
access to it. Your GP will be informed (with your consent) about your 
participation in the study. 
Who is organising and funding the research? 
The study is being organised by the team at the Lysosomal Storage Disease 
Unit, here at the Royal Free Hospital. It is being funded by an educational grant 
from Shire Human Genetic Therapies Inc  
Who has reviewed the study? 
Dr Derralynn Hughes, Dr. Marc Lipman, Dr. Atul Mehta, Dr. J. Hurst 
Contacts for further information? 
If you require any further information regarding the study at any stage, or 
in the event of an emergency please contact the following doctor or nurse. 
Dr Nadia Shafi Tel: 020 7472 6409 
OR 
Clinical Specialist Nurses:  Tel: 020 7472 6409 
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What if I have any other concerns or wish to seek independent advice 
about the study? 
If you have any complaints about the way the investigator has carried the 
study please contact the Patient Advocacy Liason Service at the Royal Free 
Hospital; telephone number 0207 4726447  
Thank you for taking the time to read this information sheet. 
You will be given a copy of this information sheet and a signed consent 
form to keep  
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4.0 Patient Information Sheet: Healthy Volunteer group 
 
Re:   Investigation of pulmonary involvement in patients with 
Anderson-Fabry Disease 
Anderson-Fabry Disease is a genetic condition, which belongs to a group of 
conditions known as Lysosomal Storage Disorders. It affects both men and 
women, and causes disease in multiple organ systems, including the lungs and 
airways. You are being asked to take part in a study which is going to investigate 
this further, by comparing the changes in the lung in AFD with those seen in 
Chronic Obstructive Pulmonary Disease (COPD), a condition with affects the 
lungs and causes narrowing of the airways, and people without any evidence of 
lung disease. Before you decide to take part, it is important for you to 
understand why this study is being done and what it will involve. Please take 
time to read the following information carefully and discuss it with others if you 
wish. Ask your doctor or people listed at the end of this sheet if there is anything 
that is not clear or if you would like more information. 
Why have I been chosen? 
You have been asked to participate in this study because you do not have 
any evidence that you are affected by Anderson Fabry Disease or lung disease, 
and so would be ideal to act as a member of one comparison group in the study.  
What is the purpose of this study? 
Lung involvement and airways disease in Anderson-Fabry patients has not 
been studied much. The purpose of this study is to try and investigate who out of 
the patients with Anderson-Fabry Disease is likely to develop lung involvement, 
and how and what causes this. We aim to do this by looking at the processes of 
inflammation and different cells found in the lungs, and comparing it to more 
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common conditions where more is known, such as COPD.    
  
Do I have to take part?It is up to you whether or not to take part. If you 
decide to take part you will be given this information sheet to keep and be asked 
to sign a consent form. If you decide to take part you are free to withdraw at any 
time and without giving a reason.  
What will happen to me if I take part? 
If you choose to take part, we will ideally need to confirm that you 
definitely do not have AFD by doing blood tests to check your plasma enzyme 
levels and genetics. Obviously, if we were to find that you do have AFD there 
may be implications for your future medical health, and that of your family, and 
potentially an impact on any future financial/insurance undertakings, which 
would be addressed with the help of the LSDU at the Royal Free. However, we 
will not exclude you from taking part if you do not wish to have this genetic test, 
if we think it is very unlikely that you have undiagnosed AFD. 
In the first instance you would have a set of lung function tests, and once 
we have confirmed that these are normal, the further tests would be as follows: 
1) Blood tests for: Haematology, biochemistry, cytokine profiles, plasma 
enzyme levels, genotyping  
2) Induced sputum sample  
3) A chest Xray if you have not had one in the last 3 months  
What are the possible disadvantages and risks of taking part? 
We do not envisage any additional risk to you if you decide to participate in 
this study.  
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What are the possible benefits of taking part? 
 As an individual you are unlikely to benefit directly from the research 
carried out.  
What will happen to the results of the research study? 
Results of your tests will be communicated to your doctor at the Royal Free 
Hospital, and the results of the research will be published once it is completed.  
Will any additional information be collected? 
To enable us to accurately interpret the results we would like to collect 
information about your treatment details and progress, and any additional 
information particularly in relation to your lungs.  
Who will have access to information about me? 
All data collected will be held at a database at the Royal Free Hospital. Only 
the doctors, nurses and technicians involved in running this study will have 
access to it. Your GP will be informed (with your consent) about your 
participation in the study. 
Who is organising and funding the research? 
The study is being organised by the team at the Lysosomal Storage Disease 
Unit, here at the Royal Free Hospital. It is being funded by an educational grant 
from Shire Human Genetic Therapies Inc  
Who has reviewed the study? 
Dr Derralynn Hughes, Dr. Marc Lipman, Dr. Atul Mehta, Dr. J. Hurst 
Contacts for further information? 
If you require any further information regarding the study at any stage, or 
in the event of an emergency please contact the following doctor or nurse. 
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Dr Nadia Shafi Tel: 020 7472 6409 
OR 
Clinical Specialist Nurses:  Tel: 020 7472 6409 
What if I have any other concerns or wish to seek independent advice 
about the study? 
If you have any complaints about the way the investigator has carried the 
study please contact the Patient Advocacy Liason Service at the Royal Free 
Hospital; telephone number 0207 4726447  
Thank you for taking the time to read this information sheet. 
You will be given a copy of this information sheet and a signed consent 
form to keep  
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6.0 Consent Form 
 
Re: Investigation of pulmonary involvement in patients with 
Anderson-Fabry Disease 
 
Name: 
 
Date of Birth: 
 
Hospital Number: 
 
Centre: 
 
Study Number: 
 
Researcher: 
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The patient should complete this sheet him/herself. (Please circle one) 
 
1. I confirm that I have read and understood the information contained in 
the information sheet        Yes/No                                                         
2. I have had the opportunity to ask questions and had satisfactory answers 
to them                  Yes/No 
3. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason.    Yes/No 
4. Do you give permission for your information to be collected, stored, and 
used for research in a database held at the Lysosomal Storage Disorder Unit at 
the Royal Free Hospital?       Yes/No 
5. Do you give permission for your left-over samples to be stored and used 
for future ethically approved studies?      Yes/No 
6. Do you give permission for your general practitioner to be informed of 
your participation in this study?      Yes/No 
7. Do you agree to take part in the Investigation of pulmonary involvement 
in patients with Anderson-Fabry Disease?     Yes/No 
Name (block letters) …………………………………………. 
Signed ……………………………………………………… 
Date ……………………………………. 
DOCTOR TAKING CONSENT (please delete) 
Name (block letters) …………………………………………… 
Signed ……………………………………………………..  
Date ……………………………………. 
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7.0 GP Letter  
 
Dear Dr.  
 
Re:   
I would like to inform you that the above patient has consented to be enrolled in 
the study: 
“Investigation of pulmonary involvement in patients with Anderson-Fabry  
  Disease” 
This is a 12 month prospective study, at the Lysosomal Storage Disease Unit, Royal 
Free Hospital. The aims of this study are: 
1. To investigate the causative factors in the development of lung involvement 
in Anderson Fabry’s disease 
2. To assess the impact of Enzyme Replacement Therapy on lung 
involvement in Anderson Fabry’s Disease 
3. To investigate if lung involvement correlates with cardiac and renal 
involvement in AFD patients 
4. To elucidate the processes responsible for the pulmonary changes in 
Anderson-Fabry Disease, and how these compare to other lung diseases 
If you would like more information please do not hesitate to contact us.  
Yours sincerely 
Dr. Nadia Shafi, MBBS, MRCP. 
Clinical Research Fellow 
Lysosomal Storage Disorders Unit 
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8.0 The Royal Free Fabry and Gaucher Clinic: FABRY ASSESSMENT 
 
  
Name: 
DOB: 
Hospital No: 
Date: 
Visit Number: 
Referral Route: 
Major Events or Concerns since last visit: 
General 
Fatigue                                              
Reduced activity level                     
Thromboembolic events                 
Lymphoedema                                 
Varicose Veins                                 
Raynauds 
Claudication 
Heat / Cold intolerance 
Currently pregnant? 
Neuro 
Acroparasthesia 
Fever pain crisis 
Chronic Pain 
Hypohydrosis 
Hyperhidrosis 
Anhidrosis 
Temperature insens 
Headache 
Seizures 
Syncope 
Neuropathy 
 
Cardiac/ Resp 
Chest pain 
SOB 
SOBoE 
Palpitations  
Oedema 
Cough 
Wheeze 
 
Renal/ Urinary 
Dysuria 
Nocturia 
Macrohaematuria 
 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
 
 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
 
 
Y/N 
Y/N 
Y/N 
GI (indicate if mild, moderate or 
severe) 
Abdo pain 
Diarrhoea (# of mvmts/day, stool 
consistency) 
Constipation 
Bloating (indicate severity) 
Nausea 
Vomitting 
Haemorhhoids 
 
Reproductive/ Endocrine 
Erectile Dys 
Priapism 
Delayed Puberty 
Growth impairment 
Sexual Dysfunction 
 
Dermatological 
Rash 
Angiokeratomas 
Telangiectasia 
 
Eye 
Cataract 
Torturous vessels 
Visual impairment 
 
Muscoloskeletal 
(Indicate pain frequency, ie daily, 
wkly, monthly, <monthly) 
Acute pain in past yr 
Muscle Pain 
Body Pain 
Joint Pain Joint Stiffness 
 
Ear 
Tinnitus 
Vertigo 
Sudden Deafness 
Hearing impairment 
 
Y/N 
Y/N 
 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
 
 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
 
 
Y/N 
Y/N 
Y/N 
 
 
Y/N 
Y/N 
Y/N 
 
 
 
Y/N 
Y/N 
Y/N 
Y/N 
 
 
Y/N 
Y/N 
Y/N 
Y/N 
 
Appendix 1   
211 
 
PAST MEDICAL HISTORY: 
 
TIA / PRIND / Stroke 
Depression / Dementia / Anxiety Dis 
LVH / MI / Angina / Heart Failure / Valve Dis / Conduction ab / Arrhythmia / 
Congenital HD 
Hypertension 
Asthma / COPD / Chronic Bronchitis 
Dialysis / Transplant / Chronic Renal Failure 
Peptic Ulcer / Pancreatitis / Other GI 
Diabetes Insipidus / Diabetes Mellitus 
Infections – Pneumonia / Septicaemia / Meningitis 
Malignancy 
Others 
 
 
 
 
 
 
 
MEDICATIONS:                                            Allergies: 
 
 
 
 
 
 
 
 
 
 
 
ENZYME: 
 
Name:                              Dose:                (Number of vials:        )   Interval:           days 
Missed infusions (4 weeks)        Y / N                      Number: 
Delayed infusions (3 weeks)       Y / N                     Number: 
Premedication:  Y / N 
 
Reactions:                                                   Administration: 
                                                                      Home / Hospital 
                                                                      Self / Nurse / Relative 
 
SOCIAL HISTORY: 
 
Alcohol intake: 
Smoking: 
Occupation: 
 
FAMILY HISTORY: 
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EXAMINATION: 
HEIGHT (cm): 
WEIGHT (kg): 
BMI (kg/m
2
):  
URINALYSIS: 
TEMP: 
General Cond: Good/ Mod/ Poor 
Heart Failure: Y/N   NYHA Grade: 
RASH: 
 
CVS:  
Pulse: 
BP: Lying                 Standing 
JVP: 
HS: 
SoA:  
Oedema: 
 
RS: 
O2 Sat 
 
 
ABDOMEN: 
 
 
 
Musculoskeletal 
Joint Swelling 
Joint Tenderness 
 
CNS: 
CN:  
II 
III,IV,VI 
V 
VII 
VIII  
IX,X 
XI,XII 
 
UL 
TONE 
POWER 
SENSATION 
COORDINATION 
Reflex - Biceps 
              Triceps 
               Supinator 
LL 
TONE 
POWER 
SENSATION 
COORDINATION 
Reflex - Knee 
              Ankle 
              Plantar 
RIGHT 
 
 
 
LEFT 
 
 
 
Checklist: 
Microalbuminuria: Consider: 
Urine Protein: Cholesterol?  
GFR: Anti-platelet? (neuro event) 
Homocysteine Folic acid? (elevated homocysteine) 
Audiology: Anti-hypertensive? (>130/80) 
Opthalmology: Other Investigations: 
Cardiac Assess: 
MAJOR CRITERIA: (tick) 
1.Uncontrolled Pain 
2. >300mg/24hr proteinuria 
3. Ischaemic Hear disease/ cardiac 
dysfunction 
4. LVH 
5. Cardiac arrhythmia 
6. Significant neurovascular disease 
 
MINOR CRITERIA: 
1. Abnormal brain MRI 
2. Episodic vertigo 
3. Intraventricular conduction defect 
4. Gastric symptoms 
5. Severe asthenia 
6. Hearing Loss 
CHANGE OR INITIATION OF THERAPY: 
FOLLOW UP: GP LETTER: 
PATIENT LETTER: REFER TO: 
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Table 1.0 Comparison of spirometry and diffusion capacity in AFD 
and healthy control matched sub-group 
% predicted 
Mean (+/- SD) 
AFD Matched healthy 
control 
p value 
(unpaired t test) 
n 9 9 - 
Age [years] 46.07 
(+/- 10.4) 
41.56 
(+/- 10.5) 
0.4 
Males, females 5, 4 5, 4 - 
FEV₁ 82.77 
(+/- 7.9) 
109.6 
(+/- 16.3) 
0.0004 
FVC 108.2 
(+/- 10.0) 
117.4 
(+/- 18.6) 
0.2 
FEV₁ /FVC 63.70 
(+/- 3.7) 
78.91 
(+/- 8.3) 
0.0001 
PEFR 98.67 
(+/- 13.8) 
119.1 
(+/- 19.7) 
0.02 
MEF50 40.82 
(+/- 9.0) 
93.96 
(+/- 38.8) 
0.001 
RV/TLC 90.97 
(+/- 14.7) 
86.30 
(+/- 14.1) 
0.5 
TLCO 89.00 
(+/- 18.9) 
95.40 
(+/- 12.1) 
0.4 
KCO 93.00 
(+/- 19.0) 
98.8 
(+/- 12.6) 
0.5 
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Table 2.0 Demographics and lung function of AFD subjects and 
matched COPD subjects 
 
 
  
% predicted 
Mean (+/- SD) 
COPD males COPD females 
n 9 5 
FEV₁ 67.5 
(+/- 14.0) 
74.3 
(+/- 10.1) 
FVC 99.4 
(+/- 16.3) 
115.1 
(+/- 20.4) 
FEV₁/FVC 0.6 
(+/-0.08) 
0.6 
(+/- 0.07) 
PEFR 76.7 
(+/- 17.5) 
95.7 
(+/-13.6) 
MEF50 24.24 
(+/- 15.6) 
29.00 
(+/- 11.9) 
RV/TLC 112.3 
(+/- 16.0) 
128.4 
(+/- 19.3) 
TLCO 68.2 
(+/- 19.3) 
73.8 
(+/- 0.45) 
kCO 79.6 
(+/- 22.5) 
76.3 
(+/- 9.6) 
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Table 3.0 Spiromtery and diffusion capacity in COPD males and 
females  
% predicted 
Mean (+/- SD) 
AFD COPD p value 
(unpaired t test) 
n (%) 14 (100) 14 (100) - 
Age [years] 50.7 
(+/- 11.4) 
65.8 
(+/- 10.0) 
0.001 
Males, females (%) 9 (64), 5 (36) 9 (64), 5 (36) - 
GOLD stage I (%) 
GOLD stage II (%) 
4 (29) 
10 (31) 
4 (29) 
10 (31) 
- 
FEV₁ 
 
82.5 
(+/- 9.2) 
70.2 
(+/- 13.1) 
0.01 
FVC 
 
105.7 
(+/- 11.9) 
103.7 
(+/- 18.0) 
0.75 
FEV₁/FVC 
 
0.64 
(+/- 0.04) 
0.60 
(+/- 0.02) 
0.04 
PEFR 
 
99.1 
(+/- 11.3) 
81.9 
(+/- 18.2) 
0.01 
MEF50 41.5 
(+/- 9.3) 
24.9 
(+/- 13.8) 
0.002 
RV/TLC 88.3 
(+/- 17.2) 
117.1 
(+/- 18.1) 
0.0005 
TLCO 
 
87.2 
(+/- 17.0) 
69.7 
(+/- 16.3) 
0.02 
KCO 94.2 
(+/- 16.1) 
78.7 
(+/- 19.4) 
0.04 
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Table 4.0 Lung function parameters in AFD subjects at baseline, 6 
months and 12 months follow up 
 
 
 
 
 
% predicted 
Mean (+/- SD) 
Baseline 6 months 12 months 
n 12 12 12 
FEV₁ 91.08 
(+/- 10.8) 
89.17 
(+/- 10.7) 
91.71 
(+/- 11.0) 
FVC 104.9 
(+/- 10.8) 
103.4 
(+/- 12.6) 
104.6 
(+/- 13.7) 
FEV₁/FVC 0.73 
(+/- 0.07) 
0.73 
(+/- 0.06) 
0.74 
(+/- 0.08) 
PEFR 107.2 
(+/- 9.6) 
98.25 
(+/- 13.6) 
107.9 
(+/- 14.3) 
MEF50 60.28 
(+/- 15.7) 
56.92 
(+/- 13.4) 
61.38 
(+/- 17.6) 
RV/TLC 87.69 
(+/- 10.9) 
83.83 
(+/- 7.1) 
92.86 
(+/- 15.6) 
TLCO 85.83 
(+/- 13.4) 
83.17 
(+/- 11.8) 
83.70 
(+/- 12.2) 
KCO 96.92 
(+/- 13.7) 
94.33 
(+/- 11.6) 
94.88 
(+/- 13.8) 
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Table 5.0 Comparison of α-galactosidase A activity in AFD males and 
females with and without airway obstruction 
Sample type 
for α- 
galactosidase 
A activity 
AFD males 
Median (range) 
AFD females 
Median (range) 
n Obstructed n Unobstructed n Obstructed n Unobstructed 
Plasma 
nmol/hr/ml 
12 0.2 
(0.1 – 0.5) 
7 0.2 
(0.1 – 4.0) 
8 3.9 
(1.8 – 6.1) 
1
7 
3.9 
(1.2 – 7.3) 
Blood 
leucocyte 
nmol/hr/mg 
protein 
10 0.7 
(0.1 – 5.6) 
4 3.6 
(1.6 – 10.6) 
p=0.07 
5 19.3 
(5.9 – 20.8) 
9 14.2 
(3.4 – 79.9) 
Sputum 
supernatant 
nmol/hr/ml 
11 1.0 
(0.3 – 3.9) 
3 1.3 
(0.3 – 2.5) 
5 7.4 
(0.7 – 21.5) 
1
2 
3.4 
(1.7 – 36.1) 
Sputum 
leucocyte 
nmol/hr/mg 
protein 
12 33.5 
(3.9 -118.0) 
4 34.2 
(21.0 -79.0) 
6 99.4 
(37.8 - 164.2) 
7 169.2 
(24.4 – 371.2) 
Sputum 
supernatant/ 
plasma 
enzyme 
activity ratio 
11 6.9 
(1.5 – 15.4) 
3 2.1 
(1.6 – 6.0) 
5 1.8 
(0.4 – 7.0) 
1
2 
1.0 
(0.6 – 7.6) 
Sputum /blood 
leucocyte 
enzyme 
activity ratio 
10 36.4 
(0.7–361.0) 
3 4.6 
(2.0 – 29.6) 
5 6.2 
(1.8 – 27.9) 
9 17.4 
  (2.7 –115.6) 
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